

Choosing a model to predict hospital admission. An observational study of new variants of predictive models for case finding.

Journal:	BMJ Open
Manuscript ID:	bmjopen-2013-003352
Article Type:	Research
Date Submitted by the Author:	05-Jun-2013
Complete List of Authors:	Billings, John; New York University, Georghiou, Theo; Nuffield Trust, Research Bardsley, Martin; Nuffield Trust, Research Blunt, Ian; Nuffield Trust, Research
Primary Subject Heading :	Health services research
Secondary Subject Heading:	Health informatics, Health policy
Keywords:	Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT
	-

SCHOLARONE^{**} Manuscripts

1	
2	
3	Choosing a model to predict hospital admission. An observational study of new variants of predictive
4	
5	models for case finding.
6	
7	
8	
9	
10	
11	
12	
13	John Billings, Associate Professor (1)
14	Theo Georghiou, Senior Research Analyst (2)
15	
16	Martin Bardsley, Director of Research (2)
17	Ian Blunt, Senior Research Analyst (2)
18	
19	
20	
21	
22	¹ Robert F. Wagner Graduate School of Public Service, New York University, 295 Lafayette Street, Room
23	3010, New York, NY 10012-9604, USA
24	² Nuffield Trust, 59 New Cavendish Street, London W1G 7LP, UK
25	
26	
27	
28	Corresponding Author theo.georghiou@nuffieldtrust.org.uk
	Key words: Predictive Risk, Urgent care, Hospital admission
29	
30	
31	
32	
33	
34	
35	Key words:
36	
37	Predictive Risk, Urgent care, Hospital admission
38	
39	
40	
41	
42	Word count: 3,911
43	
44	Word count: 3,911
45	
46	
40	
48	
49	
50	
51	
52	
53	
54	
55	
56	

ABSTRACT

Objectives: To test the performance of new variants of models to identify people at risk of an emergency hospital admission. We compared (1) the impact of using alternative data sources (hospital inpatient, A&E, outpatient, and GP electronic medical records) (2) the effects of local calibration on the performance of the models and (3) the choice of population denominators.

Design: Multivariate logistic regressions using person level data adding each data set sequentially to test value of additional variables and denominators.

Setting: Five Primary Care Trusts within England.

Participants: 1,836,099 people aged 18-95 registered with GPs on 31 July 2009.

Main outcome measures: Models to predict hospital admission and readmission were compared in terms of positive predictive value and sensitivity for various risk strata and with receiver operating curve C statistic.

Results: The addition of each data set showed moderate improvement in number of patients identified with little or no loss of positive predictive value. However, even with inclusion of GP electronic medical record information, the algorithms identified only a small number of patients with no emergency hospital admissions in the prior two years. The model pooled across all sites performed almost as well as models calibrated to local data from just one site. Using population denominators from GP registers led to better case finding.

Conclusions: These models provide a basis for wider application in the NHS. Each of the models examined produce reasonably robust performance and offers some predictive value. The addition of more complex data add some value, but we were unable to conclude that pooled models performed less well than those in individual sites. Choices about model should be linked to the intervention design. Characteristics of patients identified by the algorithms provide useful information in the design/costing of intervention strategies to improve care coordination/outcomes for these patients.



Article focus

- The use of statistical models to predict risk of hospital admissions are increasingly used to prioritise patients for preventive care. Models exist in several different forms and use a variety of input data sets.
- This paper compared the performance of a variety of models built using different datasets.

Key messages

- The addition of more detailed data sets led to moderate improvement in number of patients identified with little or no loss of positive predictive value.
- The use of GP registry data for the denominator proved to be of significant importance. By including all patients in an area, not just those with prior hospital use, improved rates of case finding were observed.
- Models calibrated to local data sets did not show a consistent improvement over models built on pooled data.

Strengths and limitations of this study

- The analysis is based on populations from only five areas in England, however this is the largest UK population (1.8M people) used in the development of a publicly available risk tool.
- The success of a predictive model depends on many factors beyond the statistical performance of the model.

INTRODUCTION

There remains continuing interest in identifying patients at risk of future hospital admissions. Policies providing penalties[1] or non-payment[2] for hospital readmissions that put providers at risk for a share of total health expenditures have been developed for in the U.S. and in England. These create even stronger incentives to identify high risk patients to target care coordination and management strategies that may potentially reduce future inpatient expenditures.

Most predictive modelling approaches have used administrative data from claims in the U.S. or hospital data from Hospital Episode Statistics (HES) or Secondary Uses Services (SUS) in England. These data provide the information on prior utilisation and diagnostic history to develop predictive models for patients at risk of future hospitalization.[3] Payor claims data in the U.S. provide rich information on care provided in hospitals, home care services and nursing home use, as well as detailed pharmacy prescription history.[4] In England, the most commonly used models (such as in the now outdated Patient at Risk of Readmission PARR algorithm)[5,6] are based on hospital admissions data (including day case use, and regular attendances) with some use of accident and emergency (A&E) and outpatient attendance data as well.[7]

While some predictive modeling efforts in the U.K. have included information from GP electronic medical records (EMRs),[8,9] using such data presents a number of challenges. These include obtaining permissions for access to EMRs for large populations, linking the records to hospital data, and use of Read codes[10] to develop GP variables. Data from EMRs include additional elements not available in the hospital data sets such as test results (e.g. blood pressure, HbA1c levels), diagnostic history for patients without recent inpatient admissions, prescription history, GP contact patterns (GP visits and telephone contacts), and other personal health markers (e.g. body mass index, smoking status). These additional data elements have the potential to add power to predictive modeling efforts, especially for patients with no or lower levels of recent inpatient use.

Despite the challenges, a number of initiatives around the UK are demonstrating population wide access to EMR data. A common application is in the use of models that assist local clinical commissioning groups (CCGs) in identifying high risk patients.

Though the choice of data sets for a predictive model makes a big difference to the investment required to run these models – at least initially – no studies have looked at the marginal value of different data sets. In this analysis we examine the added value of including data on A&E and outpatient visits (which are readily available) to predictive modeling efforts using hospital inpatient data alone. We also assess the marginal effect of adding GP EMR information to help identify patients at risk of future hospital admissions.

In addition to the depth of data used there is also a question about how generalisable models are across different sites. In many settings models are recalibrated on local data sets. Yet there is little systematic analysis of the value that this step adds and whether models built on data from one site outperform those built on a larger sample of pooled data. We therefore explore whether there is a need for development of individual site predictive models, or whether models developed from multiple sites can be applied effectively at a new individual site.

METHODS

We conducted analyses separately for five Primary Care Trust areas in England (Newham, Cornwall, Kent, Croydon, Redbridge; total adult population ranging from 209,661 to 693,089). Results are reported for the individual sites and as combined/pooled results (total population 1,836,099). Hospital data was extracted from the Secondary Users Services (SUS)[11] system which contained records of all hospital events (inpatient admissions, outpatient appointments and A&E visits) for the PCTs' registered populations between 1 August 2007 and 30 September 2010. The PCTs also extracted data from GP systems in two forms. Firstly as a register of the local adult population from 1 August 2007 and 31 July 2009, and secondly in the form of datasets recording details of GP consultations over the same time period.

Personally identifiable information was stripped out before any data were passed to the research team. Individuals' NHS numbers (the personal identifiers) were pseudonymised to allow for linkage between the hospital and the general practice data.

A series of variables were created from each data set that were believed to be potentially predictive of an unplanned (emergency) hospital admission in the last 12 months of the study period. These variables captured resource use, utilization patterns, diagnostic history, test results, and prescription history in the two years prior to the predictive period. They were created for all individuals aged 18+ registered with a GP in one of the five areas on 31 July 2009. To account for expected time required to obtain and process the hospital and GP EMR data, we included a two-month lag in our analyses, with data from 1 August 2007 to 31 July 2009 used to predict emergency admissions during the period 1 October 2009 to 30 September 2010.

Patient age and gender were obtained from the GP register. Patient area of residence was not available, and so GP practice attributed index of multiple deprivation (2007) was used as an area deprivation measure. The number of months the patient was registered with the PCT in the pre-period was calculated and included in the regression. Hospital inpatient data were used to capture utilization in the 0-90, 91-181, 180-365, and 366-730 days prior to the lag period. The number of emergency and elective admissions for these periods were included and dichotomous variables for any day case or regular attendance use were created.

BMJ Open

A broad range of diagnostic variables were developed using primary and secondary diagnosis fields and a Charlson Comorbidity Index[12] was calculated for each patient and included in the model.

A&E data were used to determine A&E visit rates for various intervals in the pre-period, both total visits and unplanned follow-up visits. A&E diagnostic information was not reliably reported across the five sites and was not included, although X-ray use was included. Outpatient data provided variables on outpatient visit rates for various intervals, as well as missed appointment rates and the number of different specialty types consulted. Diagnostic information in outpatient data was missing in more than 95% of cases and was not included.

GP EMR data were used to create proxy visit rates (these may include both actual GP visits, in addition to other events documented in a person's records) for various intervals and to capture any increase in visit rates at the end of the pre-period that may reflect increased morbidity in a patient. EMR Read codes (CTV3 version) were used to obtain test results (blood pressure, blood serum levels, HbA1c levels, etc.), body mass index, smoking history, prescription history (number and type), and a range of diagnostic variables during the pre-period.

Variables from each data set (inpatient (including day case and regular attenders), A&E, outpatient, and GP EMRs) were added and modeled sequentially using standard logistic regression in SPSS v20. Emergency admission in the next 12 months was used as the dependent variable, producing a risk score ranging from 0-100. Separate models were developed for each PCT area, and analysis was limited to patients aged 18-95 who were on the GP register in the area. Over-fitting was tested using a split sample approach, with only minor differences observed in positive predictive values (PPV), sensitivity, and specificity.

Findings provided here include both individual site results and results combined across the five sites. We also created five additional predictive models (referred to below as the 'four-site regression models'), each one combining data from four sites and applying coefficients to the fifth remaining site. With this we could compare results with individual site predictive models to help assess the value of local model development.

The full list of more than 300 potential variables was ultimately reduced to 88 by exclusion of variables with low volumes and low significance levels across the sites. The 88 variables ultimately included in the model (and regression coefficients), may be found in Appendix B, and a full listing of the variables

considered for inclusion and detailed specification of each variable are available at http://www.nuffieldtrust.org.uk/.

Cost variables were examined, with secondary care activity costed according to the method used in development of the person based formula for allocating commissioning funds to general practices in England.[13] Ultimately, these were not included in the predictive models because of concerns about difficulties in constructing these variables by possible future users, however costs are included in descriptive findings to help in design of intervention strategies.

Predictive modeling performance is typically documented reporting PPV and sensitivity at the risk score threshold of 50. However, because interventions may be targeted at patients with higher or lower risk scores and interventions strategies may be calibrated differently depending on risk level and characteristics of patients at various risk score levels, we report PPV sensitivity at 20 risk score cutoff points (vigintiles) and provide detailed patient characteristics at risk score thresholds of 50 and 30 to facilitate intervention design.

RESULTS

Pooled Individual Site Results

There were 1,836,099 people aged 18 and over who were registered with a GP practice on 31 July 2009. Table 1 shows the combined results of individual site regressions including the number of patients correctly identified, PPV, and sensitivity for four models:

- (i) IP based on hospital inpatient data only (including day cases and regular attendances)
- (ii) IPAE using inpatient and A&E data
- (iii) IPAEOP using inpatient A&E and outpatient data
- (iv) IPAEOPGP using inpatient, A&E, outpatient data and GP EMR.

At the traditional risk score threshold level of 50 all four models perform respectably in terms of PPV (ranging from .523 to .538), but sensitivity remains quite low across all models (.049 to .060). Lowering the threshold to 30 increases sensitivity somewhat with a concomitant reduction in PPV (ranging from .417 to .422). The ROC area under the curve (C statistic) improved with the addition of each data set, increasing from .731 with the inpatient-only model to .780 with the full model.

Table 1 Model performance, four models: IP, IPAE, IPAEOP, IPAE	OPGP. Five site individual runs combined.
--	---

Risk		IP Data			IP+AE Data		IP	+AE+OP Dat	а	IP	+AE+OP+GP	Data
Score Threshold	True Positive	PPV	Sensitivity	True Positive	PPV	Sensitivity	True Positive	PPV	Sensitivity	True Positive	PPV	Sensitivity
1	94,692	0.052	1.000	94,692	0.052	1.000	94,692	0.052	1.000	94,692	0.052	1.00
5	54,450	0.126	0.575	56,117	0.128	0.593	56,438	0.131	0.596	61,498	0.133	0.64
10	33,053	0.219	0.349	34,102	0.221	0.360	35,033	0.223	0.370	39,986	0.220	0.42
15	22,898	0.285	0.242	23,166	0.293	0.245	24,261	0.290	0.256	28,697	0.283	0.30
20	16,181	0.346	0.171	16,915	0.347	0.179	17,719	0.344	0.187	21,601	0.333	0.22
25	12,670	0.385	0.134	13,182	0.386	0.139	13,754	0.383	0.145	16,672	0.378	0.1
30	10,061	0.421	0.106	10,555	0.422	0.111	11,010	0.419	0.116	13,196	0.417	0.1
35	8,130	0.449	0.086	8,600	0.450	0.091	8,986	0.448	0.095	10,516	0.450	0.1
40	6,700	0.477	0.071	7,139	0.478	0.075	7,421	0.476	0.078	8,494	0.479	0.0
45	5,535	0.501	0.058	5,976	0.504	0.063	6,167	0.499	0.065	6,921	0.510	0.0
50	4,627	0.529	0.049	5,027	0.531	0.053	5,172	0.523	0.055	5,669	0.538	0.0
55	3,862	0.551	0.041	4,222	0.551	0.045	4,359	0.543	0.046	4,581	0.562	0.0
60	3,239	0.574	0.034	3,555	0.569	0.038	3,658	0.567	0.039	3,735	0.587	0.0
65	2,711	0.593	0.029	3,012	0.590	0.032	3,041	0.587	0.032	3,034	0.618	0.0
70	2,245	0.617	0.024	2,481	0.612	0.026	2,519	0.610	0.027	2,453	0.645	0.0
75	1,816	0.634	0.019	2,049	0.639	0.022	2,064	0.631	0.022	1,921	0.666	0.0
80	1,418	0.666	0.015	1,662	0.656	0.018	1,646	0.654	0.017	1,478	0.696	0.0
85	1,064	0.679	0.011	1,293	0.674	0.014	1,276	0.679	0.013	1,114	0.711	0.0
90	769	0.710	0.008	932	0.688	0.010	935	0.702	0.010	754	0.738	0.0
95	478	0.748	0.005	592	0.725	0.006	586	0.728	0.006	437	0.771	0.0
Top 1%	8,214	0.447	0.087	8,353	0.455	0.088	8,410	0.458	0.089	8,722	0.475	0.0
Top 5%	24,873	0.271	0.263	25,355	0.276	0.268	25,712	0.280	0.272	26,991	0.294	0.2
	ROC C Statistic	0.731			0.745			0.752			0.780	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Of particular note is the finding that the addition of each data set added power, that is, correctly identified more patients with an admission in the next 12 months, with only a minor reduction in PPV. At a risk threshold of 50, the addition of A&E data resulted in increase of 400 (8.6%) correctly flagged patients, with no loss in PPV. The inclusion of outpatient data added a more modest 2.9%, but with a slight loss in PPV (.531 to .523). The addition of GP EMR data added an additional 9.6% of patients, while actually increasing the accuracy of the model (PPV increasing from .523 to .538). The added power of the A&E data set is less substantial at a risk score threshold of 30 (4.9%), but outpatient and GP EMR data sets had larger increases in correctly identified patients (4.3% and 19.9%).

There were also important differences between the models in terms of the characteristics of patients identified as high risk. For example, at a risk score cutoff of 50, patients identified using inpatient data alone had high prior emergency inpatient utilization rates with 2.62 admissions in the prior year compared to 2.43 when A&E data was added; 2.34 with addition of outpatient, and 2.20 with the addition of GP EMR data - see Table 2.

The inclusion of the additional data sets also led to a reduction in observed morbidity level of patients at the 50 threshold, with lower numbers of long term conditions, fewer patients with multiple long term conditions, lower Charlson Comorbidity Index scores, less history of alcohol abuse and mental illness, and lower emergency inpatient costs in the years prior to the predictive period. Similar, but less substantial differences were observed at the risk score threshold of 30. The addition of the A&E data set resulted in higher rates of A&E visits in the pre-period among patients identified at both risk score cutoff levels, and the addition of outpatient data resulted in higher outpatient visit and missed visit rates among identified patients

These findings suggest inclusion of the additional data sets added some predictive power and generally tended to find patients who were less severely ill. Thus they potentially offer an opportunity for intervention at earlier stages in the progression of a patient's condition. However, the number of patients identified with no prior emergency inpatient utilization in the prior two years was relatively small across all models. At a risk score threshold of 50, only 0.3% of patients correctly identified by the inpatient-only model had no prior emergency admissions in the previous two years, and increasing only modestly 3.2% in the full model (Table 3). At a risk threshold of 30, the rates were higher, but only reaching 12.4% for the full model.

Table 2 Patient characteristics by risk score threshold four models: IP, IPAE, IPAEOP, IPAEOPGP. Five site

individual runs combined.

-		Risk Scor				Risk Sco		
	IP Data	IPAE	IPAEOP	IPAEOPGP	IP Data	IPAE	IPAEOP	IPAEOP
	Data	Data	Data	Data	Data	Data	Data	Data
Number of patients	8,743	9,473	9,892	10,545	23,912	25,021	26,304	31,6
Patients with adm next 12 mos	4,627	5,027	5,172	5,669	10,062	10,554	11,011	13,1
Mean Age	73.9	72.3	71.2	72.2	75.3	74.0	73.4	73
Age 18-39	6.2%	8.4%	8.7%	7.8%	5.1%	6.8%	7.0%	6.4
Age 40-54	8.7%	9.6%	10.9%	10.6%	7.0%	7.8%	8.6%	8.
Age 55-64	6.9%	7.4%	7.8%	8.1%	6.4%	6.4%	7.0%	7.
Age 65-74	14.4%	13.9%	15.0%	13.5%	13.9%	13.8%	14.4%	13.
Age 75-84	30.5%	28.9%	28.2%	27.4%	32.1%	31.1%	30.3%	29.
Age 85+	33.3%	31.8%	29.3%	32.6%	35.5%	34.1%	32.7%	34.
Female	55.2%	55.2%	54.9%	54.7%	56.9%	57.1%	56.6%	56.
Practice IMD	24.6	24.9	24.8	24.3	24.2	24.3	24.3	2
Ischaemic Heart Disease	36.2%	34.2%	33.2%	32.1%	29.8%	28.4%	27.8%	25.
Angina	21.7%	20.5%	19.5%	19.3%	17.3%	16.4%	15.7%	14.
Hypertension	64.5%	61.2%	59.9%	59.0%	59.4%	56.7%	55.1%	50.
CHF	19.2%	17.8%	16.9%	15.9%	14.0%	13.2%	12.5%	10.
CVD	21.7%	20.1%	19.3%	18.1%	16.9%	15.8%	15.2%	13.
COPD	23.4%	21.4%	20.6%	19.1%	17.2%	16.3%	15.7%	13.
Asthma	21.3%	20.9%	20.1%	18.1%	17.4%	16.6%	16.1%	13.
Diabetes	34.1%	32.4%	31.6%	28.8%	30.1%	28.8%	27.6%	23.
Renal Failure	16.5%	14.6%	14.2%	13.3%	11.2%	10.4%	10.0%	8
Any long term conditions	89.8%	87.0%	85.8%	85.0%	86.6%	83.6%	81.4%	75
Any cancer	15.4%	13.8%	13.4%	12.4%	13.3%	12.7%	12.2%	10.
Alcohol misuse	10.0%	10.0%	9.6%	9.1%	7.0%	6.7%	6.4%	5.
Mental illness	32.0%	30.6%	28.9%	27.2%	23.5%	22.3%	21.3%	18.
Number long term conditions	2.67	2.51	2.43	2.31	2.20	2.10	2.02	1
Charlson Index	3.96	3.69	3.55	3.28	3.09	2.95	2.82	2
Emerg adms 1yr prior	2.62	2.43	2.34	2.20	1.64	1.57	1.50	1
Emerg adms 2 yr prior	1.78	1.67	1.61	1.50	1.15	1.10	1.05	0
No emerg adm prior 2 yrs	0.6%	1.9%	3.3%	4.3%	4.2%	6.5%	9.2%	16.
Elect adms 1yr prior	0.32	0.29	0.31	0.28	0.27	0.26	0.27	C
Elect adms 2 yr prior	0.24	0.23	0.26	0.24	0.20	0.20	0.22	0
Any day case 1yr prior	31.9%	30.8%	31.6%	28.7%	31.5%	30.7%	30.4%	26
Any day case 2yr prior	28.9%	27.6%	28.0%	25.7%	27.8%	26.9%	26.7%	23
Emerg adm cost 1yr prior	£4,500	£4,073	£3,920	£3,688	£2,893	£2,709	£2,604	£2,
Emerg adm cost 2yr prior	£2,932	£2,675	£2,583	£2,422	£1,962	£1,822	£1,757	£1,
AE visits 1yr prior	2.90	3.59	3.45	3.17	1.83	2.26	2.17	, 1
AE visits 2yr prior	1.90	2.40	2.31	2.10	1.23	1.52	1.46	1
OP visits 1yr prior	7.27	6.94	9.65	8.23	5.65	5.63	7.39	6
OP visits 2yr prior	4.30	4.10	5.92	5.08	3.39	3.38	4.54	3
OP visits missed 1yr prior	0.47	0.48	0.74	0.65	0.35	0.36	0.53	C
OP visits missed 2yr prior	0.49	0.48	0.74	0.61	0.33	0.30	0.48	C
GP visits 1yr prior	42.9	42.7	43.3	52.5	38.5	38.4	38.8	4
GP visits 2yr prior	35.5	35.2	35.7	42.5	32.4	32.1	32.5	3
Any high risk BNFs	73.9%	71.6%	72.2%	84.0%	69.3%	67.5%	68.1%	79
Num high risk BNFs	1.94	1.85	1.88	2.20	1.64	1.59	1.61	1
High blood pressure	9.0%	9.0%	9.0%	9.0%	1.04	1.59	1.01	9
Smoker	9.0%	9.0% 19.0%	9.0% 19.0%			16.0%	10.0%	9 20
Smoker BMI 30+				23.0%	16.0% 15.0%			
	16.0%	17.0%	17.0%	17.0%	15.0%	16.0%	16.0%	18
HbA1c > 10	5.0%	5.0%	5.0%	7.0%	5.0%	5.0%	4.0%	6
Any Em adm next 12 mos	52.9%	53.1%	52.3%	53.8%	42.1%	42.2%	41.9%	41
Num Em adm next 12 mos	1.34	1.33	1.29	1.31	0.89	0.89	0.87	0
0 Em adm next 12 mos	47.1%	46.9%	47.7%	46.2%	57.9%	57.8%	58.1%	58
1 Em adm next 12 mos	23.0%	23.0%	23.2%	23.9%	21.7%	21.9%	21.7%	22
2 Em adm next 12 mos	12.5%	12.5%	12.3%	13.2%	10.0%	10.0%	10.0%	9
3 Em adm next 12 mos	7.3%	7.3%	7.0%	7.1%	4.8%	4.9%	4.8%	4
4+ Em adm next 12 mos	10.2%	10.2%	9.8%	9.7%	5.5%	5.5%	5.3%	4
Emerg adm cost next 12 mos	£2,358	£2,266	£2,199	£2,270	£1,608	£1,575	£1,546	£1,5

AE visits next 12 mos	1.88	2.11	2.04	2.04	1.24	1.37	1.36	1.29

Table 3 Proportion of patients correctly identified, who had no emergency admissions in the prior two

 years. Four models:
 IP, IPAE, IPAEOP, IPAEOPGP. Five site individual runs combined.

Prediction threshold	IP Data	IPAE Data	IPAEOP Data	IPAEOPGP Data
Risk Score 50+	0.3%	1.2%	2.3%	3.2%
Risk Score 30+	2.7%	4.4%	6.3%	12.4%
Top 1%	1.5%	2.9%	4.2%	6.5%
Тор 5%	25.9%	26.4%	26.7%	30.8%

Individual Site and 'Four-Site Regression' Model Results

Overall the performance of the models was similar at the individual site level. Only modest differences were found in PPV levels and sensitivity across the sites. For runs using non-GP data only (IPAEOP), at the risk score threshold of 50, PPVs ranged from .512 to .552 and sensitivity ranged from .047 to .071. For the model including GP EMRs, PPVs ranged from .521 to .566 and sensitivity from .053 to .073. See Appendix A. There was some variation in the magnitude of regression coefficients between sites, but in general the coefficients were comparable for models based on the non-GP data model (IPAEOP). See Appendix B. For the model including variables from GP EMRs (IPAEOPGP), the level of variation in regression coefficients (size and direction) was somewhat greater for those variables derived from GP data. We observed substantial differences in frequency of reporting of Read codes across sites which no doubt contributed to this variation. The level of significance of individual variables also varied across sites (Appendix C), but most variables were consistently strongly significant across all sites, especially variables involving prior emergency inpatient admissions. Again, higher levels of variation in levels of significance were observed for the GP variables derived from Read codes.

We compared the results for these individual site models to a pooled model combining data from four of the sites and applied coefficients to the remaining individual site. We found generally only small differences in predictive accuracy (PPV) between these two approaches (Table 4), however the individual site models identified a greater number of true positives. For example, in Cornwall at a risk

score cutoff of 50, the individual site model using hospital data identified correctly 1,041 patients while the pooled model identified only 754. In Newham however, the four-site model was more powerful, correctly identifying 858 patients compared to 734 for the individual site approach. In both cases (and in general across all sites), the model identifying larger numbers of true positives had a somewhat lower PPV, suggesting improved case finding volume came at the expense of predictive accuracy.

		IPO	PAE		IPOPAEGP						
	Individual Site Regression		Four Site Regression		Individu Regres		Four Site Regression				
	True Positives	PPV	True Positives	PPV	True Positives	PPV	True Positives	PPV			
Newham											
Risk Score 50+	734	0.552	858	0.517	768	0.566	835	0.523			
Risk Score 30+	1,409	0.450	1,564	0.414	1,570	0.439	1,798	0.409			
Cornwall											
Risk Score 50+	1,041	0.520	754	0.548	1,176	0.545	952	0.556			
Risk Score 30+	2,439	0.406	1,970	0.426	3,032	0.410	2,746	0.411			
Kent											
Risk Score 50+	1,565	0.513	1,387	0.519	1,736	0.521	1,873	0.493			
Risk Score 30+	3,372	0.401	3,067	0.403	4,079	0.397	4,432	0.369			
Croydon											
Risk Score 50+	1,089	0.528	1,192	0.523	1,182	0.550	1,230	0.537			
Risk Score 30+	2,134	0.444	2,258	0.424	2,610	0.442	2,502	0.437			
Redbridge											
Risk Score 50+	743	0.512	863	0.495	807	0.522	607	0.519			
Risk Score 30+	1,656	0.420	1,693	0.415	1,905	0.423	1,390	0.436			

Testing alternative population denominators

Models built using inpatient data only (IP) were also built for just the subset of patients who had some inpatient care in the prior two years (to reflect typical predictive modeling efforts that may have been conducted without access to GP registry information), as well as for the group who had had an emergency admission in the prior year (to replicate analyses conducted by PARR users).

Combining the results from the five sites at a risk score threshold of 50, models using GP list denominator correctly identified 4,627 patients compared with 3,572 patients in runs restricted to patients with prior inpatient care and 3,060 to runs limited to patients with an emergency admission in the prior year. This substantial increase in case finding was obtained with only moderate loss in PPV (.529 GP list, .559 prior inpatient and .589 emergency admissions in last year). Similar results were also found for all hospital data models (IPOPAE, though with any hospital use in prior two years, rather than just any inpatient use).

Using the full GP registry population did not result in finding substantial numbers of patients with no emergency admissions in the prior two years, but the increased numbers of patients identified included more patients with less prior use and lower levels of morbidity. For a profile of patients identified using these alternative denominators see http://www.nuffieldtrust.org.uk/.

DISCUSSION

This analysis has looked at the performance of new variants of predictive models for case finding. These models are intended to update and improve upon the established combined predictive model-like [14] and PARR models [5] widely used in the NHS.

Each of the models examined produced reasonably robust performance. At a risk threshold of 50, patients identified by the models had PPVs ranging from .523 to .538. While the percent of all patients with future admissions identified was relatively low (sensitivity .049 to .060), lowering the risk threshold allows the identification of more patients with relatively small loss in PPV (e.g. at a risk threshold of 30, the full model identified 14% of future admissions with a PPV of .417). Users of predictive modeling algorithms have obvious trade-offs between maximizing the number of patients identified and predictive accuracy. Lower risk score thresholds will find more patients, but these patients are increasingly less likely to have future admissions.

The implications for intervention design are important. Patients at lower risk thresholds have less prior inpatient use and lower morbidity, so an intervention here might be calibrated to be less intensive. But because the models are less accurate at lower risk scores, the amount that can be spent on an intervention is also reduced if you wish to achieve financial break-even (ie where the cost of intervention is off-set by cost savings from reduction in future admissions). As documented in Table 2, at a risk score threshold of 50, the rate of future admission for patients identified by the full model

BMJ Open

(IPAEOPGP data) was 1.31 admissions per year with an associated cost of £2,270. If there were a 10% reduction in future admissions, £227 could be spent on an intervention to improve care coordination and still achieve break-even. However, at a lower risk threshold of 30, the lower rates of future admissions and costs means that lower intervention expenditures are required to achieve break-even (£151 with a 10% reduction in future admissions). A detailed business case analysis with mean emergency inpatient costs in the next 12 months within each risk vigintile level is available via http://www.nuffieldtrust.org.uk/.

These data also provide other information that may be useful in the development of intervention strategies. As shown in Table 2, patients identified by the models have extremely high rates of chronic disease (85-90% with long term conditions at risk threshold of 50), often with multiple long term conditions and high Charlson Comorbidity Index levels, indicating serious medical needs. However, these patients already have high use of outpatient care and very high GP visit rates. This suggests simple access to ambulatory care is not the issue, but prevention needs to look at care coordination and management of complex problems and at the ability of patients and their families to manage chronic illness. High risk patients identified by the models also have relatively high rates of mental illness (27-32% at risk threshold of 50) and moderate levels of alcohol abuse, factors that are likely to complicate any intervention strategy.

It is also important to note the limitations of these data in helping frame the design of any intervention strategy. Other studies have documented that high risk patients often have important characteristics related to care needs and patient capacity not captured by administrative data and EMRs. For example, interviews with high risk patients and their families have documented high levels of social isolation for many, as well as precarious housing status.[15] These non-medical factors are likely to have significant impact on health status and utilization patterns. Moreover, not much is known about how/whether care coordination and management has actually failed for these patients. Are these high risk patients just very sick patients whose hospitalizations are largely not preventable/avoidable, or has the care delivery system failed in some important dimensions that can be corrected with improved care coordination and management? These data cannot answer this very critical question, and it is clear that the field would benefit from further study that examined the circumstances of patients identified as high risk by predictive modeling algorithms to sort out more clearly the factors contributing to high rates of emergency admission.

This study does document the value of incorporating data sets beyond inpatient records. The addition of A&E and outpatient records resulted in identification of more high risk patients with little or no loss of predictive accuracy. These data sets are readily available and have standardized reporting formats that facilitate analysis. While the absence of useful diagnostic information in these data sets is a limiting factor, the improvement in case finding and usefulness in descriptive profiling of high risk patients to help in intervention design (e.g. high rates of A&E use rates, high rates of missed outpatient appointments) suggests their inclusion is clearly merited.

Use of GP EMRs presents significant challenges. While the lack of access to these data is unlikely to remain a problem, the variation in completeness and quality of data is problematic. The use of the unwieldy Read codes system makes analysis difficult, and we observed significant differences across sites in reporting patterns. However, the potential improvement in case finding, especially among patients with lower rates of utilization in the pre-period, suggests these barriers are worth confronting. Our development of new variables beyond those included in prior predictive modeling efforts [8] contributed substantially to enhanced case finding, and further work on variable development is likely to lead to further improvements. Again, these data are also useful in providing descriptive information on high risk patients to help in intervention design (e.g. documenting potential targets of opportunity such as uncontrolled hypertension or diabetes).

This study does not provide definitive findings on the value of developing individual site models compared to simply applying coefficients from multi-site or national model coefficients to local data. Our four-site regression models generally had comparable PPVs to individual site models, but for the majority of sites (but not all) the four-site regression approach correctly identified somewhat fewer number patients with future admissions. Our analysis is somewhat limited by the small number of sites involved which might cause somewhat greater variability in regression coefficients (regression coefficients for each of the five four-site models are available at http://www.nuffieldtrust.org.uk/). Development of a national model using SUS data only is planned to further assess the need/value of locally developed models.

Finally, it is worthy of note that use of the GP registry data for the denominator also proved to be of significant importance. Many prior predictive modeling efforts have been limited to patients with utilization history in whatever data sets were included. By including all patients in an area, not just those with prior use, the impact on predictive modeling of prior use was apparently enhanced. As a

result, patients with more moderate levels of prior use and morbidity were found to be of higher risk than patients with no prior use at all, and were often assigned higher risk scores than when the analysis included just patients who had prior use. Accordingly, the use of the GP registry as the denominator can improve rates of case finding and may permit identification of patients at earlier stages.

Acknowledgments

The authors wish to thank all individuals in the PCTs who contributed data used for this study during the Whole Systems Demonstrator, Virtual Wards and Social care end of life studies.

Contributors

The preparation of data sets and input variables and costs were undertaken by TG and by IB; JB did the central modelling. MB advised on the analysis and results and managed the work of the research team at the Nuffield Trust. All authors contributed to the writing of the paper. JB is the guarantor.

Funding and disclaimer

The research received no specific grant but was funded by the Nuffield Trust. The resulting models will be used as part of the WSD trial funded by the Department of Health.

Competing interests

All authors have completed the Unified Competing Interest form at <u>www.icmje.org/coi_disclosure.pdf</u> and declare that no authors have any relationships with any companies that might have an interest in the submitted work in the previous 3 years; none of their spouses, partners or children have any financial relationships that may be relevant to the submitted work; and no authors have any non-financial interests that may be relevant to the submitted work.

Ethical approval

This study only involved the analysis of pseudonymous secondary data. Since there were no identifiable human subjects, ethics approval was not required for this research and informed consent was not sought.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

Details of the derived models variables and definitions are available from the authors at the Nuffield trust at research@nuffieldtrust.org.uk.

References

1 Section 3025 of the Affordable Care Act added section 1886(q) to the Social Security Act establishing the Hospital Readmissions Reduction Program, which requires the Center for Medicare and Medicaid Services to reduce Medicare payments to hospitals with excess rates of readmissions for selected conditions within 30 days of discharge.

2 Department of Health. Payment by Results Guidance for 2012-13. 2012. Gateway reference 17250 London: Department of Health

3 Kansagara D, Englander H, Salanitro A, Kagen D, Theobald C, Freeman M, Kripalani S Risk prediction models for hospital readmission: A systematic review. JAMA 2011;306(15):1688-1698

4 Billings J, Mijanovich T. Improving the Management of Care for High Cost Medicaid Patients. Health Affairs. 2007;26(6):1643-1655.

5 Billings J, Dixon J, Wennberg D, et al. Case Finding for Patients at Risk of Re-Hospitalisation: Development of an Algorithm to Identify High Risk Patients. BMJ 2006;333(7563):327-32,

6 Case Finding Algorithms for Patients at Risk of Re-hospitalisation: PARR1 and PARR 2. Kings Fund, February, 2006 (http://www.kingsfund.org.uk/sites/files/kf/field/field_document/PARR-case-finding-algorithms-feb06.pdf - last accessed 04/06/2013).

7 Lewis G, Curry N and Bardsley M Choosing a predictive risk model: a guide for commissioners in England

8 Combined Predictive Model: Final Report. Kings Fund, Dec 2006. (http://www.kingsfund.org.uk/sites/files/kf/field/field_document/PARR-combined-predictive-model-final-reportdec06.pdf last accessed 04/06/2013),

9 Wales Predictive Model: Final Report and Technical Documentation, 2008 (http://www.nliah.com/portal/microsites/Uploads/Resources/k5cma8PPy.pdf last accessed 04/06/2013).

10 http://systems.hscic.gov.uk/data/uktc/readcodes - last accessed 14/05/2013

11 http://www.connectingforhealth.nhs.uk/systemsandservices/sus - last accessed 14/1/2013.

12 Charlson ME, Popei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Disease. 1987;40:373-383.

13 Dixon J, Smith P, Gravelle H, Martin S, Bardsley M, Rice H, Georghiou T, Dusheiko M, Billings J, De Lorenzo M. I. A person based formula for allocating commissioning funds to general practices in England: development of a statistical model BMJ 2011;343:d6608 doi: 10.1136/bmj.d6608 Published 22 November 2011.

14 Chenore T, Pereira Gray DJ, Forrer J, Wright C., Evans PH, Emergency hospital admissions for the elderly: insights from the Devon Predictive Model J Public Health (2013)

15 Raven M, Billings J, Goldfrank L, Manheimer E, Gourevitch M. Medicaid Patients at High Risk for Frequent Hospital Admission: Real-time Identification and Remedial Risks. Journal of Urban Health. 2009;86(2):230-241.

Appendix A. PPV and sensitivity IPAEOP and IPAEOPGP models. Individual site runs.

					IP+AE+	OP Data				
Risk Score	Nev	Newham		Cornwall		nt	Croy	don	Redbridge	
Threshold	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity
1	0.049	1.000	0.061	1.000	0.052	1.000	0.046	1.000	0.047	1.00
10	0.236	0.361	0.216	0.391	0.213	0.339	0.241	0.378	0.238	0.42
20	0.368	0.201	0.328	0.188	0.326	0.158	0.377	0.210	0.357	0.23
30	0.450	0.136	0.406	0.109	0.401	0.094	0.444	0.142	0.420	0.14
40	0.506	0.098	0.477	0.072	0.457	0.062	0.486	0.100	0.475	0.09
50	0.552	0.071	0.520	0.047	0.513	0.043	0.528	0.073	0.512	0.06
60	0.585	0.052	0.560	0.030	0.569	0.031	0.580	0.055	0.532	0.04
70	0.632	0.037	0.622	0.021	0.618	0.022	0.610	0.040	0.555	0.02
80	0.678	0.024	0.655	0.013	0.673	0.014	0.659	0.028	0.571	0.02
90	0.717	0.013	0.692	0.007	0.724	0.008	0.710	0.016	0.617	0.00
Top 1%	0.501	0.102	0.470	0.077	0.417	0.080	0.482	0.106	0.474	0.1
Top 5%	0.287	0.291	0.292	0.240	0.259	0.249	0.290	0.318	0.296	0.3

					IP+AE+O	P+GP Data				
Risk Score	Newham		Corn	Cornwall		nt	Croy	don	Redbridge	
Threshold	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity
1	0.049	1.000	0.061	1.000	0.052	1.000	0.046	1.000	0.047	1.000
10	0.228	0.410	0.213	0.439	0.210	0.392	0.237	0.452	0.237	0.457
20	0.360	0.235	0.323	0.232	0.314	0.194	0.358	0.267	0.348	0.272
30	0.439	0.152	0.410	0.136	0.397	0.113	0.442	0.174	0.423	0.172
40	0.499	0.103	0.481	0.084	0.459	0.072	0.494	0.114	0.482	0.113
50	0.566	0.074	0.545	0.053	0.521	0.048	0.550	0.079	0.522	0.073
60	0.606	0.052	0.602	0.033	0.580	0.032	0.589	0.052	0.563	0.047
70	0.657	0.036	0.659	0.021	0.644	0.021	0.643	0.035	0.616	0.030
80	0.723	0.021	0.714	0.013	0.694	0.013	0.694	0.021	0.651	0.018
90	0.766	0.012	0.745	0.006	0.752	0.007	0.735	0.011	0.655	0.007
Top 1%	0.504	0.102	0.490	0.081	0.438	0.084	0.502	0.110	0.487	0.104
Top 5%	0.296	0.300	0.309	0.254	0.272	0.262	0.307	0.337	0.312	0.333

Appendix B Regression coefficients. IPAEOP and IPAEOPGP models. Individual site runs.

				+AE+OP D					E+OP+GP [
		NH	CW	КТ	CR	RB	NH	CW	КТ	CR	RB
		0.015	0.000	0.000	0.040	0.010	0.004	0.004	0.000	0.001	0.0
Age		0.015	0.003	0.009	0.010	0.019	0.001	-0.004	0.002	0.001	0.0
Age 65-74		0.280	0.409	0.295	0.380	0.261	0.236	0.276	0.203	0.244	0.2
Age 75-84		0.738	0.905	0.731	0.847	0.734	0.721	0.672	0.605	0.708	0.7
Age 85+		1.076	1.483	1.226	1.178	1.109	1.150	1.206	1.086	1.187	1.2
Female		0.239	0.002	0.044	0.178	0.058	0.114	-0.095	-0.075	-0.014	-0.0
Practice I	٨D	0.013	0.003	0.016	0.018	0.012	0.008	0.004	0.017	0.010	0.0
Months r	egistered 1 yr prior	0.014	-0.011	-0.005	-0.018	-0.013	0.011	-0.011	-0.003	-0.010	-0.
Months r	egistered 2 yrs prior	0.022	-0.019	-0.016	-0.007	-0.023	-0.021	-0.024	-0.019	-0.011	-0.
	prior 0-90 days	0.382	0.471	0.321	0.310	0.282	0.367	0.420	0.283	0.269	0.
	prior 0-90 days	0.045	0.216	0.155	0.153	0.148	0.033	0.159	0.074	0.097	0.
	der prior 0-90 days	0.115	0.027	0.001	0.041	0.073	0.135	0.026	0.010	0.042	0.
-	ase prior 0-90 days	0.094	0.234	0.110	0.111	0.251	0.037	0.173	0.039	-0.019	0.
	prior 91-180 days	0.215	0.310	0.351	0.282	0.185	0.217	0.262	0.297	0.243	0.
	prior 91-180 days	0.3213	0.150	0.062	0.202	0.081	0.283	0.128	0.027	0.243	0.
	prior 181-365 days	0.113	0.345	0.350	0.248	0.146	0.124	0.289	0.292	0.227	0.
	prior 181-365 days	0.097	0.120	0.104	0.118	0.170	0.072	0.079	0.060	0.035	0.
	2 yrs prior	0.102	0.269	0.307	0.181	0.143	0.116	0.216	0.250	0.178	0.
Any day c	ase 2 yrs prior	0.096	0.157	0.186	0.151	0.179	0.058	0.092	0.112	0.005	0
DX MI		0.108	0.097	-0.105	-0.004	0.376	-0.197	-0.003	-0.163	-0.111	0.
		-	-0.070	-0.246	-0.069	-0.337	-0.370	-0.178	-0.269	-0.110	-0.
DX CHF		0.348									
DX CVD		0.296	0.227	0.033	0.037	-0.040	0.269	0.166	-0.001	-0.099	-0
CD CTD		0.030	-0.024	0.101	-0.380	-0.029	0.071	-0.192	-0.010	-0.427	-0
DX PVD		0.245	0.124	0.099	-0.100	0.021	-0.253	0.048	0.026	-0.096	0.
DX Asthm	а	0.082	0.143	0.184	0.099	0.192	-0.114	-0.107	-0.023	-0.081	0.
DX COPD	-	0.204	0.251	0.277	0.193	0.123	-0.169	-0.139	-0.036	-0.330	-0
DX Diabet	95	0.240	0.303	0.285	0.253	0.276	-0.046	-0.052	-0.016	-0.124	0
	es with complications	0.059	-0.221	0.062	-0.014	0.334	0.040	-0.176	0.095	0.004	0
DX Renal		0.408	0.022	0.085	0.128	0.199	0.356	0.005	0.073	0.063	0.
	JISEdSE	0.408									
DX Cance		0.165	-0.019	-0.062	-0.308	0.041	0.041	0.098	-0.010	-0.207	0
DX Menta	I	0.498	0.316	0.363	0.484	0.077	0.340	0.131	0.111	0.266	-0
DX Alcoho		0.569	0.684	0.578	0.673	0.974	0.281	0.530	0.357	0.409	0
DX Deme	ntia	- 0.548	-0.589	-0.551	-0.402	-0.596	-0.530	-0.486	-0.440	-0.669	-0
		-	0.016	0.025	0.110	0.187	-0.075	0.046	0.031	0.088	0
0	ive Impairment	0.117									
DX ACS C		0.364	0.270	0.239	0.267	0.306	0.269	0.161	0.134	0.114	0
Charlson		0.055	0.063	0.060	0.101	0.025	0.048	0.062	0.037	0.086	0
	rior 0-90 days	0.236	0.267	0.355	0.309	0.359	0.179	0.230	0.265	0.199	0
	ned follow-up visits prior	-	-0.583	-0.533	-0.874	-0.383	-0.107	-0.566	-0.452	-0.703	-0
0-90 days		0.094	5.505	0.000	0.074	0.000	0.107	5.500	5.752	5.705	-0
AE X-ray	prior 0-90 days	0.348	0.437	0.058	0.104	0.367	0.303	0.382	0.027	0.040	0
AE visits p	rior 91-180 days	0.265	0.262	0.220	0.225	0.277	0.197	0.225	0.165	0.142	0
	ned follow-up visits prior	-	-0.560	-0.229	-0.296	-0.298	-0.026	-0.543	-0.177	-0.225	-0
91-180 da		0.023									
	prior 91-180 days	0.227	0.117	0.120	0.346	-0.064	0.210	0.015	0.101	0.237	0
	prior 181-365 days	0.264	0.205	0.135	0.171	0.181	0.216	0.174	0.090	0.115	0
AE unplar 181-365 d	ned follow-up visits prior	- 0.251	-0.490	-0.184	-0.261	-0.203	-0.214	-0.449	-0.131	-0.175	-0
	ays prior 181-365 days	0.251	-0.040	0.281	0.324	0.110	0.225	0.085	0.251	0.244	0
AE visits 2	yrs prior Ined follow-up visits 2 yrs	0.211	0.159	0.154	0.140	0.160	0.170	0.138	0.114	0.077	0
	neu ionow-up visits 2 yrs		-0.352	-0.239	-0.433	-0.339	-0.228	-0.317	-0.178	-0.262	-0
prior	hure prior	0.307	0.334	0 100	0 1 2 0	0 170	0.000	0.200	0.000	0.000	
AE X-ray 2		0.083	0.231	0.100	0.128	0.179	0.063	0.390	0.082	0.069	0
Outpatier 90 days	t specialty visits prior 0-	0.046	0.055	0.091	0.061	0.059	0.025	0.033	0.047	0.030	0
an agaz	a ana atalah sutati sustan sut										
Out-t	t specialty visits missed	0.155	0.182	0.250		0.146	0.108	0.118	0.171		0
prior 0-90											
prior 0-90 Outpatier	days t specialty visits prior 91-	0.030	0.013	0.023	0.034	0.029	0.007	0.003	-0.004	0.015	0
prior 0-90 Outpatier 180 days	t specialty visits prior 91-				0.034					0.015	
prior 0-90 Outpatier 180 days		0.030 0.113	0.013 0.239	0.023 0.168	0.034	0.029 0.193	0.007 0.087	0.003 0.184	-0.004 0.113	0.015	0. 0.
prior 0-90 Outpatier 180 days	t specialty visits prior 91-				0.034					0.015	

			E	BMJ Op	en					Pa
prior 91-180 days										
Outpatient specialty visits prior 181-365 days	0.016	0.010	-0.005	0.019	0.031	-0.003	0.001	-0.024	0.003	0.018
Outpatient specialty visits missed prior 181-365 days	0.128	0.164	0.075		0.140	0.086	0.095	0.036		0.122
Outpatient specialty visits 2 yrs prior	0.019	0.030	0.014	0.028	0.019	0.008	0.014	-0.009	0.011	0.021
Outpatient specialty visits missed 2 yrs prior	0.142	0.162	0.140	0.190	0.082	0.097	0.090	0.085	0.129	0.057
GP DX COPD GP - 1 long term condition						0.218 0.131	0.174 0.025	0.112 0.017	0.287 0.106	0.295 0.192
GP - 2 or more long term conditions						0.166	0.109	0.038	0.070	0.182
GP - Glomerular filtration rate group 3 last 0-365 days						-0.075	0.092	-0.017		0.050
GP - 10+ unique drugs prescribed						0.342	0.570	0.166	2.741	1.949
GP - 5-9 unique drugs prescribed						0.424	0.444	0.164	2.804	1.953
GP - 0-4 unique drugs prescribed GP - Psychoactive substance						0.328	0.254	0.114	2.559	1.809
misuse disorder						0.388	0.323	0.583	0.431	0.810
GP - 7+ distinct disorders						-0.049	0.057	0.017	-0.163	-0.062
GP - GP visits prior 0-3 months						-0.001	0.008	0.022	0.021	0.042
GP - GP visits prior 4-6 months						0.015	0.004	0.012	0.009	0.019
GP - GP visits prior 7-12 months						0.005	0.003	0.007	0.000	0.008
GP - GP visits 2yrs prior						0.000	0.002	0.004	0.006	0.002
GP - Increasing rate of GP visits during last 12 months						0.184	0.087	0.126	0.207	0.094
GP - Number of high risk BNFs						0.063	0.006	-0.036	-0.026	-0.075
GP - Any high risk						0.219	0.202	0.241	0.324	0.249
GP - Count of BNF chapters						0.066	0.053	0.059	0.066	-0.024
GP - DX Dementia						0.421	0.266	0.296	0.471	0.437
GP - Exception reported from quality indicators						0.157	0.108	0.111	0.118	0.132
GP - Health visitor or district nurse visit						0.278	0.244	0.199	0.168	0.184
GP - Record of IHD/angina						0.069	-0.048	0.110	-0.062	0.081
GP - Nebuliser used						0.113	0.315	0.207	0.191	0.448
GP - Salbutamol prescribed						0.021	0.017	0.074	0.000	-0.011
GP - Warfarin prescribed						-0.041	0.031	-0.026	-0.100	-0.244
GP - High blood pressure						-0.040	-0.001	-0.013	-0.048	-0.087
GP - Smoker						0.298	0.231	0.248	0.240	0.220
GP - BMI 30+						0.050	0.002	0.085	0.046	0.199
GP - HbA1c > 10						0.236	0.270	0.210	0.362	0.354
GD - QOF ARTF						0.176	0.064	0.095	-0.047	0.143
GP - QOF CKD						0.206	-0.003	-0.037	0.091	0.210
GP - QOF Depression GP - Number of QOF DX categories						0.069	0.248 -0.023	0.183 -0.072	0.133 -0.135	0.186 -0.009
3+ GP - Number of phone contacts last						-0.004	0.046	0.004	-0.005	-0.004
0-3 months	-	2 2 6 2	2 007	4.262	4.260					
	4.665	-3.262	-3.987	-4.363	-4.368	-4.381	-3.275	-4.069	-6.497	-5.939
Constant										

Appendix C Regression significance levels. IPAEOP and IPAEOPGP models. Individual site runs.

			P+AE+C					E+OP+GI		
	NH	CW	KT	CR	RB	NH	CW	KT	CR	R
A go	0.000	0.000	0.000	0.000	0.000	0.344	0.000	0.001	0.158	0.0
Age Age 65-74	0.000	0.000	0.000	0.000	0.000	0.344	0.000	0.001	0.138	0.0
Age 75-84	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.0
Age 85+	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.0
Female	0.007	0.897	0.000	0.000	0.125	0.000	0.000	0.000	0.000	0.0
Practice IMD	0.007	0.036	0.000	0.001	0.125	0.000	0.000	0.000	0.000	0.0
Months registered 1 yr prior	0.008	0.006	0.000	0.000	0.000	0.015	0.010	0.387	0.000	0.0
	0.002		0.085	0.247		0.009	0.001	0.387		0.2
Months registered 2 yrs prior		0.014			0.276				0.211	
EM Adms prior 0-90 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.0
EL Adms prior 0-90 days	0.664	0.000	0.000	0.029	0.081	0.714	0.000	0.070	0.102	0.3
Any attender prior 0-90 days	0.002	0.000	0.955	0.006	0.004	0.001	0.000	0.489	0.005	0.0
Any day case prior 0-90 days	0.769	0.000	0.001	0.682	0.001	0.561	0.000	0.233	0.699	0.0
EM Adms prior 91-180 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.0
EL Adms prior 91-180 days	0.000	0.000	0.068	0.022	0.528	0.000	0.001	0.437	0.016	0.0
EM Adms prior 181-365 days	0.000	0.000	0.000	0.000	0.000	0.001	0.000	0.000	0.000	0.0
EL Adms prior 181-365 days	0.548	0.000	0.000	0.757	0.019	0.167	0.009	0.030	0.372	0.0
Em Adms 2 yrs prior	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.
Any day case 2 yrs prior	0.877	0.000	0.000	0.536	0.035	0.177	0.000	0.000	0.864	0.
DX MI	0.366	0.134	0.049	0.611	0.000	0.076	0.966	0.002	0.216	0.0
DX CHF	0.024	0.253	0.000	0.448	0.008	0.001	0.005	0.000	0.194	0.
DX CVD	0.015	0.000	0.446	0.610	0.571	0.013	0.002	0.977	0.179	0.
CD CTD	0.263	0.756	0.150	0.010	0.759	0.645	0.002	0.891	0.000	0.
DX PVD	0.230	0.061	0.097	0.567	0.665	0.079	0.462	0.661	0.000	0.
DX Asthma	0.250	0.001	0.000		0.005	0.135	0.024	0.580	0.270	0.
				0.241						
DX COPD	0.005	0.000	0.000	0.009	0.098	0.098	0.021	0.483	0.002	0.
DX Diabetes	0.000	0.000	0.000	0.000	0.000	0.444	0.227	0.649	0.016	0.
DX Diabetes with complications	0.478	0.025	0.540	0.363	0.013	0.674	0.073	0.347	0.973	0.
DX Renal Disease	0.000	0.731	0.142	0.068	0.025	0.001	0.942	0.208	0.405	0.
DX Cancer	0.753	0.751	0.271	0.001	0.421	0.727	0.104	0.862	0.009	0.
DX Mental	0.000	0.000	0.000	0.000	0.370	0.000	0.005	0.008	0.000	0.
DX Alcohol	0.000	0.000	0.000	0.000	0.000	0.029	0.000	0.000	0.000	0.
DX Dementia	0.005	0.000	0.000	0.000	0.000	0.004	0.000	0.000	0.000	0.
DX Cognitive Impairment	0.430	0.804	0.620	0.191	0.026	0.456	0.474	0.534	0.199	0.
DX ACS Condition	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.001	0.
Charlson Index	0.012	0.000	0.000	0.000	0.212	0.042	0.000	0.006	0.000	0.
AE visits prior 0-90 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.
AE unplanned follow-up visits prior	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.
0-90 days	0.895	0.001	0.000	0.000	0.133	0.654	0.001	0.000	0.000	0.
5										
AE X-ray prior 0-90 days	0.002	0.000	0.301	0.374	0.052	0.004	0.002	0.636	0.662	0.
AE visits prior 91-180 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.
AE unplanned follow-up visits prior										
91-180 days	0.836	0.000	0.000	0.149	0.130	0.899	0.000	0.005	0.214	0.
AE X-ray prior 91-180 days	0.070	0.582	0.045	0.002	0.672	0.062	0.946	0.090	0.009	0.
AE visits prior 181-365 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.
AE unplanned follow-up visits prior										
181-365 days	0.182	0.000	0.001	0.122	0.124	0.098	0.001	0.013	0.127	0.
AE X-ray prior 181-365 days	0.000	0.936	0.000	0.000	0.461	0.001	0.866	0.000	0.000	0.
AE visits 2 yrs prior	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.
AE unplanned follow-up visits 2 yrs						0.000				۰.
prior	0.021	0.008	0.000	0.003	0.009	0.020	0.016	0.000	0.008	0.
AE X-ray 2yrs prior	0.183	0.555	0.000	0.003	0.009	0.020	0.320	0.048	0.008	0.
Outpatient specialty visits prior 0-	0.103	0.555	0.019	0.022	0.005	0.210	0.520	0.040	0.101	0.
	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	^
90 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.
Outpatient specialty visits missed	0.000	0.000	0.000		0.000		0.000	0.000		~
prior 0-90 days	0.000	0.000	0.000		0.002	0.000	0.000	0.000		0.
Outpatient specialty visits prior 91-										
180 days	0.196	0.043	0.003	0.002	0.016	0.516	0.630	0.648	0.054	0.
Outpatient specialty visits missed										
prior 91-180 days	0.027	0.000	0.000		0.000	0.039	0.000	0.002		0
Outpatient specialty visits prior										
181-365 days	0.763	0.009	0.400	0.094	0.000	0.595	0.844	0.000	0.491	0.
Outpatient specialty visits missed	0.705	0.007	0.400	0.077	0.000	0.575	0.011	0.000	0.471	0.
	0.000	0.000	0.009		0.000	0.001	0.002	0.206		0.
prior 181-365 days	0.000	0.000	0.009		0.000	0.001	0.002	0.200		U.
Outpatient specialty visits 2 yrs	0.000	0.000	0.000	0.000	0.000		0.000	0.0.1.	0.001	~
prior	0.000	0.000	0.000	0.000	0.000	0.068	0.000	0.046	0.001	0.
Outpatient specialty visits missed 2										
yrs prior	0.000	0.000	0.000	0.000	0.001	0.000	0.006	0.000	0.000	0.
GP DX COPD						0.002	0.000	0.001	0.000	0.

CD 1 long term condition						0.000	0.229	0.310	0.000	0.000
GP - 1 long term condition GP - 2 or more long term conditions						0.000		0.310	0.000	0.000
GP - 2 of more long term conditions GP - Glomerular filtration rate						0.001	0.000	0.100	0.098	0.000
group 3 last 0-365 days						0.097	0.002	0.463		0.162
						0.007		0.403	0.000	0.102
GP - 10+ unique drugs prescribed										
GP - 5-9 unique drugs prescribed						0.000		0.000	0.000	0.000
GP - 0-4 unique drugs prescribed						0.000	0.000	0.000	0.000	0.000
GP - Psychoactive substance						0.000		0.000	0 0 0 0	0.000
misuse disorder						0.000		0.000	0.000	0.000
GP - 7+ distinct disorders						0.311		0.523	0.002	0.263
GP visits prior 0-3 months						0.873		0.000	0.000	0.000
GP visits prior 4-6 months						0.000		0.000	0.008	0.000
GP visits prior 7-12 months						0.075		0.000	0.987	0.006
GP visits 2yrs prior						0.934	0.013	0.000	0.000	0.263
GP - Increasing rate of GP visits										
during last 12 months						0.000	0.001	0.000	0.000	0.010
GP - Number of high risk BNFs						0.009	0.691	0.004	0.216	0.002
GP - Any high risk						0.000	0.000	0.000	0.000	0.000
GP - Count of BNF chapters						0.000	0.000	0.000	0.000	0.000
GP - DX Dementia						0.000	0.000	0.000	0.000	0.000
GP - Exception reported from										
quality indicators						0.020	0.003	0.001	0.020	0.062
GP - Health visitor or district nurse										
visit						0.000	0.000	0.000	0.000	0.000
GP - Record of IHD/angina						0.355		0.006	0.202	0.288
GP - Nebuliser used						0.359		0.001	0.019	0.001
GP - Salbutamol prescribed						0.550		0.001	0.989	0.795
GP - Warfarin prescribed						0.643		0.440	0.106	0.001
GP - High blood pressure						0.269		0.549	0.725	0.325
GP - Smoker						0.209		0.000	0.723	0.323
GP - BMI 30+						0.000		0.000	0.000	0.000
GP - HbA1c > 10						0.000		0.000	0.000	0.000
GD - QOF ARTF						0.130		0.024	0.586	0.136
GP - QOF CKD						0.003		0.203	0.063	0.000
GP - QOF Depression						0.240	0.000	0.000	0.024	0.016
GP - Number of QOF DX										
categories 3+						0.974	0.717	0.123	0.342	0.948
GP - Number of phone contacts last										
0-3 months						0.927		0.600	0.788	0.899
Constant	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000

Page 25 of 26

NOTE: PLEASE SAVE THIS TO YOUR HARD DRIVE UNDER A DIFFERENT FILE NAME AFTER YOU FILL IT OUT **BMJ Open** STROBE Statement—checklist of items that should be included in reports of observational studies

Please fill out the page numbers on this form and upload the file as a supplemental file when you submit your revision

Manuscript Number_____

Indicate page number ↓ (Or n/a if not

	Item		applicab
	No	Recommendation	4
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	
Methods			
Study design	4	Present key elements of study design early in the paper	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data	
		collection	
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe	
		methods of follow-up	
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control	
		selection. Give the rationale for the choice of cases and controls	
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed	
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic	
variables	/	criteria, if applicable	
Data sources/	8*		
	0.	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe	
measurement	0	comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen	
		and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed	
		Case-control study—If applicable, explain how matching of cases and controls was addressed	
		Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study-eg numbers potentially eligible, examined for eligibility,	
		confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and	
		potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time	
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	
		Cross-sectional study-Report numbers of outcome events or summary measures	

Page	26	of	26
------	----	----	----

	1	BMJ Open	Page
		confidence interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses		17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion	-		
Key results	18	Summarise key results with reference to study objectives	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and	
		magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from sim	nilar
		studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	
Other informatio	n		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which	:h
		the present article is based	

BMJ Open

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.



Choosing a model to predict hospital admission. An observational study of new variants of predictive models for case finding.

Journal:	BMJ Open
Manuscript ID:	bmjopen-2013-003352.R1
Article Type:	Research
Date Submitted by the Author:	01-Aug-2013
Complete List of Authors:	Billings, John; New York University, Georghiou, Theo; Nuffield Trust, Research Blunt, Ian; Nuffield Trust, Research Bardsley, Martin; Nuffield Trust, Research
Primary Subject Heading :	Health services research
Secondary Subject Heading:	Health informatics, Health policy
Keywords:	Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT
	·

SCHOLARONE^{**} Manuscripts

1 2 3 4 5 6 7 8 9	Choosing a model to predict hospital admission. An observational study of new variants of predictive models for case finding.
10 11	
12	
13	John Billings, Associate Professor (1)
14 15	Theo Georghiou, Senior Research Analyst (2)
16	Ian Blunt, Senior Research Analyst (2)
17	Martin Bardsley, Director of Research (2)
18	
19	
20 21	
22	¹ Robert F. Wagner Graduate School of Public Service, New York University, 295 Lafayette Street, Room
23	3010, New York, NY 10012-9604, USA
24	² Nuffield Trust, 59 New Cavendish Street, London W1G 7LP, UK
25	
26	
27 28	Corresponding Author theo.georghiou@nuffieldtrust.org.uk
29	
30	
31	
32 33	
33 34	
35 36	Key words: Predictive Risk, Urgent care, Hospital admission
37	Predictive Risk, Urgent care, Hospital admission
38	
39 40	
41	
42	
43	Word count: 4,090
44	
45 46	
40 47	
48	
49	
50	
51 52	
52 53	
54	
55	

ABSTRACT

Objectives: To test the performance of new variants of models to identify people at risk of an emergency hospital admission. We compared (1) the impact of using alternative data sources (hospital inpatient, A&E, outpatient, and GP electronic medical records) (2) the effects of local calibration on the performance of the models and (3) the choice of population denominators.

Design: Multivariate logistic regressions using person level data adding each data set sequentially to test value of additional variables and denominators.

Setting: Five Primary Care Trusts within England.

Participants: 1,836,099 people aged 18-95 registered with GPs on 31 July 2009.

Main outcome measures: Models to predict hospital admission and readmission were compared in terms of positive predictive value and sensitivity for various risk strata and with receiver operating curve C statistic.

Results: The addition of each data set showed moderate improvement in number of patients identified with little or no loss of positive predictive value. However, even with inclusion of GP electronic medical record information, the algorithms identified only a small number of patients with no emergency hospital admissions in the prior two years. The model pooled across all sites performed almost as well as models calibrated to local data from just one site. Using population denominators from GP registers led to better case finding.

Conclusions: These models provide a basis for wider application in the NHS. Each of the models examined produce reasonably robust performance and offers some predictive value. The addition of more complex data add some value, but we were unable to conclude that pooled models performed less well than those in individual sites. Choices about model should be linked to the intervention design. Characteristics of patients identified by the algorithms provide useful information in the design/costing of intervention strategies to improve care coordination/outcomes for these patients.



Article focus

- The use of statistical models to predict risk of hospital admissions are increasingly used to prioritise patients for preventive care. Models exist in several different forms and use a variety of input data sets.
- This paper compared the performance of a variety of models built using different datasets.

Key messages

- The addition of more detailed data sets led to moderate improvement in number of patients identified with little or no loss of positive predictive value.
- The use of GP registry data for the denominator proved to be of significant importance. By including all patients in an area, not just those with prior hospital use, improved rates of case finding were observed.
- Models calibrated to local data sets did not show a consistent improvement over models built on pooled data.

Strengths and limitations of this study

- The analysis is based on populations from only five areas in England, however this is the largest UK population (1.8M people) used in the development of a publicly available risk tool.
- The success of a predictive model depends on many factors beyond the statistical performance of the model.

INTRODUCTION

There remains continuing interest in identifying patients at risk of future hospital admissions. Policies providing penalties[1] or non-payment[2] for hospital readmissions that put providers at risk for a share of total health expenditures have been developed for in the U.S. and in England. These create even stronger incentives to identify high risk patients to target care coordination and management strategies that may potentially reduce future inpatient expenditures.

Most predictive modelling approaches have used administrative data from claims in the U.S. or hospital data from Hospital Episode Statistics (HES) or Secondary Uses Services (SUS) in England. These data provide the information on prior utilisation and diagnostic history to develop predictive models for patients at risk of future hospitalization.[3] Payor claims data in the U.S. provide rich information on care provided in hospitals, home care services and nursing home use, as well as detailed pharmacy prescription history.[4] In England, the most commonly used models (such as in the now outdated Patient at Risk of Readmission PARR algorithm)[5,6] are based on hospital admissions data (including day case use, and regular attendances) with some use of accident and emergency (A&E) and outpatient attendance data as well.[7]

While some predictive modeling efforts in the U.K. have included information from GP electronic medical records (EMRs),[8,9] using such data presents a number of challenges. These include obtaining permissions for access to EMRs for large populations, linking the records to hospital data, and use of Read codes[10] to develop GP variables. Data from EMRs include additional elements not available in the hospital data sets such as test results (e.g. blood pressure, HbA1c levels), diagnostic history for patients without recent inpatient admissions, prescription history, GP contact patterns (GP visits and telephone contacts), and other personal health markers (e.g. body mass index, smoking status). These additional data elements have the potential to add power to predictive modeling efforts, especially for patients with no or lower levels of recent inpatient use.

Despite the challenges, a number of initiatives around the UK are demonstrating population wide access to EMR data. A common application is in the use of models that assist local clinical commissioning groups (CCGs) in identifying high risk patients.

BMJ Open

Though the choice of data sets for a predictive model makes a big difference to the investment required to run these models – at least initially – no studies have looked at the marginal value of different data sets. In this analysis we examine the added value of including data on A&E and outpatient visits (which are readily available) to predictive modeling efforts using hospital inpatient data alone. We also assess the marginal effect of adding GP EMR information to help identify patients at risk of future hospital admissions. Most existing models in use were developed using logistic regression techniques and we used this standard approach throughout this paper. We recognize that different modelling methods may yield different results but in this analysis we were concerned with the impact of changes in the underlying data sets. Such models will always be limited by the scope and quality of data available, the ways data are grouped and classified and the ways that users can assess up to date information. Despite these problems these models have become commonly used tools. In addition to the depth of data used there is also a question about how generalisable models are across different sites. In many settings models are recalibrated on local data sets. Yet there is little systematic analysis of the value that this step adds and whether models built on data from one site outperform those built on a larger sample of pooled data. We therefore explore whether there is a need for development of individual site predictive models, or whether models developed from multiple sites can be applied effectively at a new individual site.

METHODS

We conducted analyses separately for five Primary Care Trust areas in England (Newham, Cornwall, Kent, Croydon, Redbridge; total adult population ranging from 209,661 to 693,089). Results are reported for the individual sites and as combined/pooled results (total population 1,836,099). Hospital data was extracted from the Secondary Users Services (SUS)[11] system which contained records of all hospital events (inpatient admissions, outpatient appointments and A&E visits) for the PCTs' registered populations between 1 August 2007 and 30 September 2010. The PCTs also extracted data from GP systems in two forms. Firstly as a register of the local adult population from 1 August 2007 and 31 July 2009, and secondly in the form of datasets recording details of GP consultations over the same time period.

Personally identifiable information was stripped out before any data were passed to the research team. Individuals' NHS numbers (the personal identifiers) were concatenated with a passcode chosen by each of the five PCT areas (and unknown to the research team) and these were pseudonymised at source using secure hash algorithm SHA-256 [12]. This allowed for linkage between the hospital and the general practice data from each area, whilst preserving individuals' anonymity.

A series of variables were created from each data set that were believed to be potentially predictive of an unplanned (emergency) hospital admission in the last 12 months of the study period. These variables captured resource use, utilization patterns, diagnostic history, test results, and prescription history in the two years prior to the predictive period. They were created for all individuals aged 18+ registered with a GP in one of the five areas on 31 July 2009. To account for expected time required to obtain and process the hospital and GP EMR data, we included a two-month lag in our analyses, with data from 1 August 2007 to 31 July 2009 used to predict emergency admissions during the period 1 October 2009 to 30 September 2010.

Patient age and gender were obtained from the GP register. Patient area of residence was not available, and so GP practice attributed index of multiple deprivation (2007) was used as an area deprivation measure. The number of months the patient was registered with the PCT in the pre-period was calculated and included in the regression. Hospital inpatient data were used to capture utilization in the 0-90, 91-181, 180-365, and 366-730 days prior to the lag period. The number of emergency and elective admissions for these periods were included and dichotomous variables for any day case or regular attendance use were created.

BMJ Open

A broad range of diagnostic variables were developed using primary and secondary diagnosis fields and a Charlson Comorbidity Index[13] was calculated for each patient and included in the model.

A&E data were used to determine A&E visit rates for various intervals in the pre-period, both total visits and unplanned follow-up visits. A&E diagnostic information was not reliably reported across the five sites and was not included, although X-ray use was included. Outpatient data provided variables on outpatient visit rates for various intervals, as well as missed appointment rates and the number of different specialty types consulted. Diagnostic information in outpatient data was missing in more than 95% of cases and was not included.

GP EMR data were used to create proxy visit rates (these may include both actual GP visits, in addition to other events documented in a person's records) for various intervals and to capture any increase in visit rates at the end of the pre-period that may reflect increased morbidity in a patient. EMR Read codes (CTV3 version) were used to obtain test results (blood pressure, blood serum levels, HbA1c levels, etc.), body mass index, smoking history, prescription history (number and type), and a range of diagnostic variables during the pre-period.

Variables from each data set (inpatient (including day case and regular attenders), A&E, outpatient, and GP EMRs) were added and modeled sequentially using standard logistic regression in SPSS v20. Emergency admission in the next 12 months was used as the dependent variable, producing a risk score ranging from 0-100. Separate models were developed for each PCT area, and analysis was limited to patients aged 18-95 who were on the GP register in the area. Over-fitting was tested using a split sample approach, with only minor differences observed in positive predictive values (PPV), sensitivity, and specificity.

Findings provided here include both individual site results and results combined across the five sites. We also created five additional predictive models (referred to below as the 'four-site regression models'), each one combining data from four sites and applying coefficients to the fifth remaining site. With this we could compare results with individual site predictive models to help assess the value of local model development.

The full list of more than 300 potential variables was ultimately reduced to 88 by exclusion of variables with low volumes and low significance levels across the sites. The 88 variables ultimately included in the model (and regression coefficients), may be found in Appendix B and D, and a full listing of the variables

considered for inclusion and detailed specification of each variable are available at http://www.nuffieldtrust.org.uk/.

Cost variables were examined, with secondary care activity costed according to the method used in development of the person based formula for allocating commissioning funds to general practices in England.[14] Ultimately, these were not included in the predictive models because of concerns about difficulties in constructing these variables by possible future users, however costs are included in descriptive findings to help in design of intervention strategies.

Predictive modeling performance is typically documented reporting PPV and sensitivity at the risk score threshold of 50. However, because interventions may be targeted at patients with higher or lower risk scores and interventions strategies may be calibrated differently depending on risk level and characteristics of patients at various risk score levels, we report PPV sensitivity at 20 risk score cutoff points (vigintiles) and provide detailed patient characteristics at risk score thresholds of 50 and 30 to facilitate intervention design.

RESULTS

Pooled Individual Site Results

There were 1,836,099 people aged 18 and over who were registered with a GP practice on 31 July 2009. Table 1 shows the combined results of individual site regressions including the number of patients correctly identified, PPV, and sensitivity for four models:

- (i) IP based on hospital inpatient data only (including day cases and regular attendances)
- (ii) IPAE using inpatient and A&E data
- (iii) IPAEOP using inpatient A&E and outpatient data
- (iv) IPAEOPGP using inpatient, A&E, outpatient data and GP EMR.

At the traditional risk score threshold level of 50 all four models perform respectably in terms of PPV (ranging from .523 to .538), but sensitivity remains quite low across all models (.049 to .060). Lowering the threshold to 30 increases sensitivity somewhat with a concomitant reduction in PPV (ranging from .417 to .422). The ROC area under the curve (C statistic) improved with the addition of each data set, increasing from .731 with the inpatient-only model to .780 with the full model.

Table 1 Model performance, four models	IP, IPAE, IPAEOP, IPAEOPGP	. Five site individual runs combined.
--	----------------------------	---------------------------------------

Risk		IP Data			IP+AE Data		IP	AE+OP Dat	а	IP+AE+OP+GP Data			
Score Threshold	True Positive	PPV	Sensitivity	True Positive	PPV	Sensitivity	True Positive	PPV	Sensitivity	True Positive	PPV	Sensitivity	
1	94,692	0.052	1.000	94,692	0.052	1.000	94,692	0.052	1.000	94,692	0.052	1.0	
5	54,450	0.126	0.575	56,117	0.128	0.593	56,438	0.131	0.596	61,498	0.133	0.6	
10	33,053	0.219	0.349	34,102	0.221	0.360	35,033	0.223	0.370	39,986	0.220	0.4	
15	22,898	0.285	0.242	23,166	0.293	0.245	24,261	0.290	0.256	28,697	0.283	0.3	
20	16,181	0.346	0.171	16,915	0.347	0.179	17,719	0.344	0.187	21,601	0.333	0.2	
25	12,670	0.385	0.134	13,182	0.386	0.139	13,754	0.383	0.145	16,672	0.378	0.2	
30	10,061	0.421	0.106	10,555	0.422	0.111	11,010	0.419	0.116	13,196	0.417	0.:	
35	8,130	0.449	0.086	8,600	0.450	0.091	8,986	0.448	0.095	10,516	0.450	0.:	
40	6,700	0.477	0.071	7,139	0.478	0.075	7,421	0.476	0.078	8,494	0.479	0.0	
45	5,535	0.501	0.058	5,976	0.504	0.063	6,167	0.499	0.065	6,921	0.510	0.	
50	4,627	0.529	0.049	5,027	0.531	0.053	5,172	0.523	0.055	5,669	0.538	0.	
55	3,862	0.551	0.041	4,222	0.551	0.045	4,359	0.543	0.046	4,581	0.562	0.	
60	3,239	0.574	0.034	3,555	0.569	0.038	3,658	0.567	0.039	3,735	0.587	0.	
65	2,711	0.593	0.029	3,012	0.590	0.032	3,041	0.587	0.032	3,034	0.618	0.	
70	2,245	0.617	0.024	2,481	0.612	0.026	2,519	0.610	0.027	2,453	0.645	0.	
75	1,816	0.634	0.019	2,049	0.639	0.022	2,064	0.631	0.022	1,921	0.666	0.	
80	1,418	0.666	0.015	1,662	0.656	0.018	1,646	0.654	0.017	1,478	0.696	0.	
85	1,064	0.679	0.011	1,293	0.674	0.014	1,276	0.679	0.013	1,114	0.711	0.	
90	769	0.710	0.008	932	0.688	0.010	935	0.702	0.010	754	0.738	0.	
95	478	0.748	0.005	592	0.725	0.006	586	0.728	0.006	437	0.771	0.	
Top 1%	8,214	0.447	0.087	8,353	0.455	0.088	8,410	0.458	0.089	8,722	0.475	0.	
Top 5%	24,873	0.271	0.263	25,355	0.276	0.268	25,712	0.280	0.272	26,991	0.294	0.	
	ROC C Statistic	0.731			0.745			0.752			0.780		

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Of particular note is the finding that the addition of each data set added power, that is, correctly identified more patients with an admission in the next 12 months, with only a minor reduction in PPV. At a risk threshold of 50, the addition of A&E data resulted in increase of 400 (8.6%) correctly flagged patients, with no loss in PPV. The inclusion of outpatient data added a more modest 2.9%, but with a slight loss in PPV (.531 to .523). The addition of GP EMR data added an additional 9.6% of patients, while actually increasing the accuracy of the model (PPV increasing from .523 to .538). The added power of the A&E data set is less substantial at a risk score threshold of 30 (4.9%), but outpatient and GP EMR data sets had larger increases in correctly identified patients (4.3% and 19.9%).

There were also important differences between the models in terms of the characteristics of patients identified as high risk. For example, at a risk score cutoff of 50, patients identified using inpatient data alone had high prior emergency inpatient utilization rates with 2.62 admissions in the prior year compared to 2.43 when A&E data was added; 2.34 with addition of outpatient, and 2.20 with the addition of GP EMR data - see Table 2.

The inclusion of the additional data sets also led to a reduction in observed morbidity level of patients at the 50 threshold, with lower numbers of long term conditions, fewer patients with multiple long term conditions, lower Charlson Comorbidity Index scores, less history of alcohol abuse and mental illness, and lower emergency inpatient costs in the years prior to the predictive period. Similar, but less substantial differences were observed at the risk score threshold of 30. The addition of the A&E data set resulted in higher rates of A&E visits in the pre-period among patients identified at both risk score cutoff levels, and the addition of outpatient data resulted in higher outpatient visit and missed visit rates among identified patients.

These findings suggest inclusion of the additional data sets added some predictive power and generally tended to find additional patients who were less severely ill (more severely ill patients tended to remain high risk). Thus they potentially offer an opportunity for intervention at earlier stages in the progression of a patient's condition. However, the number of patients identified with no prior emergency inpatient utilization in the prior two years was relatively small across all models. At a risk score threshold of 50, only 0.3% of patients correctly identified by the inpatient-only model had no prior emergency admissions in the previous two years, and increasing only modestly 3.2% in the full model (Table 3). At a risk threshold of 30, the rates were higher, but only reaching 12.4% for the full model.

Table 2 Patient characteristics by risk score threshold four models: IP, IPAE, IPAEOP, IPAEOPGP. Five site

individual runs combined.

-		Risk Scor				Risk Sco		
	IP	IPAE	IPAEOP	IPAEOPGP	IP	IPAE	IPAEOP	IPAEOP
	Data	Data	Data	Data	Data	Data	Data	Data
Number of patients	8,743	9,473	9,892	10,545	23,912	25,021	26,304	31,6
Patients with adm next 12 mos	4,627	5,027	5,172	5,669	10,062	10,554	11,011	13,1
Mean Age	73.9	72.3	71.2	72.2	75.3	74.0	73.4	7
Age 18-39	6.2%	8.4%	8.7%	7.8%	5.1%	6.8%	7.0%	6.
Age 40-54	8.7%	9.6%	10.9%	10.6%	7.0%	7.8%	8.6%	8.
Age 55-64	6.9%	7.4%	7.8%	8.1%	6.4%	6.4%	7.0%	7.
Age 65-74	14.4%	13.9%	15.0%	13.5%	13.9%	13.8%	14.4%	13
Age 75-84	30.5%	28.9%	28.2%	27.4%	32.1%	31.1%	30.3%	29
Age 85+	33.3%	31.8%	29.3%	32.6%	35.5%	34.1%	32.7%	34
Female	55.2%	55.2%	54.9%	54.7%	56.9%	57.1%	56.6%	56
Practice IMD	24.6	24.9	24.8	24.3	24.2	24.3	24.3	2
Ischaemic Heart Disease	36.2%	34.2%	33.2%	32.1%	29.8%	28.4%	27.8%	25
Angina	21.7%	20.5%	19.5%	19.3%	17.3%	16.4%	15.7%	14
Hypertension	64.5%	61.2%	59.9%	59.0%	59.4%	56.7%	55.1%	50
CHF	19.2%	17.8%	16.9%	15.9%	14.0%	13.2%	12.5%	10
CVD	21.7%	20.1%	19.3%	18.1%	16.9%	15.8%	15.2%	13
COPD	23.4%	21.4%	20.6%	19.1%	17.2%	16.3%	15.7%	13
Asthma	21.3%	20.9%	20.1%	18.1%	17.4%	16.6%	16.1%	13
Diabetes	34.1%	32.4%	31.6%	28.8%	30.1%	28.8%	27.6%	23
Renal Failure	16.5%	14.6%	14.2%	13.3%	11.2%	10.4%	10.0%	8
Any long term conditions	89.8%	87.0%	85.8%	85.0%	86.6%	83.6%	81.4%	75
Any cancer	15.4%	13.8%	13.4%	12.4%	13.3%	12.7%	12.2%	10
Alcohol misuse	10.0%	10.0%	9.6%	9.1%	7.0%	6.7%	6.4%	5
Mental illness	32.0%	30.6%	28.9%	27.2%	23.5%	22.3%	21.3%	18
Number long term conditions	2.67	2.51	2.43	2.31	2.20	2.10	2.02	
Charlson Index	3.96	3.69	3.55	3.28	3.09	2.95	2.82	
Emerg adms 1yr prior	2.62	2.43	2.34	2.20	1.64	1.57	1.50	
Emerg adms 2 yr prior	1.78	1.67	1.61	1.50	1.15	1.10	1.05	(
No emerg adm prior 2 yrs	0.6%	1.9%	3.3%	4.3%	4.2%	6.5%	9.2%	16
Elect adms 1yr prior	0.32	0.29	0.31	0.28	0.27	0.26	0.27	10
Elect adms 2 yr prior	0.24	0.23	0.26	0.24	0.20	0.20	0.22	(
Any day case 1yr prior	31.9%	30.8%	31.6%	28.7%	31.5%	30.7%	30.4%	26
Any day case 2yr prior	28.9%	27.6%	28.0%	25.7%	27.8%	26.9%	26.7%	23
Emerg adm cost 1yr prior	£4,500	£4,073	£3,920	£3,688	£2,893	£2,709	£2,604	£2,
• • •	£4,500 £2,932	£4,075 £2,675	£3,920 £2,583	£2,422	£1,962	£2,709 £1,822	£2,004 £1,757	£2, £1,
Emerg adm cost 2yr prior	2.90	3.59	3.45	3.17	1.83	2.26	2.17	<u>с</u> ,
AE visits 1yr prior								
AE visits 2yr prior	1.90	2.40	2.31	2.10	1.23	1.52	1.46	
OP visits 1yr prior	7.27	6.94	9.65	8.23	5.65	5.63	7.39	(
OP visits 2yr prior	4.30	4.10	5.92	5.08	3.39	3.38	4.54	3
OP visits missed 1yr prior	0.47	0.48	0.74	0.65	0.35	0.36	0.53	(
OP visits missed 2yr prior	0.49	0.48	0.71	0.61	0.33	0.34	0.48	(
GP visits 1yr prior	42.9	42.7	43.3	52.5	38.5	38.4	38.8	4
GP visits 2yr prior	35.5	35.2	35.7	42.5	32.4	32.1	32.5	3
Any high risk BNFs	73.9%	71.6%	72.2%	84.0%	69.3%	67.5%	68.1%	79
Num high risk BNFs	1.94	1.85	1.88	2.20	1.64	1.59	1.61	
High blood pressure	9.0%	9.0%	9.0%	9.0%	10.0%	10.0%	10.0%	9
Smoker	18.0%	19.0%	19.0%	23.0%	16.0%	16.0%	16.0%	20
BMI 30+	16.0%	17.0%	17.0%	17.0%	15.0%	16.0%	16.0%	18
HbA1c > 10	5.0%	5.0%	5.0%	7.0%	5.0%	5.0%	4.0%	6
Any Em adm next 12 mos	52.9%	53.1%	52.3%	53.8%	42.1%	42.2%	41.9%	41
Num Em adm next 12 mos	1.34	1.33	1.29	1.31	0.89	0.89	0.87	(
0 Em adm next 12 mos	47.1%	46.9%	47.7%	46.2%	57.9%	57.8%	58.1%	58
1 Em adm next 12 mos	23.0%	23.0%	23.2%	23.9%	21.7%	21.9%	21.7%	22
2 Em adm next 12 mos	12.5%	12.5%	12.3%	13.2%	10.0%	10.0%	10.0%	9
3 Em adm next 12 mos	7.3%	7.3%	7.0%	7.1%	4.8%	4.9%	4.8%	4
4+ Em adm next 12 mos	10.2%	10.2%	9.8%	9.7%	5.5%	5.5%	5.3%	4

AE visits next 12 mos	1.88	2.11	2.04	2.04	1.24	1.37	1.36	1.29

Table 3 Proportion of patients correctly identified, who had no emergency admissions in the prior two

 years. Four models:
 IP, IPAE, IPAEOP, IPAEOPGP. Five site individual runs combined.

Prediction threshold	IP Data	IPAE Data	IPAEOP Data	IPAEOPGP Data
Risk Score 50+	0.3%	1.2%	2.3%	3.2%
Risk Score 30+	2.7%	4.4%	6.3%	12.4%
Тор 1%	1.5%	2.9%	4.2%	6.5%
Тор 5%	25.9%	26.4%	26.7%	30.8%

Individual Site and 'Four-Site Regression' Model Results

Overall the performance of the models was similar at the individual site level. Only modest differences were found in PPV levels and sensitivity across the sites. For runs using non-GP data only (IPAEOP), at the risk score threshold of 50, PPVs ranged from .512 to .552 and sensitivity ranged from .047 to .071. For the model including GP EMRs, PPVs ranged from .521 to .566 and sensitivity from .053 to .073. See Appendix A. There was some variation in the magnitude of regression coefficients between sites, but in general the coefficients were comparable for models based on the non-GP data model (IPAEOP). See Appendix B. For the model including variables from GP EMRs (IPAEOPGP), the level of variation in regression coefficients (size and direction) was somewhat greater for those variables derived from GP data. We observed substantial differences in frequency of reporting of Read codes across sites which no doubt contributed to this variation. The level of significance of individual variables also varied across sites (Appendix C), but most variables were consistently strongly significant across all sites, especially variables involving prior emergency inpatient admissions. Again, higher levels of variation in levels of significance were observed for the GP variables derived from Read codes.

We compared the results for these individual site models to a pooled model combining data from four of the sites and applied coefficients to the remaining individual site. We found generally only small differences in predictive accuracy (PPV) between these two approaches (Table 4), however the individual site models identified a greater number of true positives. For example, in Cornwall at a risk

score cutoff of 50, the individual site model using hospital data identified correctly 1,041 patients while the pooled model identified only 754. In Newham however, the four-site model was more powerful, correctly identifying 858 patients compared to 734 for the individual site approach. In both cases (and in general across all sites), the model identifying larger numbers of true positives had a somewhat lower PPV, suggesting improved case finding volume came at the expense of predictive accuracy.

		IPOF	PAE	IPOPAEGP						
	Individu Regres		Four Site Re	gression	Individu Regres		Four Site Regression			
	True Positives	PPV	True Positives	PPV	True Positives	PPV	True Positives	PPV		
Newham										
Risk Score 50+	734	0.552	858	0.517	768	0.566	835	0.523		
Risk Score 30+	1,409	0.450	1,564	0.414	1,570	0.439	1,798	0.409		
Cornwall										
Risk Score 50+	1,041	0.520	754	0.548	1,176	0.545	952	0.556		
Risk Score 30+	2,439	0.406	1,970	0.426	3,032	0.410	2,746	0.411		
Kent										
Risk Score 50+	1,565	0.513	1,387	0.519	1,736	0.521	1,873	0.493		
Risk Score 30+	3,372	0.401	3,067	0.403	4,079	0.397	4,432	0.369		
Croydon										
Risk Score 50+	1,089	0.528	1,192	0.523	1,182	0.550	1,230	0.537		
Risk Score 30+	2,134	0.444	2,258	0.424	2,610	0.442	2,502	0.437		
Redbridge										
Risk Score 50+	743	0.512	863	0.495	807	0.522	607	0.519		
Risk Score 30+	1,656	0.420	1,693	0.415	1,905	0.423	1,390	0.436		

Testing alternative population denominators

Models built using inpatient data only (IP) were also built for just the subset of patients who had some inpatient care in the prior two years (to reflect typical predictive modeling efforts that may have been conducted without access to GP registry information), as well as for the group who had had an emergency admission in the prior year (to replicate analyses conducted by PARR users).

Combining the results from the five sites at a risk score threshold of 50, models using the full GP register correctly identified 4,627 patients compared with 3,572 patients in runs restricted to patients with prior inpatient care and 3,060 to runs limited to patients with an emergency admission in the prior year. This substantial increase in case finding was obtained with only moderate loss in PPV (.529 GP list, .559 prior inpatient and .589 emergency admissions in last year). Similar results were also found for all hospital data models (IPOPAE, though with any hospital use in prior two years, rather than just any inpatient use).

Using the full GP registry population did not result in finding substantial numbers of patients with no emergency admissions in the prior two years, but the increased numbers of patients identified included more patients with less prior use and lower levels of morbidity. For a profile of patients identified using these alternative denominators see http://www.nuffieldtrust.org.uk/.

DISCUSSION

This analysis has looked at the performance of new variants of predictive models for case finding. These models are intended to update and improve upon the established combined predictive model-like [15] and PARR models [5] widely used in the NHS.

Each of the models examined produced reasonably robust performance, by some measures better or at least comparable to similar prior models [9]. At a risk threshold of 50, patients identified by the models had PPVs ranging from .523 to .538. While the percent of all patients with future admissions identified was relatively low (sensitivity .049 to .060), lowering the risk threshold allows the identification of more patients with relatively small loss in PPV (e.g. at a risk threshold of 30, the full model identified 14% of future admissions with a PPV of .417). Users of predictive modeling algorithms have obvious trade-offs between maximizing the number of patients identified and predictive accuracy. Lower risk score thresholds will find more patients, but these patients are increasingly less likely to have future admissions.

The implications for intervention design are important. Patients at lower risk thresholds have less prior inpatient use and lower morbidity, so an intervention here might be calibrated to be less intensive. But because the models are less accurate at lower risk scores, the amount that can be spent on an intervention is also reduced if you wish to achieve financial break-even (ie where the cost of intervention is off-set by cost savings from reduction in future admissions). As documented in Table 2,

BMJ Open

at a risk score threshold of 50, the rate of future admission for patients identified by the full model (IPAEOPGP data) was 1.31 admissions per year with an associated cost of £2,270. If there were a 10% reduction in future admissions, £227 could be spent on an intervention to improve care coordination and still achieve break-even. However, at a lower risk threshold of 30, the lower rates of future admissions and costs means that lower intervention expenditures are required to achieve break-even (£151 with a 10% reduction in future admissions). A detailed business case analysis with mean emergency inpatient costs in the next 12 months within each risk vigintile level is available via http://www.nuffieldtrust.org.uk/.

These data also provide other information that may be useful in the development of intervention strategies. As shown in Table 2, patients identified by the models have extremely high rates of chronic disease (85-90% with long term conditions at risk threshold of 50), often with multiple long term conditions and high Charlson Comorbidity Index levels, indicating serious medical needs. However, these patients already have high use of outpatient care and very high GP visit rates. This suggests simple access to ambulatory care is not the issue, but prevention needs to look at care coordination and management of complex problems and at the ability of patients and their families to manage chronic illness. High risk patients identified by the models also have relatively high rates of mental illness (27-32% at risk threshold of 50) and moderate levels of alcohol abuse, factors that are likely to complicate any intervention strategy.

It is also important to note the limitations of these data in helping frame the design of any intervention strategy. Other studies have documented that high risk patients often have important characteristics related to care needs and patient capacity not captured by administrative data and EMRs. For example, interviews with high risk patients and their families have documented high levels of social isolation for many, as well as precarious housing status.[16] These non-medical factors are likely to have significant impact on health status and utilization patterns. Moreover, not much is known about how/whether care coordination and management has actually failed for these patients. Are these high risk patients just very sick patients whose hospitalizations are largely not preventable/avoidable [17], or has the care delivery system failed in some important dimensions that can be corrected with improved care coordination and management? These data cannot answer this very critical question, and it is clear that the field would benefit from further study that examined the circumstances of patients identified as

high risk by predictive modeling algorithms to sort out more clearly the factors contributing to high rates of emergency admission.

This study does document the value of incorporating data sets beyond inpatient records. The addition of A&E and outpatient records resulted in identification of more high risk patients with little or no loss of predictive accuracy. These data sets are readily available and have standardized reporting formats that facilitate analysis. While the absence of useful diagnostic information in these data sets is a limiting factor, the improvement in case finding and usefulness in descriptive profiling of high risk patients to help in intervention design (e.g. high rates of A&E use rates, high rates of missed outpatient appointments) suggests their inclusion is clearly merited.

Use of GP EMRs presents significant challenges. While the lack of access to these data is unlikely to remain a problem, the variation in completeness and quality of data is problematic. The use of the unwieldy Read codes system makes analysis difficult, and we observed significant differences across sites in reporting patterns. Some of these differences may be caused by under reporting of diagnostic variables, others by differences in coding approaches. However, the potential improvement in case finding, especially among patients with lower rates of utilization in the pre-period, suggests these barriers are worth confronting. Our development of new variables beyond those included in prior predictive modeling efforts [8] contributed substantially to enhanced case finding, and further work on variable development is likely to lead to further improvements. Again, these data are also useful in providing descriptive information on high risk patients to help in intervention design (e.g. documenting potential targets of opportunity such as uncontrolled hypertension or diabetes).

This study does not provide definitive findings on the value of developing individual site models compared to simply applying coefficients from multi-site or national model coefficients to local data. Our four-site regression models generally had comparable PPVs to individual site models, but for the majority of sites the four-site regression approach correctly identified somewhat fewer number patients with future admissions. Though it is tempting to speculate on whether differences in the health needs of the population or coding differences affect model performance, we did not observe any clear patterns between the areas. Our analysis is somewhat limited by the small number of sites involved which might cause somewhat greater variability in regression coefficients (regression coefficients for each of the five four-site models are available at http://www.nuffieldtrust.org.uk/). Development of a

BMJ Open

national model using SUS data only is planned to further assess the need/value of locally developed models.

Finally, it is worthy of note that use of the GP registry data for the denominator also proved to be of significant importance. Many prior predictive modeling efforts have been limited to patients with utilization history in whatever data sets were included. By including all patients in an area, not just those with prior use, the impact on predictive modeling of prior use was apparently enhanced. As a result, patients with more moderate levels of prior use and morbidity were found to be of higher risk than patients with no prior use at all, and were often assigned higher risk scores than when the analysis included just patients who had prior use. Accordingly, the use of the GP registry as the denominator can improve rates of case finding and may permit identification of patients at earlier stages.

Acknowledgments

The authors wish to thank all individuals in the PCTs who contributed data used for this study during the Whole Systems Demonstrator, Virtual Wards and Social care end of life studies.

Contributors

The preparation of data sets and input variables and costs were undertaken by TG and by IB; JB did the central modelling. MB advised on the analysis and results and managed the work of the research team at the Nuffield Trust. All authors contributed to the writing of the paper. JB is the guarantor.

Funding and disclaimer

The research received no specific grant but was funded by the Nuffield Trust. The resulting models will be used as part of the WSD trial funded by the Department of Health.

Competing interests

All authors have completed the Unified Competing Interest form at <u>www.icmje.org/coi_disclosure.pdf</u> and declare that no authors have any relationships with any companies that might have an interest in the submitted work in the previous 3 years; none of their spouses, partners or children have any financial relationships that may be relevant to the submitted work; and no authors have any non-financial interests that may be relevant to the submitted work.

Ethical approval

This study only involved the analysis of pseudonymous secondary data. Since there were no identifiable human subjects, ethics approval was not required for this research and informed consent was not sought.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

Details of the derived models variables and definitions are available from the authors at the Nuffield trust at research@nuffieldtrust.org.uk.

References

1 Section 3025 of the Affordable Care Act added section 1886(q) to the Social Security Act establishing the Hospital Readmissions Reduction Program, which requires the Center for Medicare and Medicaid Services to reduce Medicare payments to hospitals with excess rates of readmissions for selected conditions within 30 days of discharge.

2 Department of Health. Payment by Results Guidance for 2012-13. 2012. Gateway reference 17250 London: Department of Health

3 Kansagara D, Englander H, Salanitro A, Kagen D, Theobald C, Freeman M, Kripalani S Risk prediction models for hospital readmission: A systematic review. JAMA 2011;306(15):1688-1698

4 Billings J, Mijanovich T. Improving the Management of Care for High Cost Medicaid Patients. Health Affairs. 2007;26(6):1643-1655.

5 Billings J, Dixon J, Wennberg D, et al. Case Finding for Patients at Risk of Re-Hospitalisation: Development of an Algorithm to Identify High Risk Patients. BMJ 2006;333(7563):327-32,

6 Case Finding Algorithms for Patients at Risk of Re-hospitalisation: PARR1 and PARR 2. Kings Fund, February, 2006 (http://www.kingsfund.org.uk/sites/files/kf/field/field_document/PARR-case-finding-algorithms-feb06.pdf - last accessed 04/06/2013).

7 Lewis G, Curry N and Bardsley M Choosing a predictive risk model: a guide for commissioners in England

8 Combined Predictive Model: Final Report. Kings Fund, Dec 2006. (http://www.kingsfund.org.uk/sites/files/kf/field/field_document/PARR-combined-predictive-model-final-reportdec06.pdf last accessed 04/06/2013),

9 Wales Predictive Model: Final Report and Technical Documentation, 2008 (http://www.nliah.com/portal/microsites/Uploads/Resources/k5cma8PPy.pdf last accessed 04/06/2013).

10 http://systems.hscic.gov.uk/data/uktc/readcodes - last accessed 14/05/2013

11 http://www.connectingforhealth.nhs.uk/systemsandservices/sus - last accessed 14/1/2013.

12 National Institute of Standards and Technology. Secure Hash Standard (180-3). October 2008.

(http://csrc.nist.gov/publications/fips/fips180-3/fips180-3_final.pdf last accessed 30 July 2013)

13 Charlson ME, Popei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Disease. 1987;40:373-383.

14 Dixon J, Smith P, Gravelle H, Martin S, Bardsley M, Rice H, Georghiou T, Dusheiko M, Billings J, De Lorenzo M. I. A person based formula for allocating commissioning funds to general practices in England: development of a statistical model BMJ 2011;343:d6608 doi: 10.1136/bmj.d6608 Published 22 November 2011.

15 Chenore T, Pereira Gray DJ, Forrer J, Wright C., Evans PH, Emergency hospital admissions for the elderly: insights from the Devon Predictive Model J Public Health (2013)

16 Raven M, Billings J, Goldfrank L, Manheimer E, Gourevitch M. Medicaid Patients at High Risk for Frequent Hospital Admission: Real-time Identification and Remedial Risks. Journal of Urban Health. 2009;86(2):230-241.

17 Joynt KE, Gawande AA, Orav EJ, JHA AK. Contribution of Preventable Acute Care Spending to Total Spending for High-Cost Medicare Patients. JAMA. 2013;309(24):2572-2578.

 BMJ Open

Appendix A. PPV and sensitivity IPAEOP and IPAEOPGP models. Individual site runs.

					IP+AE+	OP Data				
Risk Score	Nev	vham	Corn	wall	Ke	nt	Croy	don	Redbridge	
Threshold	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivit
1	0.049	1.000	0.061	1.000	0.052	1.000	0.046	1.000	0.047	1.00
10	0.236	0.361	0.216	0.391	0.213	0.339	0.241	0.378	0.238	0.42
20	0.368	0.201	0.328	0.188	0.326	0.158	0.377	0.210	0.357	0.2
30	0.450	0.136	0.406	0.109	0.401	0.094	0.444	0.142	0.420	0.1
40	0.506	0.098	0.477	0.072	0.457	0.062	0.486	0.100	0.475	0.0
50	0.552	0.071	0.520	0.047	0.513	0.043	0.528	0.073	0.512	0.0
60	0.585	0.052	0.560	0.030	0.569	0.031	0.580	0.055	0.532	0.0
70	0.632	0.037	0.622	0.021	0.618	0.022	0.610	0.040	0.555	0.0
80	0.678	0.024	0.655	0.013	0.673	0.014	0.659	0.028	0.571	0.0
90	0.717	0.013	0.692	0.007	0.724	0.008	0.710	0.016	0.617	0.0
Top 1%	0.501	0.102	0.470	0.077	0.417	0.080	0.482	0.106	0.474	0.1
Top 5%	0.287	0.291	0.292	0.240	0.259	0.249	0.290	0.318	0.296	0.3

					IP+AE+O	P+GP Data				
Risk Score Newham		wham	Corn	wall	Ke	nt	Croy	don	Redb	ridge
Threshold	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity
1	0.049	1.000	0.061	1.000	0.052	1.000	0.046	1.000	0.047	1.000
10	0.228	0.410	0.213	0.439	0.210	0.392	0.237	0.452	0.237	0.457
20	0.360	0.235	0.323	0.232	0.314	0.194	0.358	0.267	0.348	0.272
30	0.439	0.152	0.410	0.136	0.397	0.113	0.442	0.174	0.423	0.172
40	0.499	0.103	0.481	0.084	0.459	0.072	0.494	0.114	0.482	0.113
50	0.566	0.074	0.545	0.053	0.521	0.048	0.550	0.079	0.522	0.073
60	0.606	0.052	0.602	0.033	0.580	0.032	0.589	0.052	0.563	0.047
70	0.657	0.036	0.659	0.021	0.644	0.021	0.643	0.035	0.616	0.030
80	0.723	0.021	0.714	0.013	0.694	0.013	0.694	0.021	0.651	0.018
90	0.766	0.012	0.745	0.006	0.752	0.007	0.735	0.011	0.655	0.007
Top 1%	0.504	0.102	0.490	0.081	0.438	0.084	0.502	0.110	0.487	0.104
Top 5%	0.296	0.300	0.309	0.254	0.272	0.262	0.307	0.337	0.312	0.333

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Appendix B Regression coefficients, IPAFOP and IPAFOPGP models, Individual site runs,

		IP-	+AE+OP Da	ta			IP+A	E+OP+GP [Data	
	NH	CW	КТ	CR	RB	NH	CW	КТ	CR	
Age	0.015	0.003	0.009	0.010	0.019	0.001	-0.004	0.002	0.001	(
Age 65-74	0.280	0.409	0.295	0.380	0.261	0.236	0.276	0.203	0.244	
Age 75-84	0.738	0.905	0.731	0.847	0.734	0.721	0.672	0.605	0.708	
Age 85+	1.076	1.483	1.226	1.178	1.109	1.150	1.206	1.086	1.187	
Female	0.239	0.002	0.044	0.178	0.058	0.114	-0.095	-0.075	-0.014	-
Practice IMD	0.013	0.003	0.016	0.018	0.012	0.008	0.004	0.017	0.010	
Months registered 1 yr prior	0.014	-0.011	-0.005	-0.018	-0.013	0.011	-0.011	-0.003	-0.010	
Months registered 2 yrs prior	-0.022	-0.019	-0.016	-0.007	-0.023	-0.021	-0.024	-0.019	-0.011	
EM Adms prior 0-90 days	0.382	0.471	0.321	0.310	0.282	0.367	0.420	0.283	0.269	
EL Adms prior 0-90 days	0.045	0.216	0.155	0.153	0.148	0.033	0.159	0.074	0.097	
Any attender prior 0-90 days	0.115	0.027	0.001	0.041	0.073	0.135	0.026	0.010	0.042	
Any day case prior 0-90 days	0.094	0.234	0.110	0.111	0.251	0.037	0.173	0.039	-0.019	
EM Adms prior 91-180 days	0.215	0.310	0.351	0.282	0.185	0.217	0.262	0.297	0.243	
EL Adms prior 91-180 days	0.321	0.150	0.062	0.204	0.081	0.283	0.128	0.027	0.118	
EM Adms prior 181-365 days	0.113	0.345	0.350	0.248	0.146	0.124	0.289	0.292	0.227	
EL Adms prior 181-365 days	0.097	0.120	0.104	0.118	0.170	0.072	0.079	0.060	0.035	
Em Adms 2 yrs prior	0.102	0.269	0.307	0.181	0.143	0.116	0.216	0.250	0.178	
Any day case 2 yrs prior	0.096	0.157	0.186	0.151	0.179	0.058	0.092	0.112	0.005	
DX MI	-0.108	0.097	-0.105	-0.004	0.376	-0.197	-0.003	-0.163	-0.111	
DX CHF	-0.348	-0.070	-0.246	-0.069	-0.337	-0.370	-0.178	-0.269	-0.111	
DX CVD	0.296	0.227	0.033	0.037	-0.040	0.269	0.178	-0.203	-0.099	
CD CTD	0.296	-0.024	0.033	-0.380	-0.040 -0.029	0.269	-0.192	-0.001	-0.099	
DX PVD	-0.245	-0.024 0.124	0.101	-0.380	-0.029 0.021	-0.253	-0.192	0.010	-0.427	
DX Asthma	0.082	0.143	0.184	0.099	0.192	-0.114	-0.107	-0.023	-0.081	
DX COPD	0.204	0.251	0.277	0.193	0.123	-0.169	-0.139	-0.036	-0.330	
DX Diabetes	0.240	0.303	0.285	0.253	0.276	-0.046	-0.052	-0.016	-0.124	
DX Diabetes with complications	0.059	-0.221	0.062	-0.014	0.334	0.062	-0.176	0.095	0.004	
DX Renal Disease	0.408	0.022	0.085	0.128	0.199	0.356	0.005	0.073	0.063	
DX Cancer	-0.165	-0.019	-0.062	-0.308	0.041	0.041	0.098	-0.010	-0.207	
DX Mental	0.498	0.316	0.363	0.484	0.077	0.340	0.131	0.111	0.266	
DX Alcohol	0.569	0.684	0.578	0.673	0.974	0.281	0.530	0.357	0.409	
DX Dementia	-0.548	-0.589	-0.551	-0.402	-0.596	-0.530	-0.486	-0.440	-0.669	
DX Cognitive Impairment	-0.117	0.016	0.025	0.110	0.187	-0.075	0.046	0.031	0.088	
DX ACS Condition	0.364	0.270	0.239	0.267	0.306	0.269	0.161	0.134	0.114	
Charlson Index	0.055	0.063	0.060	0.101	0.025	0.048	0.062	0.037	0.086	
AE visits prior 0-90 days	0.236	0.267	0.355	0.309	0.359	0.179	0.230	0.265	0.199	
AE unplanned follow-up visits prior										
0-90 days	-0.094	-0.583	-0.533	-0.874	-0.383	-0.107	-0.566	-0.452	-0.703	
AE X-ray prior 0-90 days	0.348	0.437	0.058	0.104	0.367	0.303	0.382	0.027	0.040	
AE visits prior 91-180 days	0.265	0.262	0.220	0.225	0.277	0.197	0.225	0.165	0.142	
AE unplanned follow-up visits prior	0.205	0.202	0.220	0.225	0.277	0.157	0.225	0.105	0.142	
	-0.023	-0.560	-0.229	-0.296	-0.298	-0.026	-0.543	-0.177	-0.225	
91-180 days										
AE X-ray prior 91-180 days	0.227	0.117	0.120	0.346	-0.064	0.210	0.015	0.101	0.237	
AE visits prior 181-365 days	0.264	0.205	0.135	0.171	0.181	0.216	0.174	0.090	0.115	
AE unplanned follow-up visits prior	-0.251	-0.490	-0.184	-0.261	-0.203	-0.214	-0.449	-0.131	-0.175	
181-365 days										
AE X-ray prior 181-365 days	0.262	-0.040	0.281	0.324	0.110	0.225	0.085	0.251	0.244	
AE visits 2 yrs prior	0.211	0.159	0.154	0.140	0.160	0.170	0.138	0.114	0.077	
AE unplanned follow-up visits 2 yrs	-0.307	-0.352	-0.239	-0.433	-0.339	-0.228	-0.317	-0.178	-0.262	
prior	-0.307	-0.332	-0.233	-0.433	-0.335	-0.220	-0.317	-0.1/0	-0.202	
AE X-ray 2yrs prior	0.083	0.231	0.100	0.128	0.179	0.063	0.390	0.082	0.069	
Outpatient specialty visits prior 0-	0.010	0.055	0.001	0.001	0.050	0.005	0.000	0.017	0.000	
90 days	0.046	0.055	0.091	0.061	0.059	0.025	0.033	0.047	0.030	
Outpatient specialty visits missed			a					.		
prior 0-90 days	0.155	0.182	0.250		0.146	0.108	0.118	0.171		
Outpatient specialty visits prior 91-										
180 days	0.030	0.013	0.023	0.034	0.029	0.007	0.003	-0.004	0.015	
Outpatient specialty visits missed										
	0.113	0.239	0.168		0.193	0.087	0.184	0.113		
prior 91-180 days										
Outpatient specialty visits prior	0.016	0.010	-0.005	0.019	0.031	-0.003	0.001	-0.024	0.003	
181-365 days										
Outpatient specialty visits missed	0.128	0.164	0.075		0.140	0.086	0.095	0.036		
prior 181-365 days	5.120	5.104	5.675		0.1 10	0.000	5.655	5.050		
Outpatient specialty visits 2 yrs	0.019	0.030	0.014	0.028	0.019	0.008	0.014	-0.009	0.011	
prior	0.019	0.050	0.014	0.020	0.019	0.008	0.014	-0.009	0.011	
				22						
				1.1.						

Page 23 of 56

BMJ Open

	Outpatient specialty visits missed 2						_				
1	vrs prior	0.142	0.162	0.140	0.190	0.082	0.097	0.090	0.085	0.129	0.057
2	GP DX COPD						0.218	0.174	0.112	0.287	0.295
3	GP - 1 long term condition						0.131	0.025	0.017	0.106	0.192
	GP - 2 or more long term						0.100	0.100	0.020	0.070	0 1 0 2
4	conditions						0.166	0.109	0.038	0.070	0.182
5	GP - Glomerular filtration rate						-0.075	0.092	-0.017		0.050
6	group 3 last 0-365 days						-0.075	0.092	-0.017		0.050
7	GP - 10+ unique drugs prescribed						0.342	0.570	0.166	2.741	1.949
8	GP - 5-9 unique drugs prescribed						0.424	0.444	0.164	2.804	1.953
9	GP - 0-4 unique drugs prescribed						0.328	0.254	0.114	2.559	1.809
10	GP - Psychoactive substance						0.388	0.323	0.583	0.431	0.810
11	misuse disorder										
	GP - 7+ distinct disorders						-0.049	0.057	0.017	-0.163	-0.062
12	GP - GP visits prior 0-3 months						-0.001 0.015	0.008	0.022	0.021	0.042
13	GP - GP visits prior 4-6 months						0.015	0.004 0.003	0.012 0.007	0.009 0.000	0.019 0.008
14	GP - GP visits prior 7-12 months GP - GP visits 2yrs prior						0.005	0.003	0.007	0.000	0.008
15	GP - GP visits 2915 prior GP - Increasing rate of GP visits						0.000	0.002	0.004	0.000	0.002
16	during last 12 months						0.184	0.087	0.126	0.207	0.094
17	GP - Number of high risk BNFs						0.063	0.006	-0.036	-0.026	-0.075
18	GP - Any high risk						0.219	0.202	0.241	0.324	0.249
	GP - Count of BNF chapters						0.066	0.053	0.059	0.066	-0.024
19	GP - DX Dementia						0.421	0.266	0.296	0.471	0.437
20	GP - Exception reported from						0 4 5 7	0.400	0.444	0.440	0.400
21	quality indicators						0.157	0.108	0.111	0.118	0.132
22	GP - Health visitor or district nurse						0.278	0.244	0.199	0.168	0.184
23	visit						0.278	0.244	0.199	0.100	0.164
24	GP - Record of IHD/angina						0.069	-0.048	0.110	-0.062	0.081
25	GP - Nebuliser used						0.113	0.315	0.207	0.191	0.448
	GP - Salbutamol prescribed						0.021	0.017	0.074	0.000	-0.011
26	GP - Warfarin prescribed						-0.041	0.031	-0.026	-0.100	-0.244
27	GP - High blood pressure						-0.040	-0.001	-0.013	-0.048	-0.087
28	GP - Smoker						0.298	0.231	0.248	0.240	0.220
29	GP - BMI 30+						0.050	0.002	0.085	0.046	0.199
30	GP - HbA1c > 10						0.236	0.270	0.210	0.362	0.354
31	GD - QOF ARTF						0.176	0.064	0.095	-0.047	0.143
	GP - QOF CKD						0.206	-0.003	-0.037	0.091	0.210
32	GP - QOF Depression GP - Number of QOF DX categories						0.069	0.248	0.183	0.133	0.186
33	3+						0.003	-0.023	-0.072	-0.135	-0.009
34	GP - Number of phone contacts last										
35	0-3 months						-0.004	0.046	0.004	-0.005	-0.004
36	Constant	-4.665	-3.262	-3.987	-4.363	-4.368	-4.381	-3.275	-4.069	-6.497	-5.939
37			0.202	0.007				0.270		0	0.000
51											



54	
55	
56	
57	
58	
59	

Appendix C Regression significance levels. IPAEOP and IPAEOPGP models. Individual site runs.

	IP+AE+OP Data						IP+A	IP+AE+OP+GP Data		
	NH	CW	КТ	CR	RB	NH	CW	КТ	CR	_
Age	0.000	0.000	0.000	0.000	0.000	0.344	0.000	0.001	0.158	
Age 65-74	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	
Age 75-84	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	
Age 85+	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	
Female	0.007	0.897	0.000	0.001	0.125	0.000	0.000	0.000	0.466	
Practice IMD		0.036								
	0.008		0.000	0.000	0.000	0.015	0.010	0.000	0.000	
Months registered 1 yr prior	0.002	0.006	0.085	0.247	0.047	0.009	0.011	0.387	0.026	
Months registered 2 yrs prior	0.001	0.014	0.006	0.232	0.276	0.009	0.003	0.001	0.211	
EM Adms prior 0-90 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	
EL Adms prior 0-90 days	0.664	0.000	0.000	0.029	0.081	0.714	0.000	0.070	0.102	
Any attender prior 0-90 days	0.002	0.000	0.955	0.006	0.004	0.001	0.000	0.489	0.005	
Any day case prior 0-90 days	0.769	0.000	0.001	0.682	0.001	0.561	0.000	0.233	0.699	
EM Adms prior 91-180 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	
EL Adms prior 91-180 days	0.000	0.000	0.068	0.022	0.528	0.000	0.001	0.437	0.016	
EM Adms prior 181-365 days	0.000	0.000	0.000	0.000	0.000	0.001	0.000	0.000	0.000	
EL Adms prior 181-365 days	0.548	0.000	0.000	0.757	0.019	0.167	0.009	0.030	0.372	
Em Adms 2 yrs prior	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	
Any day case 2 yrs prior	0.877	0.000	0.000	0.536	0.035	0.177	0.000	0.000	0.864	
DX MI	0.366	0.134	0.049	0.611	0.000	0.076	0.966	0.002	0.216	
DX CHF	0.024	0.253	0.000	0.448	0.008	0.001	0.005	0.000	0.194	
DX CVD	0.015	0.000	0.446	0.610	0.571	0.013	0.002	0.977	0.179	
CD CTD	0.263	0.756	0.150	0.010	0.759	0.645	0.013	0.891	0.000	
DX PVD	0.230	0.061	0.097	0.567	0.665	0.079	0.462	0.661	0.270	
DX Asthma	0.351	0.002	0.000	0.241	0.015	0.135	0.024	0.580	0.184	
DX COPD	0.005	0.000	0.000	0.009	0.098	0.098	0.021	0.483	0.002	
DX Diabetes	0.000	0.000	0.000	0.000	0.000	0.444	0.227	0.649	0.016	
DX Diabetes with complications	0.478	0.025	0.540	0.363	0.013	0.674	0.073	0.347	0.973	
DX Renal Disease	0.000	0.731	0.142	0.068	0.025	0.001	0.942	0.208	0.405	
DX Cancer	0.753	0.751	0.271	0.001	0.421	0.727	0.104	0.862	0.009	
		0.000								
DX Mental	0.000		0.000	0.000	0.370	0.000	0.005	0.008	0.000	
DX Alcohol	0.000	0.000	0.000	0.000	0.000	0.029	0.000	0.000	0.000	
DX Dementia	0.005	0.000	0.000	0.000	0.000	0.004	0.000	0.000	0.000	
DX Cognitive Impairment	0.430	0.804	0.620	0.191	0.026	0.456	0.474	0.534	0.199	
DX ACS Condition	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.001	
Charlson Index	0.012	0.000	0.000	0.000	0.212	0.042	0.000	0.006	0.000	
AE visits prior 0-90 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	
AE unplanned follow-up visits prior										
0-90 days	0.895	0.001	0.000	0.000	0.133	0.654	0.001	0.000	0.000	
AE X-ray prior 0-90 days	0.002	0.000	0.301	0.374	0.052	0.004	0.002	0.636	0.662	
AE visits prior 91-180 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	
AE unplanned follow-up visits prior										
91-180 days	0.836	0.000	0.000	0.149	0.130	0.899	0.000	0.005	0.214	
AE X-ray prior 91-180 days	0.070	0.582	0.045	0.002	0.672	0.062	0.946	0.090	0.009	
AE visits prior 181-365 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	
	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	
AE unplanned follow-up visits prior	_									
181-365 days	0.182	0.000	0.001	0.122	0.124	0.098	0.001	0.013	0.127	
AE X-ray prior 181-365 days	0.000	0.936	0.000	0.000	0.461	0.001	0.866	0.000	0.000	
AE visits 2 yrs prior	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	
AE unplanned follow-up visits 2 yrs						2.000				
· · · ·	0.024	0.000	0.000	0.000	0.000	0.000	0.010	0.000	0.000	
prior	0.021	0.008	0.000	0.003	0.009	0.020	0.016	0.000	0.008	
AE X-ray 2yrs prior	0.183	0.555	0.019	0.022	0.005	0.210	0.320	0.048	0.161	
Outpatient specialty visits prior 0-										
90 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	
Outpatient specialty visits missed										
	0.000	0.000	0.000		0.002	0.000	0.000	0.000		
prior 0-90 days	0.000	0.000	0.000		0.002	0.000	0.000	0.000		
Outpatient specialty visits prior 91-										
180 days	0.196	0.043	0.003	0.002	0.016	0.516	0.630	0.648	0.054	
Outpatient specialty visits missed										
	0 0 2 7	0.000	0.000		0.000	0.020	0.000	0.002		
prior 91-180 days	0.027	0.000	0.000		0.000	0.039	0.000	0.002		
Outpatient specialty visits prior										
181-365 days	0.763	0.009	0.400	0.094	0.000	0.595	0.844	0.000	0.491	
Outpatient specialty visits missed										
prior 181-365 days	0.000	0.000	0.009		0.000	0.001	0.002	0.206		
	0.000	0.000	0.009		0.000	0.001	0.002	0.200		
Outpatient specialty visits 2 yrs										
prior	0.000	0.000	0.000	0.000	0.000	0.068	0.000	0.046	0.001	

Page 25 of 56

BMJ Open

	Outpatiant angeight wights missed 2										
1	Outpatient specialty visits missed 2 yrs prior	0.000	0.000	0.000	0.000	0.001	0.000	0.006	0.000	0.000	0.000
2	GP DX COPD	0.000	01000	01000	0.000	01001	0.002	0.000	0.001	0.000	0.003
	GP - 1 long term condition						0.000	0.229	0.310	0.000	0.000
3	GP - 2 or more long term										
4	conditions						0.001	0.000	0.100	0.098	0.000
5	GP - Glomerular filtration rate										
6	group 3 last 0-365 days						0.097	0.002	0.463		0.162
7	GP - 10+ unique drugs prescribed						0.000	0.000	0.000	0.000	0.000
8	GP - 5-9 unique drugs prescribed						0.000	0.000	0.000	0.000	0.000
9	GP - 0-4 unique drugs prescribed						0.000	0.000	0.000	0.000	0.000
	GP - Psychoactive substance misuse										
10	disorder						0.000	0.000	0.000	0.000	0.000
11	GP - 7+ distinct disorders						0.311	0.290	0.523	0.002	0.263
12	GP visits prior 0-3 months						0.873	0.002	0.000	0.000	0.000
13	GP visits prior 4-6 months						0.000	0.182	0.000	0.008	0.000
14	GP visits prior 7-12 months						0.075	0.136	0.000	0.987	0.006
15	GP visits 2yrs prior						0.934	0.013	0.000	0.000	0.263
	GP - Increasing rate of GP visits										
16	during last 12 months						0.000	0.001	0.000	0.000	0.010
17	GP - Number of high risk BNFs						0.009	0.691	0.004	0.216	0.002
18	GP - Any high risk						0.000	0.000	0.000	0.000	0.000
19	GP - Count of BNF chapters						0.000	0.000	0.000	0.000	0.000
20	GP - DX Dementia						0.000	0.000	0.000	0.000	0.000
21	GP - Exception reported from						0.020	0.000	0.001	0.020	0.002
	quality indicators						0.020	0.003	0.001	0.020	0.062
22	GP - Health visitor or district nurse						0.000	0.000	0.000	0.000	0.000
23	visit GP - Record of IHD/angina						0.355	0.361	0.000	0.202	0.000
24	GP - Nebuliser used						0.355	0.000	0.000	0.202	0.288
25	GP - Salbutamol prescribed						0.550	0.523	0.001	0.989	0.795
26	GP - Warfarin prescribed						0.643	0.423	0.440	0.106	0.001
27	GP - High blood pressure						0.269	0.984	0.549	0.725	0.325
	GP - Smoker						0.000	0.000	0.000	0.000	0.000
28	GP - BMI 30+						0.074	0.956	0.000	0.000	0.000
29	GP - HbA1c > 10						0.000	0.000	0.000	0.000	0.000
30	GD - QOF ARTF						0.130	0.240	0.000	0.586	0.136
31	GP - QOF CKD						0.003	0.924	0.203	0.063	0.000
32	GP - QOF Depression						0.240	0.000	0.000	0.024	0.016
33	GP - Number of QOF DX categories										
	3+						0.974	0.717	0.123	0.342	0.948
34	GP - Number of phone contacts last										
35	0-3 months						0.927	0.000	0.600	0.788	0.899
36	Constant	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
37											
38											
39											
40											
41											
42											
43											
44											
45											
46											
47											
48											
49											
50											
51											
52											
53											
54											
55											



Appendix D Further information of model variables

Variable	Variable description	Time period/Date
GP register variables	Ago	End calendar year (E months after)
Age	Age Age 65-74	End calendar year (5 months after)
Age 65-74	5	End calendar year (5 months after)
Age 75-84	Age 75-84 Age 85+	End calendar year (5 months after)
Age 85+ Female	Age 85+ Sex = female	End calendar year (5 months after)
		N/A
Practice IMD	Index of multiple deprivation - GP practice area	N/A Drier 1 12 months (inclusive)
Months registered 1 yr prior	Months registered with GP prior 1-12 months	Prior 1 - 12 months (inclusive)
Months registered 2 yrs prior	Months registered with GP prior 13-24 months	Prior 13 - 24 months (inclusive)
SUS inpatient variables	Number of encourse educionic provider 1,00 days	Drive 1 to 00 days (in alusius)
EM Adms prior 0-90 days	Number of emergency admissions - prior 1-90 days	Prior 1 to 90 days (inclusive)
EL Adms prior 0-90 days	Number of elective admissions - prior 1-90 days	Prior 1 to 90 days (inclusive)
Any attender prior 0-90 days	Any regular attendance - prior 1-90 days	Prior 1 to 90 days (inclusive)
EM Adms prior 91-180 days	Number of emergency admissions - prior 91-180 days	Prior 91 to 180 days (inclusive)
EL Adms prior 91-180 days	Number of emergency admissions - prior 181-365 days	Prior 181 to 365 days (inclusive)
Any day case prior 0-90 days	Any day case prior 1-90 days	Prior 1 to 90 days (inclusive)
Any day case prior 91-180 days	Any day case prior 91-180 days	Prior 91 to 180 days (inclusive)
Any day case prior 181-365 days	Any day case prior 181-365 days	Prior 181 to 365 days (inclusive)
Any day case 2 yrs prior	Any day case prior 366-730 days	Prior 366 to 730 days (inclusive)
Em Adms 2 yrs prior	Number of emergency admissions - prior 366-730	Prior 366 to 730 days (inclusive)
Em Adms 2 yrs prior	days	FILO SOULO 730 Udys (INClusive)
DX Diabetes	Any prim or sec diagnosis - Diabetes, prior 2 years	Prior 1 to 730 days (inclusive)
DX MI	Any prim or sec diagnosis - Myocardial infarction,	Prior 1 to 730 days (inclusive)
	prior 2 years	I to / 50 days (metasive)
DX CHF	Any prim or sec diagnosis - Congestive heart failure, prior 2 years	Prior 1 to 730 days (inclusive)
DX PVD	Any prim or sec diagnosis - Peripheral vascular disease, prior 2 years	Prior 1 to 730 days (inclusive)
DX CVD	Any prim or sec diagnosis - Cereberal vascular disease, prior 2 years	Prior 1 to 730 days (inclusive)
DX Dementia	Any prim or sec diagnosis - Dementia, prior 2 years	Prior 1 to 730 days (inclusive)
	Any prim or sec diagnosis - Connective tissue	
CD CTD	disease, prior 2 years	Prior 1 to 730 days (inclusive)
DX Cancer	Any prim or sec diagnosis - Malignant cancer, prior 2 years	Prior 1 to 730 days (inclusive)
DX Diabetes with complications	Any prim or sec diagnosis - Diabetes with complications, prior 2 years	Prior 1 to 730 days (inclusive)
DX Renal Disease	Any prim or sec diagnosis - Renal disease, prior 2	Prior 1 to 730 days (inclusive)
	years	
Charlson Index	Charlson Comorbidity Index, prior 2 years	Prior 1 to 730 days (inclusive)
DX Alcohol	Any prim or sec diagnosis - Alcohol abuse, prior 2 years	Prior 1 to 730 days (inclusive)
DX COPD	Any prim or sec diagnosis - Chronic obstructive pulmonary disease, prior 2 years	Prior 1 to 730 days (inclusive)
	Any prim or sec diagnosis - Mental illness, prior 2	
DX Mental	years	Prior 1 to 730 days (inclusive)
DX Asthma	Any prim or sec diagnosis - Asthma, prior 2 years	Prior 1 to 730 days (inclusive)
DX Cognitive Impairment	Any prim or sec diagnosis - Miscellaneous cognitive dysfunctions, prior 2 years	Prior 1 to 730 days (inclusive)
DX ACS Condition	Any prim or sec diagnosis - ACS: Any ambulatory care sensitive condition	Prior 1 to 730 days (inclusive)
SUS AE variables		
AE visits prior 0-90 days	Number of A&E visits (any) prior 1-90 days	Prior 1 to 90 days (inclusive)
AE unplanned follow-up visits prior 0- 90 days	Number of A&E visits - unplanned follow-up prior 1- 90 days	Prior 1 to 90 days (inclusive)
AE X-ray prior 0-90 days	Number of A&E visits with X-ray prior 1-90 days	Prior 1 to 90 days (inclusive)
AE visits prior 91-180 days	Number of A&E visits (any) prior 91-180 days	Prior 91 to 180 days (inclusive)
AE unplanned follow-up visits prior	Number of A&E visits - unplanned follow-up prior 91-	
91-180 days	180 days	Prior 91 to 180 days (inclusive)
AE X-ray prior 91-180 days	Number of A&E visits with X-ray prior 91-180 days	Prior 91 to 180 days (inclusive)
AE visits prior 181-365 days AE unplanned follow-up visits prior	Number of A&E visits (any) prior 181-365 days Number of A&E visits - unplanned follow-up prior	Prior 91 to 180 days (inclusive)
181-365 days	181-365 days	Prior 181 to 365 days (inclusive)
AE X-ray prior 181-365 days	Number of A&E visits with X-ray prior 181-365 days	Prior 181 to 365 days (inclusive)
AE visits 2 yrs prior	Number of A&E visits (any) prior 366-730 days	Prior 366 to 730 days (inclusive)
AE unplanned follow-up visits 2 yrs	Number of A&E visits - unplanned follow-up prior	Prior 366 to 730 days (inclusive)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	prior AE X-ray 2yrs prior	366-730 days Number of A&E visits with X-ray prior 366-730 days	Prior 366 to 730 days (inclusive)
_	SUS outpatient variables		
	Outpatient specialty visits prior 0-90	Number of outpatient visits (all) prior 1-90 days	Prior 1 to 90 days (inclusive)
	days Outpatient specialty visits missed		
	prior 0-90 days	Number of outpatient visits missed prior 1-90 days	Prior 1 to 90 days (inclusive)
	Outpatient specialty visits prior 91- 180 days	Number of outpatient visits (all) prior 91-180 days	Prior 91 to 180 days (inclusive)
	Outpatient specialty visits missed prior 91-180 days	Number of outpatient visits missed prior 91-180 days	Prior 91 to 180 days (inclusive)
	Outpatient specialty visits prior 181-	Number of outpatient visits (all) prior 181-365 days	Prior 181 to 365 days (inclusive)
	365 days Outpatient specialty visits missed	Number of outpatient visits missed prior 181-365	Driar 191 to 26E days (inclusiva)
	prior 181-365 days	days	Prior 181 to 365 days (inclusive)
	Outpatient specialty visits 2 yrs prior Outpatient specialty visits missed 2	Number of outpatient visits (all) prior 365-730 days Number of outpatient visits missed prior 365-730	Prior 366 to 730 days (inclusive)
	yrs prior	days	Prior 366 to 730 days (inclusive)
	GP consultations data		
	GP DX COPD	Diagnosis of COPD, prior 2 years	Prior 1 to 730 days (inclusive)
	GP - 1 long term condition	Chronic conditions - 1 in prior 2 years	Prior 1 to 730 days (inclusive)
	GP - 2 or more long term conditions	Chronic conditions - 2 or more in prior 2 years	Prior 1 to 730 days (inclusive)
	GP - Glomerular filtration rate group 3 last 0-365 days	Glomerular Filtration Rate Group 3 in last year	Prior 1 to 365 days (inclusive)
	GP - 10+ unique drugs prescribed	1-4 unique drugs - last 1 to 90 days	Prior 1 to 90 days (inclusive)
	GP - 5-9 unique drugs prescribed	5-9 unique drugs - last 1 to 90 days	Prior 1 to 90 days (inclusive)
	GP - 0-4 unique drugs prescribed	10+ unique drugs - last 1 to 90 days	Prior 1 to 90 days (inclusive)
	GP - Psychoactive substance misuse disorder	Psychoactive substance misuse disorder, prior 2	Prior 1 to 730 days (inclusive)
		years 7+ distinct disease disorders recorded in prior 90	
	GP - 7+ distinct disorders	days	Prior 1 to 90 days (inclusive)
	GP - GP visits prior 0-3 months	Count of different BNF chapters of prescribed	Prior 1 to 730 days (inclusive)
		medicines, prior 2 years	
	GP - GP visits prior 4-6 months GP - GP visits prior 7-12 months	Number of GP visits prior 1-3 months Number of GP visits prior 13-24 months	Prior 1 to 3 months (inclusive) Prior 13 to 24 months (inclusive)
	GP - GP visits 2yrs prior	Number of GP visits prior 4-6 months	Prior 4 to 6 months (inclusive)
	GP - Increasing rate of GP visits during	Number of GP visits prior 7-12 months	Prior 7 to 12 months (inclusive)
	last 12 months		
	GP - Number of high risk BNFs	Substantial increase in GP visits last year Number of BNF codes associated with emergency	
	GP - Any high risk	admissions, prior 2 years	Prior 1 to 730 days (inclusive)
	GP - Count of BNF chapters	Any BNF codes associated with emergency	Prior 1 to 730 days (inclusive)
		admissions, prior 2 years	
	GP - DX Dementia GP - Exception reported from quality	Diagnosis of Dementia, prior 2 years	Prior 1 to 730 days (inclusive)
	indicators	QOF register exceptions, prior 2 years	Prior 1 to 730 days (inclusive)
	GP - Health visitor or district nurse	Any home/district visit, prior 2 years	Prior 1 to 730 days (inclusive)
	visit		
	GP - Record of IHD/angina GP - Nebuliser used	Diagnosis of IHD/angina, prior 2 years Nebuliser prescribed, prior 2 years	Prior 1 to 730 days (inclusive) Prior 1 to 730 days (inclusive)
	GP - Salbutamol prescribed	Salbutamol prescribed, prior 2 years	Prior 1 to 730 days (inclusive)
	GP - Warfarin prescribed	Warfarin prescribed, prior 2 years	Prior 1 to 730 days (inclusive)
	GP - High blood pressure	High blood pressure Read code, prior 2 years	Prior 1 to 730 days (inclusive)
	GP - Smoker	Smoking status, prior 2 years	Prior 1 to 730 days (inclusive)
	GP - BMI 30+	BMI greater than equal to 30, prior 2 years	Prior 1 to 730 days (inclusive)
	GP - HbA1c > 10	HbA1c greater than 10, prior 2 years	Prior 1 to 730 days (inclusive)
	GD - QOF ARTF	QOF register: Atrial fibrillation	Prior 1 to 730 days (inclusive)
	GP - QOF CKD	QOF register: Stage 3 to 5 chronic kidney disease	Prior 1 to 730 days (inclusive)
	GP - QOF Depression	QOF register: Depression QOF register: number of different registers, 3 or	Prior 1 to 730 days (inclusive)
	GP - Number of QOF DX categories 3+	more	Prior 1 to 730 days (inclusive)
	GP - Number of phone contacts last 0-	Number of GP telephone consults prior 1-3 months	Prior 1 to 3 months (inclusive)
		reamber of or telephone consults prior 1-5 months	i nor i to o montris (inclusive)

> Choosing a model to predict hospital admission. An observational study of new variants of predictive models for case finding.

John Billings, Associate Professor (1) Theo Georghiou, Senior Research Analyst (2) Ian Blunt, Senior Research Analyst (2) Martin Bardsley, Director of Research (2)

¹ Robert F. Wagner Graduate School of Public Service, New York University, 295 Lafayette Street, Room 3010, New York, NY 10012-9604, USA

² Nuffield Trust, 59 New Cavendish Street, London W1G 7LP, UK

JK Corresponding Author theo.georghiou@nuffieldtrust.org.uk

Key words:

Predictive Risk, Urgent care, Hospital admission

Word count: 4,090

ABSTRACT

Objectives: To test the performance of new variants of models to identify people at risk of an emergency hospital admission. We compared (1) the impact of using alternative data sources (hospital inpatient, A&E, outpatient, and GP electronic medical records) (2) the effects of local calibration on the performance of the models and (3) the choice of population denominators.

Design: Multivariate logistic regressions using person level data adding each data set sequentially to test value of additional variables and denominators.

Setting: Five Primary Care Trusts within England.

Participants: 1,836,099 people aged 18-95 registered with GPs on 31 July 2009.

Main outcome measures: Models to predict hospital admission and readmission were compared in terms of positive predictive value and sensitivity for various risk strata and with receiver operating curve C statistic.

Results: The addition of each data set showed moderate improvement in number of patients identified with little or no loss of positive predictive value. However, even with inclusion of GP electronic medical record information, the algorithms identified only a small number of patients with no emergency hospital admissions in the prior two years. The model pooled across all sites performed almost as well as models calibrated to local data from just one site. Using population denominators from GP registers led to better case finding.

Conclusions: These models provide a basis for wider application in the NHS. Each of the models examined produce reasonably robust performance and offers some predictive value. The addition of more complex data add some value, but we were unable to conclude that pooled models performed less well than those in individual sites. Choices about model should be linked to the intervention design. Characteristics of patients identified by the algorithms provide useful information in the design/costing of intervention strategies to improve care coordination/outcomes for these patients.

Article focus

- The use of statistical models to predict risk of hospital admissions are increasingly used to prioritise patients for preventive care. Models exist in several different forms and use a variety of input data sets.
- This paper compared the performance of a variety of models built using different datasets.

Key messages

- The addition of more detailed data sets led to moderate improvement in number of patients identified with little or no loss of positive predictive value.
- The use of GP registry data for the denominator proved to be of significant importance. By including all patients in an area, not just those with prior hospital use, improved rates of case finding were observed.
- Models calibrated to local data sets did not show a consistent improvement over models built
 on pooled data.

Strengths and limitations of this study

- The analysis is based on populations from only five areas in England, however this is the largest UK population (1.8M people) used in the development of a publicly available risk tool.
- The success of a predictive model depends on many factors beyond the statistical performance of the model.

INTRODUCTION

There remains continuing interest in identifying patients at risk of future hospital admissions. Policies providing penalties[1] or non-payment[2] for hospital readmissions that put providers at risk for a share of total health expenditures have been developed for in the U.S. and in England. These create even stronger incentives to identify high risk patients to target care coordination and management strategies that may potentially reduce future inpatient expenditures.

Most predictive modelling approaches have used administrative data from claims in the U.S. or hospital data from Hospital Episode Statistics (HES) or Secondary Uses Services (SUS) in England. These data provide the information on prior utilisation and diagnostic history to develop predictive models for patients at risk of future hospitalization.[3] Payor claims data in the U.S. provide rich information on care provided in hospitals, home care services and nursing home use, as well as detailed pharmacy prescription history.[4] In England, -the most commonly used models (such as in the now outdated Patient at Risk of Readmission PARR algorithm)[5,6] are based on hospital admissions data (including day case use, and regular attendances) with some use of accident -and emergency (A&E) and outpatient attendance data as well.[7]

While some predictive modeling efforts in the U.K. have included information from GP electronic medical records (EMRs),[8,9] using such data presents a number of challenges. These include obtaining permissions for access to EMRs for large populations, linking the records to hospital data, and use of Read codes[10] to develop GP variables. Data from EMRs include additional elements not available in the hospital data sets such as test results (e.g. blood pressure, HbA1c levels), diagnostic history for patients without recent inpatient admissions, prescription history, GP contact patterns (GP visits and telephone contacts), and other personal health markers (e.g. body mass index, smoking status). These additional data elements have the potential to add power to predictive modeling efforts, especially for patients with no or lower levels of recent inpatient use.

Despite the challenges, a number of initiatives around the UK are demonstrating population wide access to EMR data. A common application is in the use of models that assist local clinical commissioning groups (CCGs) in identifying high risk patients.

Though the choice of data sets for a predictive model makes a big difference to the investment required to run these models – at least initially – no studies have looked at the marginal value of different data sets. In this analysis we examine the added value of including data on A&E and outpatient visits (which are readily available) to predictive modeling efforts using hospital inpatient data alone. We also assess the marginal effect of adding GP EMR information to help identify patients at risk of future hospital admissions. Most existing models in use were developed -using logistic regression techniques and we used this standard approach throughout this paper. We recognize that different modelling methods may yield different results but in this analysis we were concerned with the impact of changes in the underlying data sets. Such models will always be limited by the scope and quality of data available, the ways data are grouped and classified and the ways that users can assess up to date information. Despite these problems these models have become commonly used tools.

In addition to the depth of data used there is also a question about how generalisable models are across different sites. In many settings models are recalibrated on local data sets. Yet there is little systematic analysis of the value that this step adds and whether models built on data from one site outperform those built on a larger sample of pooled data. We therefore explore whether there is a need for development of individual site predictive models, or whether models developed from multiple sites can be applied effectively at a new individual site.

METHODS

We conducted analyses separately for five Primary Care Trust areas in England (Newham, Cornwall, Kent, Croydon, Redbridge; total adult population ranging from 209,661 to 693,089). Results are reported for the individual sites and as combined/pooled results (total population 1,836,099). Hospital data was extracted from the Secondary Users Services (SUS)[11] system which contained records of all hospital events (inpatient admissions, outpatient appointments and A&E visits) for the PCTs' registered populations between 1 August 2007 and 30 September 2010. The PCTs also extracted data from GP systems in two forms. Firstly as a register of the local adult population from 1 August 2007 and 31 July 2009, and secondly in the form of datasets recording details of GP consultations over the same time period.

Personally identifiable information was stripped out before any data were passed to the research team. Individuals' NHS numbers (the personal identifiers) were <u>concatenated with a passcode chosen by each</u> <u>of the five PCT areas (and unknown to the research team) and these were</u> pseudonymised <u>at source</u> <u>using secure hash algorithm SHA-256 [12]. This to</u> allow<u>ed</u> for linkage between the hospital and the general practice data <u>from each area</u>, whilst preserving individuals' anonymity.

A series of variables were created from each data set that were believed to be potentially predictive of an unplanned (emergency) hospital admission in the last 12 months of the study period. These variables captured resource use, utilization patterns, diagnostic history, test results, and prescription history in the two years prior to the predictive period. They were created for all individuals aged 18+ registered with a GP in one of the five areas on 31 July 2009. To account for expected time required to obtain and process the hospital and GP EMR data, we included a two-month lag in our analyses, with data from 1 August 2007 to 31 July 2009 used to predict emergency admissions during the period 1 October 2009 to 30 September 2010.

Patient age and gender were obtained from the GP register. Patient area of residence was not available, and so GP practice attributed index of multiple deprivation (2007) was used as an area deprivation measure. The number of months the patient was registered with the PCT in the pre-period was calculated and included in the regression. Hospital inpatient data were used to capture utilization in the 0-90, 91-181, 180-365, and 366-730 days prior to the lag period. The number of emergency and elective admissions for these periods were included and dichotomous variables for any day case or regular attendance use were created.

A broad range of diagnostic variables were developed using primary and secondary diagnosis fields and a Charlson Comorbidity Index [1213] was calculated for each patient and included in the model.

A&E data were used to determine A&E visit rates for various intervals in the pre-period, both total visits and unplanned follow-up visits. A&E diagnostic information was not reliably reported across the five sites and was not included, although X-ray use was included. Outpatient data provided variables on outpatient visit rates for various intervals, as well as missed appointment rates and the number of different specialty types consulted. Diagnostic information in outpatient data was missing in more than 95% of cases and was not included.

GP EMR data were used to create proxy visit rates (these may include both actual GP visits, in addition to other events documented in a person's records) for various intervals and to capture any increase in visit rates at the end of the pre-period that may reflect increased morbidity in a patient. EMR Read codes (CTV3 version) were used to obtain test results (blood pressure, blood serum levels, HbA1c levels, etc.), body mass index, smoking history, prescription history (number and type), and a range of diagnostic variables during the pre-period.

Variables from each data set (inpatient (including day case and regular attenders), A&E, outpatient, and GP EMRs) were added and modeled sequentially using standard logistic regression in SPSS v20. Emergency admission in the next 12 months was used as the dependent variable, producing a risk score ranging from 0-100. Separate models were developed for each PCT area, and analysis was limited to patients aged 18-95 who were on the GP register in the area. Over-fitting was tested using a split sample approach, with only minor differences observed in positive predictive values (PPV), sensitivity, and specificity.

Findings provided here include both individual site results and results combined across the five sites. We also created five additional predictive models (referred to below as the 'four-site regression models'), each one combining data from four sites and applying coefficients to the fifth remaining site. With this we could compare results with individual site predictive models to help assess the value of local model development.

The full list of more than 300 potential variables was ultimately reduced to 88 by exclusion of variables with low volumes and low significance levels across the sites. The 88 variables ultimately included in the model (and regression coefficients), may be found in Appendix B and D, and a full listing of the variables

considered for inclusion and detailed specification of each variable are available at http://www.nuffieldtrust.org.uk/.

Cost variables were examined, with secondary care activity costed according to the method used in development of the person based formula for allocating commissioning funds to general practices in England. [1314] Ultimately, these were not included in the predictive models because of concerns about difficulties in constructing these variables by possible future users, however costs are included in descriptive findings to help in design of intervention strategies.

Predictive modeling performance is typically documented reporting PPV and sensitivity at the risk score threshold of 50. However, because interventions may be targeted at patients with higher or lower risk scores and interventions strategies may be calibrated differently depending on risk level and characteristics of patients at various risk score levels, we report PPV sensitivity at 20 risk score cutoff points (vigintiles) and provide detailed patient characteristics at risk score thresholds of 50 and 30 to facilitate intervention design.

RESULTS

Pooled Individual Site Results

There were 1,836,099 people aged 18 and over who were registered with a GP practice on 31 July 2009. Table 1 shows the combined results of individual site regressions including the number of patients correctly identified, PPV, and sensitivity for four models:

- (i) IP based on hospital inpatient data only (including day cases and regular attendances)
- (ii) IPAE using inpatient and A&E data
- (iii) IPAEOP using inpatient A&E and outpatient data
- (iv) IPAEOPGP using inpatient, A&E, outpatient data and GP EMR.

At the traditional risk score threshold level of 50 all four models perform respectably in terms of PPV (ranging from .523 to .538), but sensitivity remains quite low across all models (.049 to .060). Lowering the threshold to 30 increases sensitivity somewhat with a concomitant reduction in PPV (ranging from .417 to .422). The ROC area under the curve (C statistic) improved with the addition of each data set, increasing from .731 with the inpatient-only model to .780 with the full model.

Risk		IP Data			IP+AE Data		IP	AE+OP Dat	а	IP	+AE+OP+GP	Data
Score Threshold	True Positive	PPV	Sensitivity	True Positive	PPV	Sensitivity	True Positive	PPV	Sensitivity	True Positive	PPV	Sensitivity
1	94,692	0.052	1.000	94,692	0.052	1.000	94,692	0.052	1.000	94,692	0.052	1.00
5	54,450	0.126	0.575	56,117	0.128	0.593	56,438	0.131	0.596	61,498	0.133	0.6
10	33,053	0.219	0.349	34,102	0.221	0.360	35,033	0.223	0.370	39,986	0.220	0.4
15	22,898	0.285	0.242	23,166	0.293	0.245	24,261	0.290	0.256	28,697	0.283	0.3
20	16,181	0.346	0.171	16,915	0.347	0.179	17,719	0.344	0.187	21,601	0.333	0.22
25	12,670	0.385	0.134	13,182	0.386	0.139	13,754	0.383	0.145	16,672	0.378	0.17
30	10,061	0.421	0.106	10,555	0.422	0.111	11,010	0.419	0.116	13,196	0.417	0.13
35	8,130	0.449	0.086	8,600	0.450	0.091	8,986	0.448	0.095	10,516	0.450	0.11
40	6,700	0.477	0.071	7,139	0.478	0.075	7,421	0.476	0.078	8,494	0.479	0.0
45	5,535	0.501	0.058	5,976	0.504	0.063	6,167	0.499	0.065	6,921	0.510	0.0
50	4,627	0.529	0.049	5,027	0.531	0.053	5,172	0.523	0.055	5,669	0.538	0.06
55	3,862	0.551	0.041	4,222	0.551	0.045	4,359	0.543	0.046	4,581	0.562	0.04
60	3,239	0.574	0.034	3,555	0.569	0.038	3,658	0.567	0.039	3,735	0.587	0.03
65	2,711	0.593	0.029	3,012	0.590	0.032	3,041	0.587	0.032	3,034	0.618	0.03
70	2,245	0.617	0.024	2,481	0.612	0.026	2,519	0.610	0.027	2,453	0.645	0.02
75	1,816	0.634	0.019	2,049	0.639	0.022	2,064	0.631	0.022	1,921	0.666	0.02
80	1,418	0.666	0.015	1,662	0.656	0.018	1,646	0.654	0.017	1,478	0.696	0.0
85	1,064	0.679	0.011	1,293	0.674	0.014	1,276	0.679	0.013	1,114	0.711	0.0
90	769	0.710	0.008	932	0.688	0.010	935	0.702	0.010	754	0.738	0.00
95	478	0.748	0.005	592	0.725	0.006	586	0.728	0.006	437	0.771	0.0
Тор 1%	8,214	0.447	0.087	8,353	0.455	0.088	8,410	0.458	0.089	8,722	0.475	0.0
Тор 5%	24,873	0.271	0.263	25,355	0.276	0.268	25,712	0.280	0.272	26,991	0.294	0.2
	ROC C Statistic	0.731			0.745			0.752			0.780	

Table 1 Model performance, four models: IP, IPAE, IPAEOP, IPAEOPGP. Five site individual runs combined.

 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Of particular note is the finding that the addition of each data set added power, that is, correctly identified more patients with an admission in the next 12 months, with only a minor reduction in PPV. At a risk threshold of 50, the addition of A&E data resulted in increase of 400 (8.6%) correctly flagged patients, with no loss in PPV. The inclusion of outpatient data added a more modest 2.9%, but with a slight loss in PPV (.531 to .523). The addition of GP EMR data added an additional 9.6% of patients, while actually increasing the accuracy of the model (PPV increasing from .523 to .538). The added power of the A&E data set is less substantial at a risk score threshold of 30 (4.9%), but outpatient and GP EMR data sets had larger increases in correctly identified patients (4.3% and 19.9%).

There were also important differences between the models in terms of the characteristics of patients identified as high risk. For example, at a risk score cutoff of 50, patients identified using inpatient data alone had high prior emergency inpatient utilization rates with 2.62 admissions in the prior year compared to 2.43 when A&E data was added; 2.34 with addition of outpatient, and 2.20 with the addition of GP EMR data - see Table 2.

The inclusion of the additional data sets also led to a reduction in observed morbidity level of patients at the 50 threshold, with lower numbers of long term conditions, fewer patients with multiple long term conditions, lower Charlson Comorbidity Index scores, less history of alcohol abuse and mental illness, and lower emergency inpatient costs in the years prior to the predictive period. Similar, but less substantial differences were observed at the risk score threshold of 30. The addition of the A&E data set resulted in higher rates of A&E visits in the pre-period among patients identified at both risk score cutoff levels, and the addition of outpatient data resulted in higher outpatient visit and missed visit rates among identified patients.

These findings suggest inclusion of the additional data sets added some predictive power and generally tended to find <u>additional</u> patients who were less severely ill <u>(more severely ill patients tended to remain high risk)</u>. Thus they potentially offer an opportunity for intervention at earlier stages in the progression of a patient's condition._-However, the number of patients identified with no prior emergency inpatient utilization in the prior two years was relatively small across all models. At a risk score threshold of 50, only 0.3% of patients correctly identified by the inpatient-only model had no prior emergency admissions in the previous two years, and increasing only modestly 3.2% in the full model (Table 3). At a risk threshold of 30, the rates were higher, but only reaching 12.4% for the full model.

Table 2 Patient characteristics by risk score threshold four models: IP, IPAE, IPAEOP, IPAEOPGP. Five site

individual runs combined.

-	Risk Score 50+				Risk Score 30+				
	IP Data	IPAE Data	IPAEOP Data	IPAEOPGP Data	IP Data	IPAE Data	IPAEOP Data	IPAEOPG Data	
Number of patients	8,743	9,473	9,892	10,545	23,912	25,021	26,304	31,65	
Patients with adm next 12 mos	4,627	5,027	5,172	5,669	10,062	10,554	11,011	13,19	
Mean Age	73.9	72.3	71.2	72.2	75.3	74.0	73.4	73	
Age 18-39	6.2%	8.4%	8.7%	7.8%	5.1%	6.8%	7.0%	6.4	
Age 40-54	8.7%	9.6%	10.9%	10.6%	7.0%	7.8%	8.6%	8.5	
Age 55-64	6.9%	7.4%	7.8%	8.1%	6.4%	6.4%	7.0%	7.3	
Age 65-74	14.4%	13.9%	15.0%	13.5%	13.9%	13.8%	14.4%	13.7	
Age 75-84	30.5%	28.9%	28.2%	27.4%	32.1%	31.1%	30.3%	29.	
Age 85+	33.3%	31.8%	29.3%	32.6%	35.5%	34.1%	32.7%	34.4	
Female	55.2%	55.2%	54.9%	54.7%	56.9%	57.1%	56.6%	56.	
Practice IMD	24.6	24.9	24.8	24.3	24.2	24.3	24.3	23	
Ischaemic Heart Disease	36.2%	34.2%	33.2%	32.1%	29.8%	28.4%	27.8%	25.2	
Angina	21.7%	20.5%	19.5%	19.3%	17.3%	16.4%	15.7%	14.5	
Hypertension	64.5%	61.2%	59.9%	59.0%	59.4%	56.7%	55.1%	50.9	
CHF CVD	19.2% 21.7%	17.8% 20.1%	16.9% 19.3%	15.9% 18.1%	14.0% 16.9%	13.2% 15.8%	12.5% 15.2%	10.1 13.3	
COPD	21.7%	20.1%	20.6%	18.1%	17.2%	15.8%	15.2%	13.	
Asthma	23.4%	21.4%	20.6%	19.1%	17.2%	16.3%	15.7%	13.4	
Diabetes	34.1%	32.4%	31.6%	28.8%	30.1%	28.8%	27.6%	23.	
Renal Failure	16.5%	14.6%	14.2%	13.3%	11.2%	10.4%	10.0%	23.	
Any long term conditions	89.8%	87.0%	85.8%	85.0%	86.6%	83.6%	81.4%	75.	
Any cancer	15.4%	13.8%	13.4%	12.4%	13.3%	12.7%	12.2%	10.	
Alcohol misuse	10.0%	10.0%	9.6%	9.1%	7.0%	6.7%	6.4%	5.8	
Mental illness	32.0%	30.6%	28.9%	27.2%	23.5%	22.3%	21.3%	18.	
Number long term conditions	2.67	2.51	2.43	2.31	2.20	2.10	2.02	1.	
Charlson Index	3.96	3.69	3.55	3.28	3.09	2.95	2.82	2.	
Emerg adms 1yr prior	2.62	2.43	2.34	2.20	1.64	1.57	1.50	1.	
Emerg adms 2 yr prior	1.78	1.67	1.61	1.50	1.15	1.10	1.05	0.	
No emerg adm prior 2 yrs	0.6%	1.9%	3.3%	4.3%	4.2%	6.5%	9.2%	16.	
Elect adms 1yr prior	0.32	0.29	0.31	0.28	0.27	0.26	0.27	0.	
Elect adms 2 yr prior	0.24	0.23	0.26	0.24	0.20	0.20	0.22	0.	
Any day case 1yr prior	31.9%	30.8%	31.6%	28.7%	31.5%	30.7%	30.4%	26.	
Any day case 2yr prior	28.9%	27.6%	28.0%	25.7%	27.8%	26.9%	26.7%	23.	
Emerg adm cost 1yr prior	£4,500	£4,073	£3,920	£3,688	£2,893	£2,709	£2,604	£2,2	
Emerg adm cost 2yr prior	£2,932	£2,675	£2,583	£2,422	£1,962	£1,822	£1,757	£1,5	
AE visits 1yr prior	2.90	3.59	3.45	3.17	1.83	2.26	2.17	1.	
AE visits 2yr prior	1.90	2.40	2.31	2.10	1.23	1.52	1.46	1	
OP visits 1yr prior	7.27	6.94	9.65	8.23	5.65	5.63	7.39	6	
OP visits 2yr prior	4.30	4.10	5.92	5.08	3.39	3.38	4.54	3.	
OP visits missed 1yr prior	0.47	0.48	0.74	0.65	0.35	0.36	0.53	0. 0.	
OP visits missed 2yr prior	0.49	0.48	0.71	0.61	0.33	0.34	0.48		
GP visits 1yr prior	42.9	42.7	43.3	52.5	38.5 32.4	38.4	38.8	4	
GP visits 2yr prior Any high risk BNFs	35.5 73.9%	35.2 71.6%	35.7 72.2%	42.5 84.0%	32.4 69.3%	32.1 67.5%	32.5 68.1%	3 79.	
Num high risk BNFs	1.94	1.85	1.88	2.20	1.64	1.59	1.61	/9.	
High blood pressure	9.0%	9.0%	1.88	9.0%	1.64	1.59	1.61	9.	
Smoker	18.0%	19.0%	19.0%	23.0%	16.0%	16.0%	16.0%	20.	
BMI 30+	16.0%	17.0%	17.0%	17.0%	15.0%	16.0%	16.0%	18.	
HbA1c > 10	5.0%	5.0%	5.0%	7.0%	5.0%	5.0%	4.0%	6.	
Any Em adm next 12 mos	52.9%	53.1%	52.3%	53.8%	42.1%	42.2%	41.9%	41.	
Num Em adm next 12 mos	1.34	1.33	1.29	1.31	0.89	0.89	0.87		
0 Em adm next 12 mos	47.1%	46.9%	47.7%	46.2%	57.9%	57.8%	58.1%	58.	
1 Em adm next 12 mos	23.0%	23.0%	23.2%	23.9%	21.7%	21.9%	21.7%	22.	
2 Em adm next 12 mos	12.5%	12.5%	12.3%	13.2%	10.0%	10.0%	10.0%	9.9	
		7.3%	7.0%	7.1%	4.8%	4.9%	4.8%	4.	
3 Em adm next 12 mos	7.3%	1.570	7.0%	7.170	4.0/0	4.570	4.0/0		
3 Em adm next 12 mos 4+ Em adm next 12 mos	7.3% 10.2%	10.2%	9.8%	9.7%	5.5%	5.5%	5.3%	4.9	

BMJ Open

AE visits next 12 mos	1.88	2.11	2.04	2.04	1.24	1.37	1.36	1.29

Table 3 Proportion of patients correctly identified, who had no emergency admissions in the prior two

 years. Four models:
 IP, IPAE, IPAEOP, IPAEOPGP. Five site individual runs combined.

Prediction threshold	IP Data	IPAE Data	IPAEOP Data	IPAEOPGP Data
Risk Score 50+	0.3%	1.2%	2.3%	3.2
Risk Score 30+	2.7%	4.4%	6.3%	12.4
Top 1%	1.5%	2.9%	4.2%	6.5
Тор 5%	25.9%	26.4%	26.7%	30.8

Individual Site and 'Four-Site Regression' Model Results

Overall the performance of the models was similar at the individual site level. Only modest differences were found in PPV levels and sensitivity across the sites. For runs using non-GP data only (IPAEOP), at the risk score threshold of 50, PPVs ranged from .512 to .552 and sensitivity ranged from .047 to .071. For the model including GP EMRs, PPVs ranged from .521 to .566 and sensitivity from .053 to .073. See Appendix A. There was some variation in the magnitude of regression coefficients between sites, but in general the coefficients were comparable for models based on the non-GP data model (IPAEOP). See Appendix B. For the model including variables from GP EMRs (IPAEOPGP), the level of variation in regression coefficients (size and direction) was somewhat greater for those variables derived from GP data. We observed substantial differences in frequency of reporting of Read codes across sites which no doubt contributed to this variation. The level of significance of individual variables also varied across sites (Appendix C), but most variables were consistently strongly significant across all sites, especially variables involving prior emergency inpatient admissions. Again, higher levels of variation in levels of significance were observed for the GP variables derived from Read codes.

We compared the results for these individual site models to a pooled model combining data from four of the sites and applied coefficients to the remaining individual site. We found generally only small differences in predictive accuracy (PPV) between these two approaches (Table 4), however the individual site models identified a greater number of true positives. For example, in Cornwall at a risk

score cutoff of 50, the individual site model using hospital data identified correctly 1,041 patients while the pooled model identified only 754. In Newham however, the four-site model was more powerful, correctly identifying 858 patients compared to 734 for the individual site approach. In both cases (and in general across all sites), the model identifying larger numbers of true positives had a somewhat lower PPV, suggesting improved case finding volume came at the expense of predictive accuracy.

		IPO	PAE	IPOPAEGP					
	Individual Site Regression		Four Site Regression		Individual Site Regression		Four Site Regressi		
	True Positives	PPV	True Positives	PPV	True Positives	PPV	True Positives	PPV	
Newham									
Risk Score 50+	734	0.552	858	0.517	768	0.566	835	0.523	
Risk Score 30+	1,409	0.450	1,564	0.414	1,570	0.439	1,798	0.409	
Cornwall									
Risk Score 50+	1,041	0.520	754	0.548	1,176	0.545	952	0.556	
Risk Score 30+	2,439	0.406	1,970	0.426	3,032	0.410	2,746	0.411	
Kent									
Risk Score 50+	1,565	0.513	1,387	0.519	1,736	0.521	1,873	0.493	
Risk Score 30+	3,372	0.401	3,067	0.403	4,079	0.397	4,432	0.369	
Croydon									
Risk Score 50+	1,089	0.528	1,192	0.523	1,182	0.550	1,230	0.537	
Risk Score 30+	2,134	0.444	2,258	0.424	2,610	0.442	2,502	0.437	
Redbridge									
Risk Score 50+	743	0.512	863	0.495	807	0.522	607	0.519	
Risk Score 30+	1,656	0.420	1,693	0.415	1,905	0.423	1,390	0.436	

 Table 4 Individual site and four-site regression models. Case finding and predictive accuracy.

Testing alternative population denominators

Models built using inpatient data only (IP) were also built for just the subset of patients who had some inpatient care in the prior two years (to reflect typical predictive modeling efforts that may have been conducted without access to GP registry information), as well as for the group who had had an emergency admission in the prior year (to replicate analyses conducted by PARR users).

Combining the results from the five sites at a risk score threshold of 50, models using <u>the full</u> GP <u>register</u> list denominator correctly identified 4,627 patients compared with 3,572 patients in runs restricted to patients with prior inpatient care and 3,060 to runs limited to patients with an emergency admission in the prior year. This substantial increase in case finding was obtained with only moderate loss in PPV (.529 GP list, .559 prior inpatient and .589 emergency admissions in last year). Similar results were also found for all hospital data models (IPOPAE, though with any hospital use in prior two years, rather than just any inpatient use).

Using the full GP registry population did not result in finding substantial numbers of patients with no emergency admissions in the prior two years, but the increased numbers of patients identified included more patients with less prior use and lower levels of morbidity. For a profile of patients identified using these alternative denominators see http://www.nuffieldtrust.org.uk/.

DISCUSSION

This analysis has looked at the performance of new variants of predictive models for case finding. These models are intended to update and improve upon the established combined predictive model-like [1415] and PARR models [5] widely used in the NHS.

Each of the models examined produced reasonably robust performance, by some measures better or at least comparable to similar prior models [9]. At a risk threshold of 50, patients identified by the models had PPVs ranging from .523 to .538. While the percent of all patients with future admissions identified was relatively low (sensitivity .049 to .060), lowering the risk threshold allows the identification of more patients with relatively small loss in PPV (e.g. at a risk threshold of 30, the full model identified 14% of future admissions with a PPV of .417). Users of predictive modeling algorithms have obvious trade-offs between maximizing the number of patients identified and predictive accuracy. Lower risk score thresholds will find more patients, but these patients are increasingly less likely to have future admissions.

The implications for intervention design are important. Patients at lower risk thresholds have less prior inpatient use and lower morbidity, so an intervention here might be calibrated to be less intensive. But because the models are less accurate at lower risk scores, the amount that can be spent on an intervention is also reduced if you wish to achieve financial break-even (ie where the cost of intervention is off-set by cost savings from reduction in future admissions). As documented in Table 2,

at a risk score threshold of 50, the rate of future admission for patients identified by the full model (IPAEOPGP data) was 1.31 admissions per year with an associated cost of £2,270. If there were a 10% reduction in future admissions, £227 could be spent on an intervention to improve care coordination and still achieve break-even. However, at a lower risk threshold of 30, the lower rates of future admissions and costs means that lower intervention expenditures are required to achieve break-even (£151 with a 10% reduction in future admissions). A detailed business case analysis with mean emergency inpatient costs in the next 12 months within each risk vigintile level is available via http://www.nuffieldtrust.org.uk/.

These data also provide other information that may be useful in the development of intervention strategies. As shown in Table 2, patients identified by the models have extremely high rates of chronic disease (85-90% with long term conditions at risk threshold of 50), often with multiple long term conditions and high Charlson Comorbidity Index levels, indicating serious medical needs. However, these patients already have high use of outpatient care and very high GP visit rates. This suggests simple access to ambulatory care is not the issue, but prevention needs to look at care coordination and management of complex problems and at the ability of patients and their families to manage chronic illness. High risk patients identified by the models also have relatively high rates of mental illness (27-32% at risk threshold of 50) and moderate levels of alcohol abuse, factors that are likely to complicate any intervention strategy.

It is also important to note the limitations of these data in helping frame the design of any intervention strategy. Other studies have documented that high risk patients often have important characteristics related to care needs and patient capacity not captured by administrative data and EMRs. For example, interviews with high risk patients and their families have documented high levels of social isolation for many, as well as precarious housing status. [1516] These non-medical factors are likely to have significant impact on health status and utilization patterns. Moreover, not much is known about how/whether care coordination and management has actually failed for these patients. Are these high risk patients just very sick patients whose hospitalizations are largely not preventable/avoidable [17], or has the care delivery system failed in some important dimensions that can be corrected with improved care coordination and management? These data cannot answer this very critical question, and it is clear that the field would benefit from further study that examined the circumstances of patients identified as

high risk by predictive modeling algorithms to sort out more clearly the factors contributing to high rates of emergency admission.

This study does document the value of incorporating data sets beyond inpatient records. The addition of A&E and outpatient records resulted in identification of more high risk patients with little or no loss of predictive accuracy. These data sets are readily available and have standardized reporting formats that facilitate analysis. While the absence of useful diagnostic information in these data sets is a limiting factor, the improvement in case finding and usefulness in descriptive profiling of high risk patients to help in intervention design (e.g. high rates of A&E use rates, high rates of missed outpatient appointments) suggests their inclusion is clearly merited.

Use of GP EMRs presents significant challenges. While the lack of access to these data is unlikely to remain a problem, the variation in completeness and quality of data is problematic. The use of the unwieldy Read codes system makes analysis difficult, and we observed significant differences across sites in reporting patterns. Some of these differences may be caused by under reporting of diagnostic variables, others by differences in coding approaches. However, the potential improvement in case finding, especially among patients with lower rates of utilization in the pre-period, suggests these barriers are worth confronting. Our development of new variables beyond those included in prior predictive modeling efforts [8] contributed substantially to enhanced case finding, and further work on variable development is likely to lead to further improvements. Again, these data are also useful in providing descriptive information on high risk patients to help in intervention design (e.g. documenting potential targets of opportunity such as uncontrolled hypertension or diabetes).

This study does not provide definitive findings on the value of developing individual site models compared to simply applying coefficients from multi-site or national model coefficients to local data. Our four-site regression models generally had comparable PPVs to individual site models, but for the majority of sites- the four-site regression approach correctly identified somewhat fewer number patients with future admissions. Though it is tempting to speculate on whether differences in the health needs of the population or coding differences affect model performance, we did not observe any clear patterns between the areas. Our analysis is somewhat limited by the small number of sites involved which might cause somewhat greater variability in regression coefficients (regression coefficients for each of the five four-site models are available at http://www.nuffieldtrust.org.uk/). Development of a

national model using SUS data only is planned to further assess the need/value of locally developed models.

Finally, it is worthy of note that use of the GP registry data for the denominator also proved to be of significant importance. Many prior predictive modeling efforts have been limited to patients with utilization history in whatever data sets were included. By including all patients in an area, not just those with prior use, the impact on predictive modeling of prior use was apparently enhanced. As a result, patients with more moderate levels of prior use and morbidity were found to be of higher risk than patients with no prior use at all, and were often assigned higher risk scores than when the analysis included just patients who had prior use. Accordingly, the use of the GP registry as the denominator can improve rates of case finding and may permit identification of patients at earlier stages.

Acknowledgments

The authors wish to thank all individuals in the PCTs who contributed data used for this study during the Whole Systems Demonstrator, Virtual Wards and Social care end of life studies.

Contributors

The preparation of data sets and input variables and costs were undertaken by TG and by IB; JB did the central modelling. MB advised on the analysis and results and managed the work of the research team at the Nuffield Trust. All authors contributed to the writing of the paper. JB is the guarantor.

Funding and disclaimer

The research received no specific grant but was funded by the Nuffield Trust. The resulting models will be used as part of the WSD trial funded by the Department of Health.

Competing interests

All authors have completed the Unified Competing Interest form at <u>www.icmje.org/coi disclosure.pdf</u> and declare that no authors have any relationships with any companies that might have an interest in the submitted work in the previous 3 years; none of their spouses, partners or children have any financial relationships that may be relevant to the submitted work; and no authors have any nonfinancial interests that may be relevant to the submitted work.

Ethical approval

This study only involved the analysis of pseudonymous secondary data. Since there were no identifiable human subjects, ethics approval was not required for this research and informed consent was not sought.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

Details of the derived models variables and definitions are available from the authors at the Nuffield trust at research@nuffieldtrust.org.uk.

References

1 Section 3025 of the Affordable Care Act added section 1886(q) to the Social Security Act establishing the Hospital Readmissions Reduction Program, which requires the Center for Medicare and Medicaid Services to reduce Medicare payments to hospitals with excess rates of readmissions for selected conditions within 30 days of discharge.

2 Department of Health. Payment by Results Guidance for 2012-13. 2012. Gateway reference 17250 London: Department of Health

3 Kansagara D, Englander H, Salanitro A, Kagen D, Theobald C, Freeman M, Kripalani S Risk prediction models for hospital readmission: A systematic review. JAMA 2011;306(15):1688-1698

4 Billings J, Mijanovich T. Improving the Management of Care for High Cost Medicaid Patients. Health Affairs. 2007;26(6):1643-1655.

5 Billings J, Dixon J, Wennberg D, et al. Case Finding for Patients at Risk of Re-Hospitalisation: Development of an Algorithm to Identify High Risk Patients. BMJ 2006;333(7563):327-32,

6 Case Finding Algorithms for Patients at Risk of Re-hospitalisation: PARR1 and PARR 2. Kings Fund, February, 2006 (http://www.kingsfund.org.uk/sites/files/kf/field/field_document/PARR-case-finding-algorithms-feb06.pdf - last accessed 04/06/2013).

7 Lewis G, Curry N and Bardsley M Choosing a predictive risk model: a guide for commissioners in England

8 Combined Predictive Model: Final Report. Kings Fund, Dec 2006. (http://www.kingsfund.org.uk/sites/files/kf/field/field_document/PARR-combined-predictive-model-final-reportdec06.pdf last accessed 04/06/2013),

9 Wales Predictive Model: Final Report and Technical Documentation, 2008 (http://www.nliah.com/portal/microsites/Uploads/Resources/k5cma8PPy.pdf last accessed 04/06/2013).

10 http://systems.hscic.gov.uk/data/uktc/readcodes - last accessed 14/05/2013

11 http://www.connectingforhealth.nhs.uk/systemsandservices/sus - last accessed 14/1/2013.

12 National Institute of Standards and Technology. Secure Hash Standard (180-3). October 2008.

(http://csrc.nist.gov/publications/fips/fips180-3/fips180-3 final.pdf last accessed 30 July 2013)

12-13 Charlson ME, Popei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Disease. 1987;40:373-383.

13-14 Dixon J, Smith P, Gravelle H, Martin S, Bardsley M, Rice H, Georghiou T, Dusheiko M, Billings J, De Lorenzo M.
I. A person based formula for allocating commissioning funds to general practices in England: development of a statistical model BMJ 2011;343:d6608 doi: 10.1136/bmj.d6608 Published 22 November 2011.

14-<u>15</u> Chenore T, Pereira Gray DJ, Forrer J, Wright C., Evans PH, Emergency hospital admissions for the elderly: insights from the Devon Predictive Model J Public Health (2013)

15-16 Raven M, Billings J, Goldfrank L, Manheimer E, Gourevitch M. Medicaid Patients at High Risk for Frequent Hospital Admission: Real-time Identification and Remedial Risks. Journal of Urban Health. 2009;86(2):230-241.

<text> 17 Joynt KE, Gawande AA, Orav EJ, JHA AK. Contribution of Preventable Acute Care Spending to Total Spending for High-Cost Medicare Patients. JAMA. 2013;309(24):2572-2578.

Appendix A. PPV and sensitivity IPAEOP and IPAEOPGP models. Individual site runs.

					IP+AE+	OP Data				
Risk Score Newham		vham	Corr	wall	Ke	nt	Croy	don	Redbridge	
Threshold PPV Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity		
1	0.049	1.000	0.061	1.000	0.052	1.000	0.046	1.000	0.047	1.00
10	0.236	0.361	0.216	0.391	0.213	0.339	0.241	0.378	0.238	0.42
20	0.368	0.201	0.328	0.188	0.326	0.158	0.377	0.210	0.357	0.23
30	0.450	0.136	0.406	0.109	0.401	0.094	0.444	0.142	0.420	0.14
40	0.506	0.098	0.477	0.072	0.457	0.062	0.486	0.100	0.475	0.09
50	0.552	0.071	0.520	0.047	0.513	0.043	0.528	0.073	0.512	0.06
60	0.585	0.052	0.560	0.030	0.569	0.031	0.580	0.055	0.532	0.04
70	0.632	0.037	0.622	0.021	0.618	0.022	0.610	0.040	0.555	0.02
80	0.678	0.024	0.655	0.013	0.673	0.014	0.659	0.028	0.571	0.01
90	0.717	0.013	0.692	0.007	0.724	0.008	0.710	0.016	0.617	0.00
Top 1%	0.501	0.102	0.470	0.077	0.417	0.080	0.482	0.106	0.474	0.10
Top 5%	0.287	0.291	0.292	0.240	0.259	0.249	0.290	0.318	0.296	0.3

	IP+AE+OP+GP Data													
Risk Score	Newham		Corn	wall	Ke	nt	Croydon		Redb	ridge				
Threshold	Threshold PPV S	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity	PPV	Sensitivity				
1	0.049	1.000	0.061	1.000	0.052	1.000	0.046	1.000	0.047	1.00				
10	0.228	0.410	0.213	0.439	0.210	0.392	0.237	0.452	0.237	0.45				
20	0.360	0.235	0.323	0.232	0.314	0.194	0.358	0.267	0.348	0.27				
30	0.439	0.152	0.410	0.136	0.397	0.113	0.442	0.174	0.423	0.1				
40	0.499	0.103	0.481	0.084	0.459	0.072	0.494	0.114	0.482	0.1				
50	0.566	0.074	0.545	0.053	0.521	0.048	0.550	0.079	0.522	0.0				
60	0.606	0.052	0.602	0.033	0.580	0.032	0.589	0.052	0.563	0.04				
70	0.657	0.036	0.659	0.021	0.644	0.021	0.643	0.035	0.616	0.0				
80	0.723	0.021	0.714	0.013	0.694	0.013	0.694	0.021	0.651	0.0				
90	0.766	0.012	0.745	0.006	0.752	0.007	0.735	0.011	0.655	0.0				
Top 1%	0.504	0.102	0.490	0.081	0.438	0.084	0.502	0.110	0.487	0.10				
Top 5%	0.296	0.300	0.309	0.254	0.272	0.262	0.307	0.337	0.312	0.3				

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Appendix B Regression	coefficients IPAEC	P and IPAFOPGP	models	Individual site runs
Appendix D Regiession	T COETHCIENCS. IF ALC	F and IFALOFUE	mouels.	individual site runs.

			AE+OP Da					E+OP+GP [
	NH	CW	КТ	CR	RB	NH	CW	КТ	CR
Age	0.015	0.003	0.009	0.010	0.019	0.001	-0.004	0.002	0.001
Age 65-74	0.280	0.409	0.295	0.380	0.261	0.236	0.276	0.203	0.244
Age 75-84	0.738	0.905	0.731	0.847	0.734	0.721	0.672	0.605	0.708
Age 85+	1.076	1.483	1.226	1.178	1.109	1.150	1.206	1.086	1.187
Female	0.239	0.002	0.044	0.178	0.058	0.114	-0.095	-0.075	-0.014
Practice IMD	0.013	0.003	0.016	0.018	0.012	0.008	0.004	0.017	0.010
Months registered 1 yr prior	0.014	-0.011	-0.005	-0.018	-0.013	0.011	-0.011	-0.003	-0.010
Months registered 2 yrs prior	-0.022	-0.019	-0.016	-0.007	-0.023	-0.021	-0.024	-0.019	-0.011
EM Adms prior 0-90 days	0.382	0.471	0.321	0.310	0.282	0.367	0.420	0.283	0.269
EL Adms prior 0-90 days	0.045	0.216	0.155	0.153	0.148	0.033	0.159	0.074	0.097
Any attender prior 0-90 days	0.115	0.027	0.001	0.041	0.073	0.135	0.026	0.010	0.042
Any day case prior 0-90 days	0.094	0.234	0.110	0.111	0.251	0.037	0.173	0.039	-0.019
EM Adms prior 91-180 days	0.215	0.310	0.351	0.282	0.185	0.217	0.262	0.297	0.243
EL Adms prior 91-180 days	0.321	0.150	0.062	0.204	0.081	0.283	0.128	0.027	0.118
EM Adms prior 181-365 days	0.113	0.345	0.350	0.248	0.146	0.124	0.289	0.292	0.227
EL Adms prior 181-365 days	0.097	0.120	0.104	0.118	0.170	0.072	0.079	0.060	0.035
Em Adms 2 yrs prior	0.102	0.269	0.307	0.181	0.143	0.116	0.216	0.250	0.178
Any day case 2 yrs prior	0.096	0.157	0.186	0.151	0.179	0.058	0.092	0.112	0.005
DXMI	-0.108	0.097	-0.105	-0.004	0.376	-0.197	-0.003	-0.163	-0.111
DX CHF	-0.348	-0.070	-0.246	-0.069	-0.337	-0.370	-0.178	-0.269	-0.110
DX CVD	0.296	0.227	0.033	0.037	-0.040	0.269	0.166	-0.001	-0.099
CD CTD	0.030	-0.024	0.101	-0.380	-0.029	0.071	-0.192	-0.010	-0.427
DX PVD	-0.245	0.124	0.099	-0.100	0.021	-0.253	0.048	0.026	-0.096
DX Asthma	0.082	0.143	0.184	0.099	0.192	-0.114	-0.107	-0.023	-0.081
DX COPD	0.204	0.251	0.277	0.193	0.123	-0.169	-0.139	-0.036	-0.330
DX Diabetes	0.240	0.303	0.285	0.253	0.276	-0.046	-0.052	-0.016	-0.124
DX Diabetes with complications	0.059	-0.221	0.062	-0.014	0.334	0.062	-0.176	0.095	0.004
DX Renal Disease	0.408	0.022	0.085	0.128	0.199	0.356	0.005	0.073	0.063
DX Cancer	-0.165	-0.019	-0.062	-0.308	0.041	0.041	0.005	-0.010	-0.207
DX Mental	0.498	0.316	0.363	0.484	0.077	0.340	0.131	0.111	0.266
DX Alcohol	0.569	0.684	0.505	0.673	0.974	0.281	0.530	0.357	0.200
DX Alconol DX Dementia	-0.548	-0.589	-0.551	-0.402	-0.596	-0.530	-0.486	-0.440	-0.669
DX Cognitive Impairment						-0.330	0.046	-0.440	
0	-0.117	0.016	0.025	0.110	0.187				0.088
DX ACS Condition	0.364	0.270	0.239	0.267	0.306	0.269	0.161	0.134	0.114
Charlson Index	0.055	0.063	0.060	0.101	0.025	0.048	0.062	0.037	0.086
AE visits prior 0-90 days	0.236	0.267	0.355	0.309	0.359	0.179	0.230	0.265	0.199
AE unplanned follow-up visits prior	-0.094	-0.583	-0.533	-0.874	-0.383	-0.107	-0.566	-0.452	-0.703
0-90 days									
AE X-ray prior 0-90 days	0.348	0.437	0.058	0.104	0.367	0.303	0.382	0.027	0.040
AE visits prior 91-180 days	0.265	0.262	0.220	0.225	0.277	0.197	0.225	0.165	0.142
AE unplanned follow-up visits prior	-0.023	-0.560	-0.229	-0.296	-0.298	-0.026	-0.543	-0.177	-0.225
91-180 days									
AE X-ray prior 91-180 days	0.227	0.117	0.120	0.346	-0.064	0.210	0.015	0.101	0.237
AE visits prior 181-365 days	0.264	0.205	0.135	0.171	0.181	0.216	0.174	0.090	0.115
AE unplanned follow-up visits prior	-0.251	-0.490	-0.184	-0.261	-0.203	-0.214	-0.449	-0.131	-0.175
181-365 days	0.251	0.450	0.104	0.201	0.205	0.214	0.445	0.151	0.175
AE X-ray prior 181-365 days	0.262	-0.040	0.281	0.324	0.110	0.225	0.085	0.251	0.244
AE visits 2 yrs prior	0.211	0.159	0.154	0.140	0.160	0.170	0.138	0.114	0.077
AE unplanned follow-up visits 2 yrs	0.207	0 252	0 220	0 4 2 2	0.220	0 220	0 217	0 1 70	0.20
prior	-0.307	-0.352	-0.239	-0.433	-0.339	-0.228	-0.317	-0.178	-0.26
AE X-ray 2yrs prior	0.083	0.231	0.100	0.128	0.179	0.063	0.390	0.082	0.069
Outpatient specialty visits prior 0-	0.046	0.055	0.004	0.004	0.050	0.025	0.000	0.047	0.000
90 days	0.046	0.055	0.091	0.061	0.059	0.025	0.033	0.047	0.030
Outpatient specialty visits missed									
prior 0-90 days	0.155	0.182	0.250		0.146	0.108	0.118	0.171	
Outpatient specialty visits prior 91-									
180 days	0.030	0.013	0.023	0.034	0.029	0.007	0.003	-0.004	0.015
Outpatient specialty visits missed									
prior 91-180 days	0.113	0.239	0.168		0.193	0.087	0.184	0.113	
Outpatient specialty visits prior									
181-365 days	0.016	0.010	-0.005	0.019	0.031	-0.003	0.001	-0.024	0.003
Outpatient specialty visits missed									
	0.128	0.164	0.075		0.140	0.086	0.095	0.036	
prior 181-365 days Outpatient specialty visits 2 yrs									
				0.020	0.010	0.000	0.014	-0.009	0.011
prior	0.019	0.030	0.014	0.028	0.019	0.008	0.014	-0.009	0.011

Formatted Table

Page	50	of	56
------	----	----	----

32 33 34 35 36 - 37 38 39 40 41 42 43 44 45 46 47 48	$\begin{array}{c}1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\2\\13\\14\\5\\6\\17\\18\\9\\20\\21\\22\\24\\25\\26\\27\\28\\9\\31\end{array}$	
41 42 43 44 45 46 47	33 34 35 36 37 38 39	
	41 42 43 44 45 46	

		0.140		0.082	0.097	0.090	0.085	0.129	
					0.218	0.174	0.112	0.287	
					0.131	0.025	0.017	0.106	
					0.166	0.109	0.038	0.070	
					-0.075	0.092	-0.017		
					0.342	0.570	0.166	2.741	
					0.328	0.254	0.114	2.559	
					0.388	0.323	0.583	0.431	
					0.040	0.057	0.017	0 162	
					0.000	0.002	0.004	0.006	
					0.184	0.087	0.126	0.207	
					0.421	0.266	0.296	0.471	
					0.157	0.108	0.111	0.118	
					0.278	0.244	0.199	0.168	
						0.231		0.240	
						0.002		0.046	
					0.236	0.270	0.210	0.362	
					0.176	0.064	0.095	-0.047	
					0.206	-0.003	-0.037	0.091	
					0.069	0.248	0.183	0.133	
					0.002	0.022	0.072	0 1 2 5	
					0.003	-0.023	-0.072	-0.135	
					0.004	0.046	0.004	0.005	
					-0.004	0.040	0.004	-0.005	
-4.665	-3.262	-3.987	-4.363	-4.368	-4.381	-3.275	-4.069	-6.497	
	-4.665	-4.665 -3.262	-4.665 -3.262 -3.987	-4.665 -3.262 -3.987 -4.363	-4.665 -3.262 -3.987 -4.363 -4.368	-0.049 -0.001 0.015 0.000 0.184 0.063 0.219 0.066 0.421 0.157 0.278 0.069 0.113 0.278 0.069 0.113 0.21 -0.041 -0.041 -0.041 -0.041 -0.041 -0.041 -0.041	0.328 0.254 0.388 0.323 -0.049 0.057 -0.001 0.008 0.015 0.004 0.005 0.002 0.184 0.087 0.063 0.022 0.066 0.053 0.421 0.266 0.157 0.108 0.278 0.244 0.069 -0.048 0.113 0.315 0.021 0.017 -0.041 0.031 -0.041 0.031 -0.044 -0.001 0.298 0.231 0.050 0.002 0.236 0.270 0.176 0.003 0.069 0.248 0.003 -0.023 -0.004 0.004	0.328 0.254 0.114 0.388 0.323 0.583 -0.049 0.057 0.017 -0.001 0.008 0.022 0.015 0.004 0.012 0.005 0.003 0.007 0.000 0.002 0.004 0.184 0.087 0.126 0.066 0.053 0.005 0.219 0.202 0.241 0.066 0.053 0.059 0.421 0.266 0.296 0.157 0.108 0.111 0.278 0.244 0.199 0.069 -0.048 0.110 0.113 0.315 0.207 0.021 0.017 0.074 -0.041 0.031 -0.026 -0.040 -0.001 -0.013 0.298 0.231 0.248 0.550 0.002 0.085 0.236 0.270 0.210 0.176 0.064 0.095 0.206 -0.003 -0.037 0.069 0.248 0.183 0.003 -0.023 -0.072 -0.004 0.046 0.004	0.328 0.254 0.114 2.559 0.388 0.323 0.583 0.431 -0.049 0.057 0.017 -0.163 -0.001 0.008 0.022 0.021 0.015 0.004 0.012 0.009 0.005 0.003 0.007 0.006 0.005 0.003 0.007 0.006 0.184 0.087 0.126 0.207 0.066 0.053 0.059 0.066 0.219 0.222 0.241 0.324 0.066 0.053 0.059 0.066 0.421 0.266 0.296 0.471 0.157 0.108 0.111 0.118 0.278 0.244 0.199 0.168 0.069 -0.048 0.110 -0.062 0.113 0.315 0.207 0.191 0.021 0.017 0.074 0.000 -0.041 0.031 -0.026 -0.104 0.236

Annendix C Regression significance levels	IPAEOP and IPAEOPGP models. Individual site runs.
Appendix C Regression significance revers	

	P Data			IP+AE+OP+GP Data						
	NH	CW	КТ	CR	RB	NH	cw	КТ	CR	R
Age	0.000	0.000	0.000	0.000	0.000	0.344	0.000	0.001	0.158	0.0
Age 65-74	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.0
Age 75-84	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.0
Age 85+	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.0
Female	0.007	0.897	0.000	0.001	0.125	0.000	0.000	0.000	0.466	0.1
Practice IMD	0.008	0.036	0.000	0.000	0.000	0.015	0.010	0.000	0.000	0.0
Months registered 1 yr prior	0.002	0.006	0.085	0.247	0.047	0.009	0.011	0.387	0.026	0.2
Months registered 2 yrs prior	0.001	0.014	0.006	0.232	0.276	0.009	0.003	0.001	0.211	0.0
EM Adms prior 0-90 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.0
EL Adms prior 0-90 days	0.664	0.000	0.000	0.029	0.081	0.714	0.000	0.070	0.102	0.3
Any attender prior 0-90 days	0.002	0.000	0.955	0.006	0.004	0.001	0.000	0.489	0.005	0.0
Any day case prior 0-90 days	0.769	0.000	0.001	0.682	0.001	0.561	0.000	0.233	0.699	0.0
EM Adms prior 91-180 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.0
EL Adms prior 91-180 days	0.000	0.000	0.068	0.022	0.528	0.000	0.001	0.437	0.016	0.6
EM Adms prior 181-365 days	0.000	0.000	0.000	0.000	0.000	0.001	0.000	0.000	0.000	0.0
EL Adms prior 181-365 days	0.548	0.000	0.000	0.757	0.019	0.167	0.009	0.030	0.372	0.0
Em Adms 2 yrs prior	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.0
Any day case 2 yrs prior	0.877	0.000	0.000	0.536	0.035	0.177	0.000	0.000	0.864	0.0
DX MI	0.366	0.134	0.049	0.611	0.000	0.076	0.966	0.002	0.216	0.0
DX CHF	0.024	0.253	0.000	0.448	0.008	0.001	0.005	0.000	0.194	0.0
DX CVD	0.015	0.000	0.446	0.610	0.571	0.013	0.002	0.977	0.179	0.5
CD CTD	0.263	0.756	0.150	0.010	0.759	0.645	0.013	0.891	0.000	0.7
DX PVD	0.230	0.061	0.097	0.567	0.665	0.079	0.462	0.661	0.270	0.9
DX Asthma	0.351	0.001	0.000	0.241	0.015	0.135	0.024	0.580	0.184	0.6
DX COPD	0.005	0.002	0.000	0.009	0.098	0.133	0.024	0.483	0.002	0.0
DX Diabetes	0.000	0.000	0.000	0.000	0.000	0.058	0.227	0.649	0.002	0.0
DX Diabetes DX Diabetes with complications	0.000	0.000	0.540	0.363	0.000	0.444	0.227	0.347	0.973	0.0
DX Renal Disease					0.015		0.942			
	0.000	0.731	0.142	0.068		0.001		0.208	0.405	0.2
DX Cancer	0.753	0.751	0.271	0.001	0.421	0.727	0.104	0.862	0.009	0.
DX Mental	0.000	0.000	0.000	0.000	0.370	0.000	0.005	0.008	0.000	0.4
DX Alcohol	0.000	0.000	0.000	0.000	0.000	0.029	0.000	0.000	0.000	0.0
DX Dementia	0.005	0.000	0.000	0.000	0.000	0.004	0.000	0.000	0.000	0.
DX Cognitive Impairment	0.430	0.804	0.620	0.191	0.026	0.456	0.474	0.534	0.199	0.0
DX ACS Condition	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.001	0.0
Charlson Index	0.012	0.000	0.000	0.000	0.212	0.042	0.000	0.006	0.000	0.
AE visits prior 0-90 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.
AE unplanned follow-up visits prior										
0-90 days	0.895	0.001	0.000	0.000	0.133	0.654	0.001	0.000	0.000	0.
AE X-ray prior 0-90 days	0.002	0.000	0.301	0.374	0.052	0.004	0.002	0.636	0.662	0.0
AE visits prior 91-180 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.0
AE unplanned follow-up visits prior										
91-180 days	0.836	0.000	0.000	0.149	0.130	0.899	0.000	0.005	0.214	0.0
AE X-ray prior 91-180 days	0.070	0.582	0.045	0.002	0.672	0.062	0.946	0.090	0.009	0.9
AE visits prior 181-365 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.0
AE unplanned follow-up visits prior	2.500	2.500	2.500	2.500		0.000	2.300	2.000	2.500	0.0
181-365 days	0.182	0.000	0.001	0.122	0.124	0.098	0.001	0.013	0.127	0.0
AE X-ray prior 181-365 days	0.000	0.936	0.001	0.000	0.461	0.001	0.866	0.000	0.000	0.
AE visits 2 yrs prior	0.000	0.000	0.000	0.000	0.000	0.001	0.000	0.000	0.000	0.0
AE unplanned follow-up visits 2 yrs	0.000	0.000	0.000	0.000	5.000	0.000	0.000	0.000	0.000	0.0
prior	0.021	0.008	0.000	0.003	0.009	0.020	0.016	0.000	0.008	0.0
-	0.021	0.555	0.000	0.003	0.009	0.020	0.320	0.000	0.008	0.0
AE X-ray 2yrs prior	0.183	0.555	0.019	0.022	0.005	0.210	0.520	0.048	0.101	0.0
Outpatient specialty visits prior 0-	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	~
90 days	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.0
Outpatient specialty visits missed	0.000	0.000	0.000		0.000	o oo-	0.000	0.000		~
prior 0-90 days	0.000	0.000	0.000		0.002	0.000	0.000	0.000		0.0
Outpatient specialty visits prior 91-										
180 days	0.196	0.043	0.003	0.002	0.016	0.516	0.630	0.648	0.054	0.:
Outpatient specialty visits missed										
prior 91-180 days	0.027	0.000	0.000		0.000	0.039	0.000	0.002		0.0
Outpatient specialty visits prior										
181-365 days	0.763	0.009	0.400	0.094	0.000	0.595	0.844	0.000	0.491	0.
Outpatient specialty visits missed										
prior 181-365 days	0.000	0.000	0.009		0.000	0.001	0.002	0.206		0.0
Outpatient specialty visits 2 yrs										
	0.000	0.000	0.000	0.000	0.000	0.068	0.000	0.046	0.001	0.0
prior	0.000									
prior	0.000	0.000	0.000							

2 3	
3	
4 5 6 7 8	
5	
6	
7	
8	
9 10	
10	
11	
11	
12 13	
13	
12 13 14 15 16 17	
15	
16	
17	
18	
10	
18 19 20 21 22 23 24 25 26 27 28	
20	
21	
22	
23	
24	
25	
26	
27	
21	
29 30 31	
30	
31	
32	
32 33 34 35 36 37 38 39 40	
34	
35	
20	
30	
37	
38	
39	
40	
41	
42	
43	
43 44	
45	
46	
47	
48	
49	
50	
51	
52	
54	
55	
56	
57	
58	
59	
60	
00	

0.000	0.000	0.000	0.000	0.001		0.000 0.002 0.000 0.001 0.097 0.000 0.000 0.000	0.006 0.000 0.229 0.000 0.002 0.000 0.000	0.000 0.001 0.310 0.100 0.463 0.000 0.000	0.000 0.000 0.000 0.098 0.000 0.000	0.00 0.00 0.00 0.00 0.16 0.00
						0.000 0.001 0.097 0.000 0.000	0.229 0.000 0.002 0.000 0.000	0.310 0.100 0.463 0.000	0.000 0.098 0.000	0.00 0.00 0.16 0.00
						0.001 0.097 0.000 0.000	0.000 0.002 0.000 0.000	0.100 0.463 0.000	0.098	0.00 0.16 0.00
						0.097 0.000 0.000	0.002 0.000 0.000	0.463 0.000	0.000	0.16 0.00
						0.097 0.000 0.000	0.002 0.000 0.000	0.463 0.000	0.000	0.16 0.00
						0.000 0.000	0.000 0.000	0.000		0.00
						0.000 0.000	0.000 0.000	0.000		0.00
						0.000	0.000			
								0.000	() ()()()	
										0.00
						0.000	0.000	0.000	0.000	0.00
						0.000	0.000	0.000	0.000	0.00
						0.311	0.290	0.523	0.000	0.00
						0.873	0.002	0.000	0.002	0.20
						0.000	0.182	0.000	0.008	0.00
						0.075	0.136	0.000	0.987	0.00
						0.934	0.013	0.000	0.000	0.26
						0.000	0.001	0.000	0.000	0.01
							0.691	0.004	0.216	0.00
						0.000	0.000	0.000	0.000	0.00
						0.000	0.000	0.000	0.000	0.00
						0.000	0.000	0.000	0.000	0.00
						0.020	0.003	0.001	0.020	0.06
										0.00
										0.28
										0.00
										0.79 0.00
										0.00
										0.00
										0.00
										0.00
										0.13
										0.00
							0.000	0.000	0.024	0.01
						0.974	0.717	0.123	0.342	0.94
						0.927	0.000	0.600	0.788	0.89
0.000	0.000	0.000	0.000	0.000		0.000	0.000	0.000	0.000	0.00
	0.000	0.000 0.000	0.000 0.000 0.000	0.000 0.000 0.000 0.000	0.000 0.000 0.000 0.000		0.009 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.355 0.359 0.550 0.643 0.269 0.000 0.074 0.000 0.074 0.000 0.130 0.000 0.130 0.003 0.240 0.974 0.927 0.000 0.000 0.000 0.000 0.000	0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.355 0.361 0.355 0.361 0.359 0.000 0.550 0.523 0.643 0.423 0.269 0.984 0.000 0.000 0.074 0.956 0.000 0.000 0.130 0.240 0.003 0.924 0.240 0.000	0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.355 0.001 0.355 0.001 0.643 0.423 0.440 0.269 0.984 0.001 0.643 0.423 0.440 0.269 0.984 0.000 0.074 0.956 0.000 0.074 0.956 0.000 0.000 0.000 0.000 0.130 0.240 0.024 0.000 0.000 0.130 0.240 0.024 0.000 0.000 0.974 0.717 0.123 0.927 0.000 0.000	0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.020 0.003 0.001 0.020 0.000 0.000 0.000 0.000 0.355 0.361 0.006 0.202 0.359 0.000 0.001 0.019 0.550 0.523 0.001 0.989 0.643 0.423 0.440 0.106 0.269 0.984 0.549 0.725 0.000 0.000 0.000 0.000 0.074 0.956 0.000 0.000 0.174 0.956 0.000 0.000 0.130 0.240 0.023 0.633 0.240 0.000 0.000 0.024 0.974 0.717 0.123 0.342 0.927 0.

Appendix	D Further	information	of mode	variables
----------	------------------	-------------	---------	-----------

Variable description Age Age 65-74 Age 75-84 Age 85+ Sex = female Index of multiple deprivation - GP practice area Months registered with GP prior 1-12 months	Time period/Date End calendar year (5 months a End calendar year (5 months a End calendar year (5 months a End calendar year (5 months a N/A
Age 65-74 Age 75-84 Age 85+ Sex = female Index of multiple deprivation - GP practice area	End calendar year (5 months a End calendar year (5 months a End calendar year (5 months a N/A
Age 65-74 Age 75-84 Age 85+ Sex = female Index of multiple deprivation - GP practice area	End calendar year (5 months a End calendar year (5 months a End calendar year (5 months a N/A
Age 75-84 Age 85+ Sex = female Index of multiple deprivation - GP practice area	End calendar year (5 months a End calendar year (5 months a N/A
Age 85+ Sex = female Index of multiple deprivation - GP practice area	End calendar year (5 months a N/A
Sex = female Index of multiple deprivation - GP practice area	N/A
Index of multiple deprivation - GP practice area	
Index of multiple deprivation - GP practice area	
	N/A
÷ .	Prior 1 - 12 months (inclusive)
Months registered with GP prior 13-24 months	Prior 13 - 24 months (inclusive
Number of emergency admissions - prior 1-90 days	Prior 1 to 90 days (inclusive)
	Prior 1 to 90 days (inclusive)
	Prior 1 to 90 days (inclusive)
	Prior 91 to 180 days (inclusive
Number of emergency admissions - prior 181-365	
	Prior 181 to 365 days (inclusiv
	Prior 1 to 90 days (inclusivo)
	Prior 1 to 90 days (inclusive)
	Prior 91 to 180 days (inclusive
Any day case prior 181-365 days	Prior 181 to 365 days (inclusiv
	Prior 366 to 730 days (inclusion
	Prior 366 to 730 days (inclusiv
	Prior 1 to 720 days (inclusivo)
	Prior 1 to 730 days (inclusive)
	Prior 1 to 730 days (inclusive)
prior 2 years	
Any prim or sec diagnosis - Congestive heart failure,	
	Prior 1 to 730 days (inclusive)
	Prior 1 to 730 days (inclusive)
disease, prior 2 years	
Any prim or sec diagnosis - Cereberal vascular 🔬	Drior 1 to 720 days (inclusiva)
disease, prior 2 years	Prior 1 to 730 days (inclusive)
	Prior 1 to 730 days (inclusive)
	Thor I to 750 days (inclusive)
	Prior 1 to 730 days (inclusive)
Any prim or sec diagnosis - Malignant cancer, prior 2	Prior 1 to 720 days (inclusiva)
years	Prior 1 to 730 days (inclusive)
Any prim or sec diagnosis - Diabetes with	
	Prior 1 to 730 days (inclusive)
	Prior 1 to 730 days (inclusive)
years	Thor I to 750 days (meldsive)
Charlson Comorbidity Index, prior 2 years	Prior 1 to 730 days (inclusive)
	Prior 1 to 730 days (inclusive)
Any prim or sec diagnosis - Chronic obstructive	Prior 1 to 730 days (inclusive)
pulmonary disease, prior 2 years	Thor I to 750 days (inclusive)
	Prior 1 to 730 days (inclusive)
-	Prior 1 to 720 days (inclusion)
	Prior 1 to 730 days (inclusive)
	Prior 1 to 730 days (inclusive)
dysfunctions, prior 2 years	
Any prim or sec diagnosis - ACS: Any ambulatory care	
	Prior 1 to 730 days (inclusive)
Number of ARE visite (april) artist 1.00 days	Drior 1 to 00 days (inclusion)
	Prior 1 to 90 days (inclusive)
	Prior 1 to 90 days (inclusive)
90 days	
Number of A&E visits with X-ray prior 1-90 days	Prior 1 to 90 days (inclusive)
	Prior 91 to 180 days (inclusive
	Thor ST to 100 days (inclusive
Number of A&E visits (any) prior 91-180 days	
Number of A&E visits - unplanned follow-up prior 91-	Prior 91 to 180 days (inclusive
	Prior 91 to 180 days (inclusive
Number of A&E visits - unplanned follow-up prior 91-	, .
Number of A&E visits - unplanned follow-up prior 91- 180 days Number of A&E visits with X-ray prior 91-180 days	Prior 91 to 180 days (inclusive
Number of A&E visits - unplanned follow-up prior 91- 180 days Number of A&E visits with X-ray prior 91-180 days Number of A&E visits (any) prior 181-365 days	Prior 91 to 180 days (inclusive
Number of A&E visits - unplanned follow-up prior 91- 180 days Number of A&E visits with X-ray prior 91-180 days Number of A&E visits (any) prior 181-365 days Number of A&E visits - unplanned follow-up prior	Prior 91 to 180 days (inclusive Prior 91 to 180 days (inclusive
Number of A&E visits - unplanned follow-up prior 91- 180 days Number of A&E visits with X-ray prior 91-180 days Number of A&E visits (any) prior 181-365 days Number of A&E visits - unplanned follow-up prior 181-365 days	Prior 91 to 180 days (inclusive Prior 91 to 180 days (inclusive Prior 181 to 365 days (inclusiv
Number of A&E visits - unplanned follow-up prior 91- 180 days Number of A&E visits with X-ray prior 91-180 days Number of A&E visits (any) prior 181-365 days Number of A&E visits - unplanned follow-up prior	Prior 91 to 180 days (inclusive Prior 91 to 180 days (inclusive Prior 181 to 365 days (inclusiv
Number of A&E visits - unplanned follow-up prior 91- 180 days Number of A&E visits with X-ray prior 91-180 days Number of A&E visits (any) prior 181-365 days Number of A&E visits - unplanned follow-up prior 181-365 days	Prior 91 to 180 days (inclusive Prior 91 to 180 days (inclusive Prior 181 to 365 days (inclusiv Prior 181 to 365 days (inclusiv
Number of A&E visits - unplanned follow-up prior 91- 180 days Number of A&E visits with X-ray prior 91-180 days Number of A&E visits (any) prior 181-365 days Number of A&E visits - unplanned follow-up prior 181-365 days Number of A&E visits with X-ray prior 181-365 days	Prior 91 to 180 days (inclusive Prior 91 to 180 days (inclusive Prior 91 to 180 days (inclusive Prior 181 to 365 days (inclusiv Prior 181 to 365 days (inclusiv Prior 366 to 730 days (inclusis
	Number of elective admissions - prior 1-90 days Any regular attendance - prior 1-90 days Number of emergency admissions - prior 91-180 days Number of emergency admissions - prior 181-365 days Any day case prior 1-90 days Any day case prior 181-365 days Any day case prior 181-365 days Any day case prior 366-730 days Number of emergency admissions - prior 366-730 days Any prim or sec diagnosis - Diabetes, prior 2 years Any prim or sec diagnosis - Myocardial infarction, prior 2 years Any prim or sec diagnosis - Congestive heart failure, prior 2 years Any prim or sec diagnosis - Corgestive heart failure, prior 2 years Any prim or sec diagnosis - Cereberal vascular disease, prior 2 years Any prim or sec diagnosis - Cereberal vascular disease, prior 2 years Any prim or sec diagnosis - Cereberal vascular disease, prior 2 years Any prim or sec diagnosis - Connective tissue disease, prior 2 years Any prim or sec diagnosis - Connective tissue disease, prior 2 years Any prim or sec diagnosis - Diabetes with complications, prior 2 years Any prim or sec diagnosis - Diabetes with complications, prior 2 years Any prim or sec diagnosis - Renal disease, prior 2 years Any prim or sec diagnosis - Alcohol abuse, prior 2 years Any prim or sec diagnosis - Alcohol abuse, prior 2 years Any prim or sec diagnosis - Chronic obstructive pulmonary disease, prior 2 years Any prim or sec diagnosis - Chronic obstructive pulmonary disease, prior 2 years Any prim or sec diagnosis - Sental illness, prior 2 years Any prim or sec diagnosis - Asthma, prior 2 years Any prim or sec diagnosis - Asthma, prior 2 years Any prim or sec diagnosis - Asthma, prior 2 years Any prim or sec diagnosis - Asthma, prior 2 years Any prim or sec diagnosis - Asthma, prior 2 years

1
2
3
4
5
6
7
8
9
10
11
12
12
13
14
15
16
17
2 3 4 5 6 7 8 9 10 11 2 13 14 15 6 17 8 9 10 11 2 13 14 15 16 17 8 19 20 21 22 32 4 25 26 27 28 29 30 1 32 33 34 35 36 37 38 9 10
19
20
21
22
23
24
25
20
20
21
28
29
30
31
32
33
34
35
36
37
38
30
39 40
40
42
43
44
45
46
47
48
49
50
51
52
53
53 54
54 55
56
57
58
59
60

prior	366-730 days Number of A&E visits with X-ray prior 366-730 days	Prior 266 to 720 days (inclusivo)
AE X-ray 2yrs prior SUS outpatient variables	Number of Age visits with x-ray prior 566-750 days	Prior 366 to 730 days (inclusive)
Outpatient specialty visits prior 0-90		
days	Number of outpatient visits (all) prior 1-90 days	Prior 1 to 90 days (inclusive)
Dutpatient specialty visits missed	North and the tradition of the science of the test of the science	
prior 0-90 days	Number of outpatient visits missed prior 1-90 days	Prior 1 to 90 days (inclusive)
Dutpatient specialty visits prior 91-	Number of outpatient visits (all) prior 91-180 days	Prior 91 to 180 days (inclusive)
180 days	Number of outpatient visits (any prior 51-100 days	Thor 51 to 100 days (inclusive)
Outpatient specialty visits missed	Number of outpatient visits missed prior 91-180 days	Prior 91 to 180 days (inclusive)
prior 91-180 days		
Outpatient specialty visits prior 181- 365 days	Number of outpatient visits (all) prior 181-365 days	Prior 181 to 365 days (inclusive)
Outpatient specialty visits missed	Number of outpatient visits missed prior 181-365	
prior 181-365 days	days	Prior 181 to 365 days (inclusive)
Outpatient specialty visits 2 yrs prior	Number of outpatient visits (all) prior 365-730 days	Prior 366 to 730 days (inclusive)
Outpatient specialty visits missed 2	Number of outpatient visits missed prior 365-730	
yrs prior	days	Prior 366 to 730 days (inclusive)
GP consultations data		
SP DX COPD	Diagnosis of COPD, prior 2 years	Prior 1 to 730 days (inclusive)
GP - 1 long term condition	Chronic conditions - 1 in prior 2 years	Prior 1 to 730 days (inclusive)
GP - 2 or more long term conditions	Chronic conditions - 2 or more in prior 2 years	Prior 1 to 730 days (inclusive)
GP - Glomerular filtration rate group 3	Glomerular Filtration Rate Group 3 in last year	Prior 1 to 365 days (inclusive)
ast 0-365 days GP - 10+ unique drugs prescribed	1-4 unique drugs - last 1 to 90 days	Prior 1 to 90 days (inclusive)
GP - 5-9 unique drugs prescribed	5-9 unique drugs - last 1 to 90 days	Prior 1 to 90 days (inclusive)
GP - 0-4 unique drugs prescribed	10+ unique drugs - last 1 to 90 days	Prior 1 to 90 days (inclusive)
GP - Psychoactive substance misuse	Psychoactive substance misuse disorder, prior 2	
disorder	years	Prior 1 to 730 days (inclusive)
	7+ distinct disease disorders recorded in prior 90	
GP - 7+ distinct disorders	days	Prior 1 to 90 days (inclusive)
GP - GP visits prior 0-3 months	Count of different BNF chapters of prescribed	Prior 1 to 730 days (inclusive)
dP - GP visits prior 0-3 months	medicines, prior 2 years	Phon 1 to 750 days (inclusive)
GP - GP visits prior 4-6 months	Number of GP visits prior 1-3 months	Prior 1 to 3 months (inclusive)
GP - GP visits prior 7-12 months	Number of GP visits prior 13-24 months	Prior 13 to 24 months (inclusive)
GP - GP visits 2yrs prior	Number of GP visits prior 4-6 months	Prior 4 to 6 months (inclusive)
GP - Increasing rate of GP visits during	Number of GP visits prior 7-12 months	Prior 7 to 12 months (inclusive)
last 12 months GP - Number of high risk BNFs	Substantial increase in GP visits last year	
GF - NUMBER OF HIGH LISK BINES	Number of BNF codes associated with emergency	
GP - Any high risk	admissions, prior 2 years	Prior 1 to 730 days (inclusive)
	Any BNF codes associated with emergency	
GP - Count of BNF chapters	admissions, prior 2 years	Prior 1 to 730 days (inclusive)
GP - DX Dementia	Diagnosis of Dementia, prior 2 years	Prior 1 to 730 days (inclusive)
GP - Exception reported from quality	QOF register exceptions, prior 2 years	Prior 1 to 730 days (inclusive)
indicators	QUE register exceptions, prior 2 years	Filor 1 to 750 days (inclusive)
GP - Health visitor or district nurse	Any home/district visit, prior 2 years	Prior 1 to 730 days (inclusive)
visit		
GP - Record of IHD/angina	Diagnosis of IHD/angina, prior 2 years	Prior 1 to 730 days (inclusive)
GP - Nebuliser used	Nebuliser prescribed, prior 2 years	Prior 1 to 730 days (inclusive)
GP - Salbutamol prescribed	Salbutamol prescribed, prior 2 years	Prior 1 to 730 days (inclusive)
GP - Warfarin prescribed GP - High blood pressure	Warfarin prescribed, prior 2 years High blood pressure Read code, prior 2 years	Prior 1 to 730 days (inclusive) Prior 1 to 730 days (inclusive)
GP - Smoker	Smoking status, prior 2 years	Prior 1 to 730 days (inclusive)
GP - BMI 30+	BMI greater than equal to 30, prior 2 years	Prior 1 to 730 days (inclusive)
GP - HbA1c > 10	HbA1c greater than 10, prior 2 years	Prior 1 to 730 days (inclusive)
GD - QOF ARTF	QOF register: Atrial fibrillation	Prior 1 to 730 days (inclusive)
GP - QOF CKD	QOF register: Stage 3 to 5 chronic kidney disease	Prior 1 to 730 days (inclusive)
GP - QOF Depression	QOF register: Depression	Prior 1 to 730 days (inclusive)
	QOF register: number of different registers, 3 or	
GP - Number of QOF DX categories 3+	more	Prior 1 to 730 days (inclusive)
GP - Number of phone contacts last 0-	Number of GP telephone consults prior 1-3 months	Prior 1 to 3 months (inclusive)
3 months	reamper of or telephone consults prior 1-5 months	i noi ± to 5 months (inclusive)

Page 55 of 56

NOTE: PLEASE SAVE THIS TO YOUR HARD DRIVE UNDER A DIFFERENT FILE NAME AFTER YOU FILL IT OUT **BMJ Open** STROBE Statement—checklist of items that should be included in reports of observational studies

Please fill out the page numbers on this form and upload the file as a supplemental file when you submit your revision

Manuscript Number___

Indicate page number ↓ (Or n/a if not

			(Or n/a if n applicab
	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	
Methods			
Study design	4	Present key elements of study design early in the paper	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data	
Setting	U	collection	
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe	
i unorpanas	0	methods of follow-up	
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control	
		selection. Give the rationale for the choice of cases and controls	
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed	
X7 · 11	7	Case-control study—For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic	
-		criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe	
measurement		comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen	
		and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	_
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed	
		Case-control study—If applicable, explain how matching of cases and controls was addressed	
		Cross-sectional study-If applicable, describe analytical methods taking account of sampling strategy	_
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study-eg numbers potentially eligible, examined for eligibility,	
		confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and	
		potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time	
	-	Case-control study—Report numbers in each exposure category, or summary measures of exposure	
		Cross-sectional study—Report numbers of outcome events or summary measures	

Page	56	of	56
------	----	----	----

	1		BMJ Open	Page
			confidence interval). Make clear which confounders were adjusted for and why they were included	
			(b) Report category boundaries when continuous variables were categorized	
			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses		17	Report other analyses done-eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion				
Key results	18	Summa	arise key results with reference to study objectives	
Limitations	19	Discus	s limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and	
		magnit	ude of any potential bias	
Interpretation	20	Give a	cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar	
		studies	, and other relevant evidence	
Generalisability	21	Discus	s the generalisability (external validity) of the study results	
Other informatio	on			
Funding	22	Give th	he source of funding and the role of the funders for the present study and, if applicable, for the original study on which	
		the pre	sent article is based	

BMJ Open

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

en and gives available on the Web acpident.com/). Information. Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.